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ABBREVIATIONS 
FBPase   Fructose-1,6-bisphosphatase 
Fru-1,6-P2   Fructose 1,6-bisphosphate 
Fru-2,6-P2   Fructose 2,6-bisphosphate 
Fru-6-P   Fructose 6-phosphate 
Glc-6-P   Glucose 6-phosphate 
ED   1,2-ethanediol 
MPD   2-methyl-2,4-pentanediol 
MD   Molecular dynamics 
PEP    Phosphoenolpyruvate 
PFK-1   Phosphofructokinase or fructose-6-phosphate-1-kinase 
Pi    Inorganic phosphate 
PD   1,2-propanediol 
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ABSTRACT 
Fructose-1, 6-bisphosphate (D-fructose-1, 6-bisphosphate 1-phosphohydrolase; EC 3. 
1. 3; FBPase) is an essential regulatory enzyme in gluconeogenesis and has long been 
considered as a drug target towards type II diabete. In mammalian, the activity of FBPase is 
regulated by AMP and fructose 2,6-bisphosphate (Fru-2,6-P2). AMP is an allosteric inhibitor 
that binds to FBPase with positive coopertivity, and Fru-2,6-P2 is an active site inhibitor 
which is up-regulated by hormone. Despite the 30 Å distance between their binding sites, 
both of AMP and Fru-2,6-P2 transform FBPase from active R-state to inactive T-state.  
Large conformational rearrangements are coupled to the R- to T-state transition: subunit 
pairs within tetrameric FBPase rotate over ten degree relative to each other and an essential 
catalytic loop (residue 50-72) is forced away from active site. Mutagenesis, kinetics, 
crystallography and molecular dynamics simulations are combined here to investigate 
structure-function relationship of FBPase. Tetramer is a functional unit of FBPase; 
disturbing the tetrameric packing of FBPase leads to loss of AMP cooperativity. A 
hydrophobic cavity at the center of FBPase tetramer is populated by well-defined clathrate-
like waters. The cavity together with waters in it is shown to be thermodynamic determinant 
for quaternary states of FBPase. Kinetics and crystallographic studies indicate a negative 
correlation between subunit pair rotation and relative activity of FBPase. Filling the cavity 
by point mutations selectively hinges subunit pair rotation induced by Fru-2,6-P2 and largely 
reduce the synergism between AMP and Fru-2,6-P2. Mutation that stops subunit pair 
rotations causes complete loss of AMP inhibition but retains Fru-2,6-P2 inhibition; whereas 
mutation promotes the subunit pair rotation turn off cooperative binding of AMP as well as 
AMP/Fru-2,6-P2 synergism. MD simulation together with crystal structures of intermediate 
states of FBPase reveals correlation between subunit pair rotation and status of loop 50-72. 
Moreover, knowledge of allosteric regulation of porcine liver FBPase and FBPase from 
Escherichia coli was used predict the regulatory properties of all Type-I FBPases, for which 
sequence information is available.  Subsequent expression of FBPase from a bacterial 
organism, predicted to have the regulatory properties of a eukaryotic FBPase, proved correct 
and established a basis for the evolution of regulatory properties for all Type-I FBPases. 
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CHAPTER I. GENERAL INTRODUCTION 
Blood glucose homeostasis is highly controlled in mammals.  On one hand, glucose is 
the main energy source for all mammalian cells and the sole energy source for brain (1).  A 
short period of hypoglycemia will lead to permanent damage to brain (2).  On the other hand, 
chronic hyperglycemia is a hallmark for diabetes mellitus and can cause serious health 
problems such as kidney damage, neurological damage, and cardiovascular damage and so 
on (3).  Glucose metabolism mainly occurs in liver and kidney.  Gluconeogenesis and 
glucogenolysis produce glucose from either metabolic intermediates (such as pyruvate, 
lactate, glycerol, and some amino acids) or glycogen; whereas glycolysis degrades glucose to 
pyruvate for energy and glycogenesis converts glucose to glycogen for storage.  These 
pathways are highly regulated to maintain blood glucose homeostasis. 
Fructose-1, 6-bisphosphate (D-fructose-1, 6-bisphosphate 1-phosphohydrolase; EC 3. 
1. 3; FBPase) governs a key regulatory step in gluconeogenesis, hydrolyzing fructose-1,6-
bisphosphate (Fru-1,6-P2) to fructose 6-phosphate (F6P) and inorganic phosphate (4,5).  
FBPase and phosphofructokinase (PFK), the counterpart of FBPase in the glycolysis pathway 
(6), creates a fultile cycle that consumes ATP.  Activity of mammalian FBPase and PFK is 
under dynamic hormone control.  Fructose 2,6-bisphosphate (Fru-2,6-P2) and AMP are 
inhibitors for FBPase, while both serve as activators for PFK (6-12).  During starvation, 
glucagon is secreted and a downstream bifunctional enzyme fructose-6-phosphate-2-
kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2) is phosphorylated, which leads to the 
degradation of Fru-2,6-P2; whereas in the fed state, insulin reverses the effect of glucagon 
and raises the level of  Fru-2,6-P2 (13-16).  The increment in Fru-2,6-P2 level is not enough 
to inhibit FBPase completely by itself; however, AMP inhibition is enhanced up to 10 fold in 
the presence of Fru-2,6-P2, which is named AMP/Fru-2,6-P2 synergism (8-9).  Thus, even 
though AMP concentration is relatively constant in vivo, the fluctuation of Fru-2,6-P2 levels 
can dynamically alter FBPase activity (17). 
Porcine liver FBPase is a homotetramer, with a molecular weight of 37 kDa for each 
monomer.  The four subunits are arranged in D2 symmetry and named C1 to C4, clockwisely 
(Figure 1, A) (18).  Two distinct subunit interfaces, C1-C2 and C1-C4, are in the FBPase 
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tetramer and play important roles in the functional properties of FBPase.  Investigations of 
hybrid tetramers of FBPase (subunits of the tetramer have nonequivalent primary structures) 
indicate subunit exchange among tetramers, dimers (C1-C2 and C3-C4) and monomers (19).  
At least two quaternary states exist when different effectors bind to FBPase: FBPase complex 
with products and divalent cations creates the R-state whereas the complex with AMP and/or 
Fru-2,6-P2 defines T-state (20-22).  R-state and T-state FBPase differ by a 15 degree rotation 
of the C1-C2 dimer relative to the C3-C4 dimer (Figure 1, A). 
The active site of FBPase is near the C1-C2 interface and requires residues from both 
subunits to recognize the 6-phosphoryl group of the substrate (23).  Divalent metal ions 
(Mg
2+
, Mn
2+
, or Zn
2+
) are required for hydrolysis of Fru-1,6-P2 (4-5).  In product complexes 
of FBPase, three metals formed coordinate bonds to the 1-phosphoral group of Fru-1,6-P2 
(26).  Hydrolysis of Fru-1,6-P2 requires the presence of all three metals.  Metal at Site-I is 
independent of inhibitor ligations; whereas metal at Site-III only shows up in active forms of 
FBPase (26-27).  The binding of Mg
2+
 to the Site-II and Site-III in the same subunit is 
cooperative (28).  A dynamic loop (residue 50-72) can exist in engaged, disordered or 
disengaged conformations (29).  Metal at Site-III is stabilized only with the engaged dynamic 
loop (26) (Figure 1, B).  When metals at Site-II and Site-III are missing, part of dynamic loop 
(usually 58-70) becomes disordered (20-25).  The cycle between engaged and partially 
disordered conformation of dynamic loop could be important for substrate binding and 
product release.  Certain monovalent cations such as K
+
, NH4
+
 and Tl
+
 are activators for 
FBPase at low concentrations (30-32).  However, when at high concentrations, Tl
+
 displace 
active site Mg
2+
, partially disorder the dynamic loop and inhibit FBPase (33).  Ca
2+
 and Cd
2+
 
are potent inhibitors for FBPase.  Product complex of FBPase with Ca
2+
 reveals only two 
metal binding and a partially disordered dynamic loop (Gao, Y., and Honzatko, R. B., 
unpublished data) (Figure 2). 
AMP is an allosteric inhibitor for FBPase (5).  AMP binding sites are near the C1-C4 
interface, some 28 Å away from nearest active site (21) (Figure 1).  Hydrogen bonds near or 
at the C1-C4 interface are disrupted/formed in response to AMP ligation (36).  As a 
consequence, the C1-C2 dimer rotates 15 degrees with respect to C3-C4 dimer and the 
dynamic loop adopts its disengaged conformation (27) (Figure 1). 
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Backbone dihedral angles of residues 50-51, which is the N-terminal hinge of the 
dynamic loop, change dramatically in the transition from an engaged to disengaged dynamic 
loop (27, 36).  Residues that interact with divalent cations on the C-terminal end of dynamic 
loop shift more than 10 Å from the active site (27).  Kinetically, AMP is a non-competitive 
inhibitor with respect to Fru-1,6-P2 and a competitive inhibitor with respect to Mg
2+
.  The 
competitive relationship between AMP and Mg
2+
 is likely mediated by the dynamic loop (37-
38).  Tryptophan fluorescence confirms the status of dynamic loop with or without AMP in 
solution (29).  Introduction of a proline into the hinge of the dynamic loop eliminates AMP 
inhibition (36).  The mutation Ala
54Leu, which destabilizes disengaged conformation of 
dynamic loop, decreases AMP inhibition over one thousand fold (39).  Crystal structures of 
Leu
54
 FBPase complexed with AMP and products are in two distinct conformations: T-state 
with a 15 degree subunit-pair rotation and a disordered dynamic loop, and a near R-state 
(called the IR-state) with 3 degree rotation and engaged loop (39).  Based on structures of 
Leu
54
 FBPase, Iancu suspects that dimer-dimer rotation is the direct consequence of AMP 
binding (39); however, how dimer-dimer rotation is coupled to loop displacement is unclear. 
AMP inhibition is cooperative, with a hill coefficient of two (7, 40-41).  The positive 
coopertivity, in principal, forces FBPase into one of two quaternary states, depending on a 
threshold concentration of AMP (and Fru-2,6-P2).  The binding of at least two AMP 
molecules drives the R- to T-state transition of FBPase (42).  The interaction between the C1-
C2 dimer and C3-C4 dimer is essential for AMP cooperativity: AMP cooperativity is not 
present in hybrid FBPase tetramers with AMP molecules bound only at subunits C1 and C2, 
but is present in hybrid FBPase tetramers with AMP molecules bound to each dimer of the 
tetramer (42).  Point mutations at the C1-C4 interface, the C1-C2 interface and the dynamic 
loop eliminate AMP coopertivity (36, 43-48).  Among them, the case of Arg
22Met FBPase 
is most compelling as the resulting mutant enzyme retains wild-type properties in catalysis 
and regulation save AMP coopertivity (43).  Arg
22
 from subunit C1 is near the AMP binding 
site of that subunit and hydrogen bonds with residues near the AMP binding site of subunit 
C4.  The special location and long polar sidechain of Arg
22
 provides a direct connection 
between two AMP binding sites; however, how changes at the C1-C2 interface, dynamic 
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loop and other parts of the C1-C4 interface influence AMP cooperativity need further 
exploration. 
Fru-2,6-P2 was found in 1981 independently by Pilkis and Van Shaftingen (8-9).  The 
inhibition of Fru-2,6-P2 towards FBPase is competitive with respect to Fru-1,6-P2 (8-9).  
Binding of Fru-2,6-P2 to active site of FBPase is confirmed by chemical modification (49), 
NMR (50) and X-ray crystallography (22).  Fru-2,6-P2 can enhance AMP inhibition by 
several fold.  Binding studies by NMR confirms the synergism between AMP and Fru-2,6-P2.  
In UV spectroscopy, AMP and Fru-2,6-P2 induce similar conformational change (51).  
FBPase complexed with AMP and Fru-2,6-P2 is in the T-state (22); however, early 
crystallographic studies failed to reveal conformation changes induced by Fru-2,6-P2 alone 
(Fru-2,6-P2 in crystal soaks caused no change (52) and co-crystallizations revealed degraded 
Fru-2,6-P2 (53)).  Hines successfully co-crystallized FBPase with Fru-2,6-P2 (54).  FBPase 
complexed with Fru-2,6-P2 exhibits a 13 degree of rotation between the C1-C2 dimer and 
C3-C4 dimer, which is similar to the T-state (54) (Figure 2).  Fru-2,6-P2 binding induces 
local structural rearrangement which is not favorable for a engaged dynamic loop (54).  Two 
metals sit in the active site and the dynamic loop is in its disengaged conformation (54).  The 
similar end state caused by AMP and Fru-2,6-P2 separately could explain the AMP/ Fru-2,6-
P2 synergism.  The remaining question is how the binding of Fru-2,6-P2 to C1-C2 interface 
affects rotations at C1-C4 interface. 
FBPase from muscle (mFBPase) shares 80-90% sequence identify to its liver isoform. 
Same as liver FBPase, mFBPase requires divalent cations for catalysis and AMP and Fru-
2,6-P2 for inhibition (4-5,55-56); however, mFBPase is 50-100 times more sensitive to AMP 
inhibition, which indicates that mFBPase is inhibited under normal condition (55-56).  
Aldolase interacts with mFBPase and can partially releive AMP inhibition (57-58).  The 
interaction between liver aldolase and liver FBPase is not observed (57).  Gizak shows that 
N-terminal residues of mFBPase are essential for mFBPase/aldolase interaction (59).  In vivo, 
mFBPase localizes in both sides of z-lines as well as in nuclei (60-63).  The exact function of 
mFBPase is unclear.  
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FBPase in plant chloroplast (cFBPase) works as part of Calvin cycle in carbon 
fixation.  cFBPase is redox-regulated by light, by a mechanism entirely different from its 
mammalian homologs (64-66).  cFBPase is a homotetramer, with active sites nearly identical 
to porcine liver FBPase.  Unlike porcine FBPase, there are no quaternary structural changes 
linked to inactivation (67-68).  cFBPase tetramer is close to the T-state of porcine FBPase, 
with a 20 degree dimer-dimer rotation relative to the R-state of porcine FBPase and 5 degree 
rotation relative to T-state porcine FBPase (Figure 2).  A regulatory loop with three 
conserved cysteine residues is inserted between strands β4 and β5 (69-70).  Light induces 
formation of a disulfide bond between two cysteines in the loop (65-66).  When these 
cysteines are in the reducted state, the enzyme is active; on the other hand, formation of the 
disulfide bond turns off cFBPase.  Disulfide bond formation promotes a shift in strands β1 
and β2 and pushes a valine sidechain into cation binding sites (68).  The movement of the 
valine would conflict with the engaged conformation of the dynamic loop (68); however, 
electron density for the dynamic loop is not observed in any of the cFBPase crystal structures 
(67-68).  Hence, without clear evidence of a cFBPase in an active conformation, the 
mechanism of inhibition remains speculative. 
FBPases in prokaryotic systems are classified to five types according to their 
sequence similarity (71-73).  Type I FBPase is homolog to eukaryotic FBPase.  Type I-III 
FBPases are found in bacteria (71).  Type IV FBPase from archaea, though not physiological 
FBPase in archaea, are structurally similar to Type I FBPase and carries both FBPase activity 
inositol monophosphatase activity (72).  A common sugar phosphatase fold is shared by all 
type I-IV FBPase as well as eukaryotic FBPase.  However, type V FBPase, which is widely 
found in thermophilic prokaryotes, is completely different from type I-IV in both sequences 
and structures (73).  The regulatory mechanism for type II-V FBPase is largely unknown.  In 
contrast, type I FBPase from E coli (eFBPase) is well studied (54,74-77). 
eFBPase shares 41% sequence identity with porcine liver FBPase.  In solution, 
eFBPase exists in equilibrium between dimer and tetramer (76).  Dilution of eFBPase leads 
to slow loss of activity, indicating that dimer form of eFBPase is less active than tetramer.  
Anion activators, such as phosphoenolpyruvate (PEP) or citrate, bind to an allosteric site at 
the C1-C4 interface and promotes the formation of tetramers (76).  The tetramer complex 
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with product and PEP/citrate defines the active R-state of eFBPase, which is in the same 
quaternary state as the porcine R-state.  Unlike the porcine enzyme, the dynamic loop is 
disordered in the complexes of eFBPase loop (76) (Figure 2).  SO4
2–
 is a weak activator for 
eFBPase, binds to the same allosteric site as PEP/citrate and induces a 3-degree rotation 
between dimers C1-C2 and C3-C4 (75).  The corresponding allosteric activator site in 
porcine FBPase is filled by a negatively charged side chain (Glu
192
 in porcine FBPase).  
AMP and glucose 6-phosphate (Glc-6-P) are synergistic inhibitors to eFBPase (77).  The 
AMP binding site is topologically identical to that of as porcine FBPase, whereas the Glc-6-P 
binding site is at C1-C2 interface (77).  The eFBPase complex with product, AMP and Glc-6-
P reveals extensive conformational change at both C1-C4 and C1-C2 interfaces.  The C1-C2 
dimer rotates 9 degree relative to the C3-C4 dimer, which is similar to the effect of AMP 
effect porcine FBPase (Figure 2).  The two subunits that make up the dimer rotate 3 degrees 
relative to each other, causing significant disruption to the active site.  If the AMP inhibitory 
mechanism is the same in eFBPase and porcine FBPase, rotations at C1-C4 interface would 
correlate with displacement of dynamic loop.  However, in both active and inactive form of 
eFBPase structures, the dynamic loops are disordered (75-77).  The inhibition of Glc-6-P and 
AMP towards eFBPase is antagonized by PEP and/or citrate.  Within different nutritional 
states, the concentration of metabolism intermediates, PEP, citrate and Glc-6-P changes 
dramatically, providing the basis for dynamic control of FBPase activity.  Fru-2,6-P2 is not 
presented in E. coli, but Fru-2,6-P2 is a potent inhibitor for eFBPase (74).  eFBPase stays in 
the R-state in the presence of Fru-2,6-P2 (54) (Figure 2), consistent with the absence of Fru-
2,6-P2/AMP synergism in eFBPase (74). 
Due to the central regulatory role of FBPase in glucose production, FBPase has been 
considered a target in the development of drugs for the treatment of Type II diabetes (78-89).  
The highly hydrophilic nature of active site makes it a less attractive target. Thus, most of 
drug screening efforts focus on the AMP binding site (78-87).  Formycine monophosphate 
and 3-deoxy-AMP inhibit FBPase with potency similar to AMP (78).  Rational modifications 
based on AMP achieve 10-fold enhancements in binding affinity (79-81).  Some chemicals, 
with entirely different scaffold with respect to AMP, can inhibit FBPase effectively by 
binding to the AMP site (82-83).  A novel series of benzoxazole chemicals occupy the AMP 
7 
 
site and a small cavity in proximity to the AMP site (84-86).  Inhibitors with a linker 
connecting two AMP analogs from adjacent sites gain 10
5
 potency in FBPase inhibition (87).  
Animal experiments shown that some of the predrugs can efficiently reduce gluconeogenesis 
as well as blood glucose levels (79,81,86). 
Recent drug searches also reveal a novel allosteric inhibitory site at the center of 
FBPase (88-89).  OC252, one of these inhibitors, is characterized kinetically and structurally 
(89).  OC252 inhibits FBPase with positive cooperativity.  Synergism exists between OC252 
and both AMP and Fru-2,6-P2.  FBPase complexed with products and OC252 yields a T-like 
state, with a 12-degree dimer-dimer rotation and disengaged dynamic loops (Figure 2).  The 
inhibition of OC252 is uncompetitive with respect to Fru-1,6-P2; effective inhibition of 
OC252 benefits from high concentrations of substrate not available in vivo. 
Although current drug screening effort towards FBPase achieves a number of 
successes, potent, selective and cell penetrable compounds are still in high demand.  
Understanding the inhibitory mechanism of FBPase would support drug-design efforts at 
known sites and could lead to the discovery of new inhibitory sites. 
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Figure 1. R- to T-state conformational change of FBPase. A.  Schemes of FBPase in R- and T-states are 
drawn with subunits labeled C1-C4 by convention.  The relative position of active sites, allosteric sites and 
dynamic loops are circled.  During the R- to T-state transition, the C1-C2 dimer rotates 15 degrees relative to 
C3-C4 dimer and the dynamic loop moves from engaged to disengaged conformations.  B. Cα carbon trace of 
subunit C4-subunit in R- and T-states.  AMP, Mg
2+
, Fru-6-P (F6P) are shown in spheres.  Dynamic loops are 
red. 
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Figure 2. Inhibitory/activation mechanisms of FBPase.  Mechanism of mammalian liver FBPase (left), 
chloroplast FBPase (right top) and bacteria type I FBPase (right bottom) are shown.   
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Thesis Organization 
 
The dissertation contains eight chapters. Chapter 1 is a general introduction chapter, 
describes the current status of research on allosteric regulation of FBPase. Chapters 2-7 are 
the main body of my Ph. D. work on illustrating the inhibitory mechanism of FBPase. 
Chapter 2 elucidates the conformational transition of FBPase from active R-state to inactive 
T-state. Chapter 3 characterizes a large hydrophobic cavity at the center of FBPase tetramer, 
which is populated by ordered water and acts as a thermodynamic determinate for quaternary 
structure of FBPase. Chapter 4 confirms the essential physiological role of central cavity in 
allosteric regulation of FBPase, the presence of which determines AMP/Fru-2,6-P2 synergism. 
Chapter 5 re-examines the point mutations with reduced AMP cooperativity on dimer-dimer 
interface and sorts the mutant FBPases to two clusters, some with distablized tetramer and 
others with T-state-like AMP binding site in the absence of AMP. Chapter 6 verifies subunit 
pair rotation as structural basis for AMP cooperativity in tetrameric FBPase. Chapter 7 
characterized FBPase from Leptospira interrogans, and verified it as an evolutionary 
precursor for eukaryotic FBPases. Final chapter gives a brief summary of the experiments 
described in previous chapter.  
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Abstract 
AMP triggers a 15° subunit-pair rotation in fructose-1,6-bisphosphatase (FBPase) 
from its active R-state to its inactive T-state.  During this transition, a catalytically essential 
loop (residues 50–72) leaves its active (engaged) conformation.  Structures of Ile10→Asp 
FBPase and molecular dynamic simulations here reveal factors responsible for loop 
displacement.  AMP/Mg
2+
 and AMP/Zn
2+
 complexes of Asp
10
 FBPase are in intermediate 
quaternary conformations (completing 12° of subunit-pair rotation), but the complex with 
Zn
2+
 provides the first instance of an engaged loop in a near-T quaternary state.  The 12° 
subunit-pair rotation generates close contacts involving the hinges (residues 50–57) and 
hairpin turns (residues 58–72) of the engaged loops.  Additional subunit-pair rotation toward 
the T-state would make such contacts unfavorable, presumably causing displacement of the 
loop.  Targeted molecular dynamics simulations reveal no steric barriers to subunit-pair 
rotations up to 14°, followed by the displacement of the loop from the active site.  Principal 
component analysis reveals high-amplitude motions that exacerbate steric clashes of engaged 
loops in the near-T state.  The results of simulations and crystal structures are in agreement: 
subunit-pair rotations just short of the canonical T-state, coupled with high-amplitude modes, 
sterically displace the dynamic loop from the active site. 
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Introduction 
Fructose-1,6-bisphosphatase (D-fructose -1,6-bisphosphate 1-phosphohydrolase, EC 
3.1.3.11; FBPase
1
) catalyzes the hydrolysis of fructose 1,6-bisphosphate (Fru-1,6-P2) to 
fructose 6-phosphate (Fru-6-P) and inorganic phosphate (Pi) (1, 2).  FBPase controls a tightly 
regulated step of gluconeogenesis: AMP and fructose 2,6-bisphosphate (Fru-2,6-P2) bind to 
allosteric and active sites, respectively, and inhibit FBPase while activating fructose-6-
phosphate 1-kinase in glycolysis (3, 4).  Physiological levels of Fru-2,6-P2 are subject to 
control by glucagon and insulin (4, 5).  As Fru-2,6-P2 enhances the binding of AMP to 
FBPase by up to an order of magnitude (6), AMP should become a more potent inhibitor of 
FBPase in vivo as concentrations of Fru-2,6-P2 increase.  AMP binds 28 Å away from the 
nearest active site, inhibiting catalysis noncompetitively with respect to Fru-1,6-P2.  Yet, 
AMP is a competitive inhibitor of catalysis with respect to essential divalent cations (Mg
2+
, 
Mn
2+
, or Zn
2+
), all of which probably bind with the 1-phosphoryl group of Fru-1,6-P2 (7–10). 
FBPase is a homotetramer [subunit Mr of 37,000 (11)] and exists in at least two 
distinct quaternary states called R and T (12–13), as well as intermediate conformations that 
are R-like (IR-state) (14) and T-like (IT-state) (15).  For the wild-type enzyme, the binding of 
AMP alone can drive the R- to T-state transition, in which the upper subunit-pair rotates 15° 
relative to the bottom subunit-pair of the FBPase tetramer.  Substrates or products in 
combination with metal cations stabilize the R-state conformation. 
A dynamic loop (residues 5072), essential for activity, has been observed in three 
conformations called engaged, disengaged, and disordered (16).  AMP alone or with Fru-2,6-
P2 stabilizes a disengaged loop (16, 17), whereas metals with products stabilize an engaged 
loop (10, 18–20).  In active forms of the enzyme, loop 5072 probably cycles between its 
engaged and disordered conformations (16, 18).  Fluorescence from a tryptophan reporter 
group at position 57 is consistent with the conformational states for loop 5072 observed in 
crystal structures (21, 22).  Thus far, the engaged conformation of loop 5072 has appeared 
only in R-state crystal structures, and the disengaged conformer only in T-state structures; 
however, disordered conformations of the dynamic loop have appeared in both the R- and T-
states (14, 18, 19, 23, 24).  Although the engaged conformation of the dynamic loop 
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correlates with the R-state, and the disengaged conformer with the T-state, the mechanism of 
loop displacement in the R- to T-state transition has yet to be defined. 
Here, we present results from molecular dynamics simulations and crystal structures 
that identify factors responsible for loop-displacement in the R- to T-state transition.  
Targeted molecular dynamics (TMD) simulations of the R- to T-transition reveal unhindered 
subunit-pair rotations (dynamic loop engaged) until just short of the T-state.  Consistent with 
TMD simulations is the crystal structure of the AMP•Zn2+ complex of Ile10→Asp FBPase, 
presented here, which reveals an engaged dynamic loop in a near-T quaternary state with 
tight contacts involving the hinge and hairpin turn of the loop.  Principal component analysis 
(PCA) of MD trajectories of this near-T state identifies large-amplitude motions that 
exacerbate steric clashes of the engaged loop.  Hence, the quaternary transition to the T-state 
harnesses large-amplitude modes to sterically eject the loop from the active site. 
 
Experimental procedures 
Materials Fru-1,6-P2, Fru-2,6-P2, and AMP were purchased from Sigma.  DNA-modifying 
and restriction enzymes, T4 polynucleotide kinase and ligase were from Promega.  Glucose-
6-phophate dehydrogenase and phosphoglucose isomerase came from Roche.  Other 
chemicals were of reagent grade or equivalent.  Escherichia coli strains BMH 71-18 mutS 
and XL1-Blue came from Clontech and Stratagene, respectively.  The FBPase-deficient E. 
coli strain DF 657 came from the Genetic Stock Center at Yale University. 
Mutagenesis of wild-type FBPase— The mutation of Ile10 to aspartate was accomplished as 
described previously (16).  The mutation and the integrity of the construct were confirmed by 
sequencing the promoter region and the entire open reading frame.  The Iowa State 
University sequencing facility provided DNA sequences, using the fluorescent dye-dideoxy 
terminator method. 
Expression and Purification of Asp
10
 FBPase Cell-free extracts of wild-type and Asp10 
FBPase were subjected to heat treatment (63 °C for 7 minutes), followed by centrifugation.  
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The supernatant solution was loaded onto a Cibracon Blue sepharose column, previously 
equilibrated with 20 mM Tris-HCl, pH 7.5.  The column was washed first with 20 mM Tris-
HCl, pH 7.5.  Enzyme was eluted with a solution of 500 mM NaCl and 20 mM Tris-HCl of 
the same pH.  After pressure concentration (Amicon PM-30 membrane) and dialysis against 
10 mM Tris-HCl, pH 8.0, the protein sample was loaded onto a DEAE sepharose column 
equilibrated with 10 mM Tris-HCl, pH 8.0.  Purified enzyme was eluted with a NaCl gradient 
(0–0.5 M) in 10 mM Tris-HCl, pH 8.0, and then dialyzed extensively against 50 mM Hepes, 
pH 7.4.  Purity and protein concentrations of FBPase preparations were confirmed by SDS-
polyacrylamide gel electrophoresis (25) and the Bradford assay (26), respectively. 
Crystallization of the product complex Crystals of Asp10 FBPase were grown by the 
method of hanging drops.  Equal parts of a protein solution and a precipitant solution were 
combined in a droplet of 4 L total volume.  Wells contained 500 L of the precipitant 
solution.  R-state crystals grew from a protein solution [Asp
10
 FBPase (10 mg/ml), Hepes (25 
mM, pH 7.4), MgCl2 (5 mM), and Fru-1,6-P2 (5 mM)] combined with a precipitant solution 
[Hepes (100 mM, pH 7.4), polyethylene glycol 3350 (8% (w/v)), glycerol (27% (v/v)), and t-
butanol (5% (v/v))].  Crystals of the T-like AMP complex grew from a protein solution 
[Asp
10
 FBPase (10 mg/ml), Hepes (25 mM, pH 7.4), ZnCl2 (5 mM), Fru-1,6-P2 (5 mM), and 
AMP (5mM)] combined with a precipitant solution [Hepes (100 mM, pH 7.4), polyethylene 
glycol 3350 (12% (w/v)), glycerol (23% (v/v)), and t-butanol (5% (v/v))].  Crystals of the T-
state AMP complex grew from a protein solution [Asp
10
 FBPase (10 mg/ml), Hepes (25 mM, 
pH 7.4), MgCl2 (5 mM), Fru-1,6-P2 (5 mM), and AMP (5 mM)] combined with a precipitant 
solution [Hepes (100 mM, pH 7.4), polyethylene glycol 3350 (14% (w/v)), 2-methyl-2,4-
pentanediol (21% (v/v)), and t-butanol (5% (v/v))].  Crystals were of equal dimensions (0.2–
0.4 mm), growing in approximately three days at 20 C.  Conditions of crystallization include 
cryoprotectants, allowing crystals to be transferred directly from droplet to liquid nitrogen. 
Data collection Data were collected at Brookhaven National Laboratory on beamlines 
X4A (R- and IT-state structures) and X12C (T-state structure) at a temperature of 110 K.  
Data were reduced with the program HKL (27). 
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Structure determination, model building and refinement Crystals of Asp10 FBPase are 
isomorphous to either the AMP•Zn2+•product complex (18) or the Zn2+•product complex (10).  
Phase angles, used in the generation of initial electron density maps, were based on model 
1EYJ or 1CNQ of the PDB, from which water molecules, metal cations, small-molecule 
ligands, and residues 5072 had been omitted.  Residues 5072 were built into the electron 
density of omit maps, using the program XTALVIEW (28).  Ligands were added to account 
for omit electron density at the active site and/or the AMP site.  The resulting models 
underwent refinement, using CNS (29) with force constants and parameters of 
stereochemistry from Engh & Huber (30).  A cycle of refinement consisted of slow cooling 
from 1000–300 K in steps of 25 K, followed by 120 cycles of conjugate gradient 
minimization, and concluded by the refinement of individual thermal parameters.  Thermal 
parameter refinement employed restraints of 1.5 Å
2
 on nearest neighbor and next-to-nearest 
neighbor main chain atoms, 2.0 Å
2
 on nearest neighbor side chain atoms, and 2.5 Å
2
 on next-
to-nearest neighbor side chain atoms. 
In subsequent cycles of refinement, water molecules were fit to difference electron 
density of 2.5 or better and were added until no significant decrease was evident in the Rfree 
value.  Water molecules in the final models make suitable donor-acceptor distances to each 
other and the protein and have thermal parameters under 60 Å
2
.  Stereochemistry of the 
models was examined by the use of PROCHECK (31). 
Measurement of the rotation angle Hines et al. (32) defined the rotation angle by 
alignment to the R-state structure.  This method is intractable in determining subunit-pair 
rotations of thousands of structures from MD trajectories.  Subunit-pair rotations from MD 
simulations are determined as follows: Firstly, Cα atoms of residues 33–49, 75–265 and 272–
330 define the center of mass of each subunit.  Secondly, the acute angle defined by the line 
segments connecting mass centers within the subunit pair (C1 and C2 or C3 and C4) is taken 
as the subunit-pair rotation angle.  Subunit-pair rotation angles for R-, IR-, IT- and T-states 
become 15.1, 18.2, 24.6 and 28.6°, respectively, corresponding to 0, 3, 12, 15° as determined 
by superpositions of crystal structures. 
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MD simulations MD simulations here employed NAMD (33) with the CHARMM 27 force 
field (34).  The initial coordinates for R- IR-, and IT- and T-states were RCSB database 
entries 1CNQ, 1YYZ, 2F3D, and 1EYJ, respectively (10).  The system included an entire 
tetramer of FBPase and approximately 30,000 TIP3P water molecules (35) in a rectangular 
water box with a buffering distance of 15 Å.  Sodium and chloride ions were added to 
neutralize the net charge of system.  Periodic boundary conditions were applied and the 
Particle mesh Ewald algorithm (36) was used for the calculation of long-range electrostatic 
interactions.  The cutoff was set to 12 Å for non-bonded Van der Waals interactions and the 
integration time step was 2.0 fs.  All models were energy-minimized for 10 ps and gradually 
heated to 310 K to relax unfavorable contacts (if any), followed by another 10 ps simulation 
to equilibrate the system.  Finally, simulations of 15 ns were carried out with constant 
pressure and temperature (1.01325 bar at 310 K).  Results from simulation were analyzed 
with VMD (37) and user-written programs described in the next section. 
Principal component analysis (PCA) Motions from MD simulations can be recast into an 
orthogonal set of principal components, each of which corresponds to a specific motion and 
amplitude.  Principle components with large amplitudes correspond to collective motions in 
protein, which can be important functionally (38, 39).  Principle components were calculated 
as follows: A covariance matrix C was calculated from the MD trajectory as: 
   jjiiij rrrrC 
,    Eqn. 1 
where i,j = 1,...3N, N is the total number of Cα atoms in the structure, r is the Cartesian 
coordinates of i
th
 Cα atom, and the angle brackets denote an average over the entire MD 
trajectory.  Rigid-body translations and rotations of the tertramer were removed before PCA 
by aligning trajectory structures onto the starting structure.  3N eigenvectors and associated 
eigenvalues were obtained by diagonalization of the matrix C.  Each eigenvector corresponds 
to a principal component of motion and the associated eigenvalue reflects its contribution to 
the collective motion.  The root-mean-square inner product (RMSIP, 40) was used to 
compare PCA results from different trajectories: 
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,  Eqn. 2 
where νi and νj are the i
th
 and j
th
 eigenvectors of the two sets having the ten largest associated 
eigenvalues. 
Targeted molecular dynamics simulations (TMD) Details of the TMD procedure are in the 
original paper (41) and early applications (42, 43).  TMD employs an artificial energy 
constraint to force a conformational change toward a target structure, and can be a powerful 
tool in the exploration of transition pathways (42-45).  The energy constraint is as follows: 
 
 2* )()(
2
1
tRMStRMS
N
k
UTMD 
, Eqn. 3 
where k is the force constant, N is the total number of atoms, RMS(t) is the root-mean-
squared deviation (RMSD) between a given trajectory structure and the target structure at 
transition time t while the RMS*(t) is the expected RMSD, assuming a linear decrease in 
RMSD proportional to time.  TMD simulations here employed NAMD under the CHARMM 
27 force-field with an integration time step of 1 fs.  As the starting and target structures 
should have the same atoms, residues 6-9 and two Mg
2+
 in the R-state structure and AMP in 
T-state structure were removed.  The simulation system included 10659 TIP3P water 
molecules and 20364 protein atoms (the value of N in Eqn. 3).  The initial and target 
structures were energy-minimized and equilibrated, followed by the TMD simulations at 
constant temperature (310 K).  TMD simulations were performed with different time steps 
and force constants to determine the sensitivity of the observed transition pathways to 
parameters of the simulation. 
 
Results 
Rationale for the Ile
10→Asp mutation— The side chain of Ile10 packs against hydrophobic 
residues from loop 190 in the R-state, and against hydrophobic residues of the disengaged 
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dynamic loop in the T-state.  (Figures of Ile
10
 and nearby residues are in references 14 and 
16).  The Ile
10→Asp mutation then introduces an electrostatic charge that destabilizes the R- 
and T-states.  The R-state hydrophobic cluster is not present in the R-like AMP complex (14), 
and hence, Ile
10→Asp should have little or no effect on the stability of intermediate 
quaternary states with engaged dynamic loops.  Moreover, as Zn
2+
 (relative to Mg
2+
) 
stabilizes the engaged conformation of the dynamic loop by fully occupying metal site-3 of 
the active site (10, 18), the AMP•Zn2+•product complex of Asp10 FBPase offers a reasonable 
opportunity to capture an intermediate quaternary state of FBPase with bound AMP and an 
engaged dynamic loop. 
Product complex of Asp
10
 FBPase (PDB identifier 2F3B) Preparations of Asp10 FBPase 
used here are at least 95% pure, as judged by SDS-polyacryamide gel electrophoresis (data 
not shown).  Gels indicated no proteolysis of the purified enzyme. 
Crystals (space group I222, a=52.94, b=82.50 and c=165.0 Å) are isomorphous to 
those of wild-type FBPase in its R-state, containing one subunit of the tetramer in the 
asymmetric unit of the crystal (10, 18–20).  The model begins at residue 10 (electron density 
for residues 19 is weak or absent) and continues to the last residue of the sequence.  
Thermal parameters vary from 11 to 55 Å
2
.  This and all other models presented here have 
stereochemistry comparable to that of structures of equivalent resolution (31).  Statistics for 
data collection and refinement are in Table 1. 
The product complex of Asp
10
 FBPase has one molecule each of Fru-6-P and Pi 
bound to the active site with three atoms of Zn
2+
.  The dynamic loop (residues 5072) is in 
its engaged conformation.  We refer the reader to other descriptions of R-state product 
complexes (10, 18–20) for more detailed descriptions of active site interactions. 
Superposition reveals a close match to the wild-type R-state; however, deviations in 
the relative positions of C atoms in excess of 0.5 Å are evident for residues 10–19 (Fig. 1).  
Asp
10
 has dissociated from the hydrophobic surface against which Ile
10
 packs in the R-state 
of the wild-type tetramer.  Helix H1 shifts essentially as a rigid body, and its movement 
perturbs the connecting element between helices H1 and H2 that contains residues critical to 
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the recognition of AMP.  The mutation of Ile
10
 to aspartate and the binding of AMP to Leu
54
 
FBPase (14) have comparable effects on helix H1 and the conformation of its N-terminal 
segment. 
AMP•product T-like complex of Asp10 FBPase (PDB identifier 2F3D) Crystals 
(space group I222, a=55.84, b=82.50 and c=165.0 Å) contain one subunit in the asymmetric 
unit and are nearly isomorphous to those of wild-type FBPase R-state crystals (10, 18–20).  
The model begins at residue 10 (electron density absent for residues 1–9) and continues to 
the last residue of the sequence.  Thermal parameters vary from 9 to 59 Å
2
. 
The subunit of the AMP/product complex of Asp
10
 FBPase has one molecule each of 
Fru-6-P and Pi with three atoms of Zn
2+
 at the active site (Fig. 2).  In addition, strong electron 
density for bound AMP is present in the allosteric inhibitor pocket.  The dynamic loop 
(residues 5072) adopts the engaged conformation.  Superposition of the Asp10 tetramer onto 
canonical wild-type R- and T-states reveals an intermediate quaternary state in which 
subunit-pair C1–C2 has rotated approximately 12° relative to subunit pair C3–C4.  The 
subunit-pair rotation is near that of the wild-type enzyme in its complex with the allosteric 
inhibitor OC252 (15). 
The superposition of the IR-state subunit (AMP complex of Leu
54
 FBPase) onto 
subunits of the IT-state tetramer of the AMP complex of Asp
10
 FBPase reveals tertiary 
conformational changes that accompany the 9º subunit-pair rotation from the IR- to IT-states.  
For the most part, changes in the relative positions of Cα atoms are less that 0.2 Å; however, 
shifts in Cα atoms of 0.5–4.0 Å define four symmetry-related bands, connecting the AMP 
binding sites of subunits C1, C2, C3, and C4 to the active sites of subunits C2, C1, C4, and 
C3, respectively (Fig. 2).  Shifts extend from the AMP molecule to helix H1, from helix H1 
to loop 190, and then across subunit boundaries to the dynamic loop. 
AMP and helix H1 move through comparable displacements of 0.5–1.0 Å during the 
IR- to IT-state transition (Fig. 3, top).  In the IT-state structure, Thr
39
 hydrogen bonds with 
Glu
192
 of a neighboring subunit (C1–C4 contact); this hydrogen bond was disrupted in the 
AMP complex of Leu
54
 FBPase (14).  The movement in helix H1 carries over to residues 
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194–197, and from there to residues 53–55 of the dynamic loop (Figure 3, middle).  The 
entire dynamic loop shifts toward Arg
313
 by approximately 0.5 Å.  In contrast, residues 264–
274 move in opposition to the general thrust of the dynamic loop, generating tight contacts 
(Figure 3, bottom).  In the IR-state, the side chain of Arg
313
 hydrogen bonds with the 
backbone carbonyls of residues 66 and 274 (donor-acceptor distances of 2.8–2.9 Å), and is in 
contact with the Cβ atom of Thr66 (distance of 3.6 Å).  In the IT-state, however, the donor-
acceptor contacts diminish to 2.5 Å, and the contact involving the Cβ atom of Thr66 becomes 
2.9 Å.  In short, the transition from the IR- to IT-state lessens the space for the engaged 
conformation of the dynamic loop. 
The movement in loop 264–274 is relatively large (up to 4 Å), and results in the 
elimination of a tight internal contact between the backbone carbonyl group of residue 272 
and the backbone amide group of residue 314.  In the IR-state (as well as the R-state), the 
contact distance is approximately 2.8 Å.  Although the contact distance is reasonable for a 
donor-acceptor pair, the axis of the backbone carbonyl 272 is perpendicular to the plane of 
the peptide link between residues 313 and 314.  Hence, an unfavorable contact exits between 
residues 272 and 314 in the IR-state, and a small rotation of the carbonyl group of residue 272 
relieves this tight contact in the IT-state (contact distance becomes 3.1 Å), and drives the 
observed motion of loop 264–274 in the IR- to IT-state transition. 
AMP/product T-state complex of Asp
10
 FBPase (PDB identifier 2F3H) Crystals (space 
group P21212, a=60.28, b=167.0 and c=79.06) are isomorphous to those of AMP complexes 
of FBPase (16, 17).  The subunit pair C1–C2 is in the asymmetric unit of this crystal form.  
The model begins at residue 10 and continues to the last residue of the sequence, but segment 
5572 is unreliable, as evidenced by thermal parameters as high as 100 Å2.  The enzyme in 
this crystal form is in the T-state (quaternary transition angle of 15°); however, unlike loop-
disengaged AMP complexes of the wild-type enzyme, the dynamic loop in T-state Asp
10
 
FBPase is disordered.  The active site retains Fru-6-P and Mg
2+
 bound to site 1.  Conditions 
of crystallization of the T-state and IT-state AMP complexes of Asp
10
 FBPase differ only in 
the type of metal ion, Mg
2+
 for the former and Zn
2+
 for the latter.  As anticipated, the 
Ile
10→Asp mutation has destabilized the disengaged conformation of the dynamic loop. 
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MD simulations of FBPases— Structures were stable over simulations of 15 ns as indicated 
by the time evolution of the energy function and root-mean-squared displacements in Cα 
atoms.  Hydrogen and coordinate bonds involving protein residues and active-site ligands 
were stable.  Although Asp
68
 and Arg
276
 remained bonded to the Mg
2+
 at site 3 and to Pi, 
respectively, the hydrogen bond between Asp
68
 and Arg
276
 observed in crystal structures was 
disrupted early in all simulations without noticeable secondary responses.  Subunit-pair 
rotations for the R-, IR-, IT- and T-states averaged to 15, 19, 29 and 29°, respectively, with 
standard deviations of approximately 1° and extremes of ±3°.  The average values remain 
close to the starting crystallographic angles (15.1, 18.2, 24.6 and 28.6°, respectively) except 
for the IT-state, which drifted toward the canonical T-state.  Dynamic loops remained in 
engaged conformations during the R-state simulation; however, in the IR- and IT-state 
simulations, residues 59–70 and loop 264–274 of one subunit exhibited substantial transitory 
movements readily seen as high fluctuations (Fig. 4).  Residues 59–70 (hairpin turn of the 
engaged loop) exit the active site as observed in first stage of loop displacement in targeted 
molecular dynamics (see next section). 
PCA of residues 5072 and 264274 in each subunit of the R-, IR- and IT-state 
simulations reveal relatively simple motions for the first 10 eigenvectors representing 
collectively 50% of the total motion.  Root-mean-squared inner products (RMSIP, 40) 
between the first 10 eigenvectors from each subunit exceed 0.5, indicating similar motions 
for all subunits in all states.  Segments 5972 and 264274 have correlated and anti-
correlated motions (Fig. 5).  Correlated motions between these segments preserve contact 
distances, whereas anti-correlated motions periodically increase and decrease contact 
distances.  Anti-correlated motions involving segments 5972 and 264274 cause significant 
steric clashes, which tend to force the dynamic loop out of its engaged conformation.  Both 
correlated and anti-correlated motions have similar magnitudes in the R-, IR- and IT-states; 
however, in the T-state the amplitude decreases by 50% (Fig. 6A).  In subunit C3 of the IR-
state and subunit C4 of the IT-state, the amplitude of the anti-correlated motions exceeds that 
of the correlated motions (Fig. 6B).  These are subunits in which engaged loops become 
transiently displaced from the active site during the simulation. 
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TMD simulation of the R- to T-state transition— R- and T-state FBPase define the extremes 
of TMD simulations with force constants (k) of 10, 100, 1000, 10000 kcal•mol−1•Å−2 
distributed over 20364 atoms.  The highest force constant represents a force per atom 
substantially less than that of a hydrogen bond.  The RMSD for k=10 kcal•mol−1•Å−2 drops 
from 6.3 to 5.7 Å over the simulation largely due to an increase of 5° in the subunit-pair 
rotation (Fig. 7A).  The dynamic loop, however, remains in place (RMSD declines from 7.4 
to 7.0 Å).  Force constants of 100 and 1000 kcal•mol-1•Å−2 drive the subunit-pair rotation to 
completion, with final RMSD values of 3.5 and 1.2 Å, respectively.  For k=100 
kcal•mol−1•Å−2, residues 5972 dissociate from the active site while residues 5058 remain 
in the engaged conformation.  For k=1000 kcal•mol−1•Å−2, the entire dynamic loop 
dissociates from the active site, and with a force constant of 10000 kcal•mol−1•Å−2), the 
structure goes to the T-state (final RMSD <0.5 Å).  For the latter simulation, subunit-pairs 
first rotate through ~15°, and then loops move out of their engaged conformation to the 
disengaged conformation. 
Simulations with transition times from 200–2000 ps with k=10000 kcal•mol−1•Å−2 are 
similar in appearance (Fig. 7B).  The simulation with a transition time of 2000 ps (final 
RMSD 0.36 Å relative to T-state) reveals four stages: (i) subunit-pair rotation of ~15°, 
dynamic loops remains engaged, (ii) hairpin turn of the dynamic loop (residues 59-72) exits 
the active site, (iii) residues 56 and 57 leave hydrophobic pockets of the engaged conformer 
followed by loss of helical conformation for residues 50–53, and (iv) residues 54–58 become 
coiled followed by a rapid acquisition of the disengaged conformation (Fig. 8). 
 
Discussion 
Studies here and elsewhere are consistent with the following sequence of events in 
the R- to T-state transition: two AMP molecules bind to the R-state, disrupting hydrogen 
bonds (Thr
39
 to Glu
192
) across the C1–C4 interface (14).  The disrupted hydrogen bonds 
reform after a sterically unhindered subunit-pair rotation of 12–14°.  Movements in structural 
elements across the C1–C2 interface (Fig. 2) attend the subunit-pair rotation, creating tight 
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contacts at the hinges and hairpin turns of engaged loops (Fig. 3).  High-amplitude modes 
(Fig. 5&6) exacerbate these contacts, displacing loops from the active site.  The displaced 
dynamic loop undergoes conformational change (Fig. 8), leading to the formation of a cluster 
of hydrophobic residues in the canonical T-state.  The R- to T-state transition pathway from 
TMD simulation agrees well with observed crystals structures (Fig. 9), passing through the 
IR- and IT- states to the T-state before the engaged dynamic loop undergoes its transition to 
the disengaged conformation. 
The reduction of space for the engaged loop comes by direct action of AMP moving 
helix H1 into residues 194–197 and indirectly through subunit-pair rotation.  Loops 190 from 
subunits C1 and C4 are in contact, and subunit-pair rotation mutually pushes each loop 
toward the hinge of the dynamic loop.  The entire dynamic loop translates toward loop 264–
274, causing a conformational change in that loop.  That change was noted previously in a 
comparison of R- and T-state structures, but dismissed as an artifact of different packing 
environments in crystal forms of FBPase (10).  Crystals of the R-, IR-, and IT-states of 
FBPase, however, are nearly isomorphous with a maximum change of 5% in the b parameter 
of the unit cell.  Hence, conformational changes in loop 264–274 are an integral part of the 
quaternary transition. 
Molecular dynamics simulations indicate little steric hindrance in subunit-pair 
rotations at any point in the R- to T-state transition.  During simulations of the R-, IR-, IT- and 
T-states, subunit-pair rotations wander over a range of 6°.  Even with minimal force 
constants employed in targeted molecular dynamics, the change in the subunit-pair rotation 
proceeds smoothly (Fig. 7).  As the binding of AMP to the R-state causes a loss of hydrogen 
bonds across the C1–C4 interface (14), AMP could facilitate subunit-pair rotation by 
weakening interactions between the C1-C4 interfaces. 
The stepwise displacement of the loop from its engaged conformation in targeted 
molecular dynamics simulations has support from crystallography.  Residues 59–72 (hairpin 
turn of the engaged loop) are the first to exit the engaged conformation in simulations, an 
event that requires the disruption of the coordinate bond between Asp
68
 and the metal at site 
3.  Residues 59–70 are disordered in a crystal structure at high ionic strength (19), consistent 
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with the partial dislocation of the dynamic loop.  The second step of loop displacement is the 
release of Tyr
57
 from its hydrophobic pocket, after which the RMSD decays exponentially.  
In several crystal structures the entire loop is disordered (14, 18, 19, 23, 24).  Such disorder 
could be due to inter-conversion between conformers as the loop relaxes toward its 
disengaged conformation.  The final step is a formation of residues 54–58 into a short helix 
and the rapid acquisition of the disengaged conformation (crystallographic T-state). 
As the catalytic loop remains engaged over 12–14° of subunit-pair rotation, the 
enzyme is likely active in quaternary states of intermediate rotation (such as the IT-state).  
The observation (16) of potent but partial AMP inhibition of Asp
10
 FBPase is probably due to 
an active AMP-bound IT-state, which accommodates the engaged dynamic loop, albeit with 
elevated steric stress.  Other mutations of FBPase have resulted in partial inhibition at 
saturating levels of AMP (48, 50–51).  For these, investigators have suggested an active T-
state (52), but as demonstrated here by the AMP complex of Asp
10
 FBPase, the inability to 
form the disengaged conformation of the loop could leave the tetramer in an intermediate 
quaternary state.  Leu
54
 FBPase may be an extreme case in which the AMP-bound enzyme 
remains in a near R-state. 
High-amplitude modes are a characteristic in the functional transitions of other 
systems (39, 53-57).  Such modes play roles in the extraction cycle of myosin (53), allosteric 
activation of epidermal growth factor receptor (56), substrate specificity of α-lytic protease 
(39) and substrate induced conformational changes (55, 55, 57).  There are two perspectives 
regarding the coupling of motion to macromolecular function.  Specific motions can facilitate 
ligand-induced conformational change, such as for the myosin motor (53).  Alternatively, 
molecular motion can establish a pre-existing equilibrium of conformational states, some 
subset of which is recognized by the ligand (58).  In the case of mammalian FBPase, the apo-
enzyme could exist in a variety of quaternary states.  But under physiological conditions 
(substrate and metals present), the enzyme favors the R-state, and AMP-inhibition is 
necessarily an induced process.  AMP binds to the R-state as demonstrated by hybrid 
tetramers with a single functional AMP site (49) and by crystallographic investigations of 
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Leu
54
 FBPase (14).  The role of dynamics then for mammalian FBPase comes in the 
displacement of the engaged dynamic loop and relaxation to the inactive state. 
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Table 1.  Statistics of data collection and refinement for Asp
10
 FBPase. 
Crystalline complex
a
 R-state IT-state T-state 
Resolution limit (Å) 1.80 1.83 2.7 
Number of measurements 784,010 707,677 380,196 
Number of unique reflections 31,968 40,278 31,820 
Completeness of data (%): 
    Overall 93.7 94.7 93.1 
    Last shell/resolution-range (Å) 74.3/1.86-1.80 93.6/1.91-1.83 95.7/2.85-2.7 
Rsym
b
  
    Overall 0.062 0.055 0.167 
    Last shell/resolution-range (Å) 0.095/1.86-1.80 0.118/1.91-1.83 0.332/2.85-2.7 
Number of reflections in refinement 30,433 32,827 18,448 
Number of atoms 2,672 2,736 5,307 
Number of solvent sites 179 186 201 
Rfactor
c
 0.226 0.214 0.198 
Rfree
d
 0.25 0.243 0.284 
Mean B (Å
2
) overall/protein 23/22 25/24 40/40 
Mean B (Å
2
) for AMP - 36 37/31 
Root mean square deviations (deg): 
    Bond lengths (Å) 0.005 0.005 0.006 
    Bond angles 1.4 1.3 1.3 
    Dihedral angles 22.9 22.7 23.1 
    Improper angles 0.76 0.76 0.77 
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a 
Unit cell lengths (a, b, c) in Å for the R-, IT- and T-state complexes are (52.94, 82.50, 
164.96), (55.84, 82.50, 165.02), and (60.28, 167.00, 79.06), respectively.  Unit cell angles (, 
, ) are 90 for space groups I222 and P21212. 
b 
Rsym = ji | Iij - <Ij> | /ijIij, where i runs over multiple observations of the same intensity, 
and j runs over all crystallographically unique intensities. 
c 
Rfactor =  || Fobs | - | Fcalc || / | Fobs |, where | Fobs | > 0. 
d 
Rfree based upon 10% of the data randomly culled and not used in the refinement. 
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Figure 1.  Conformational changes in the R-state structure of Asp
10
 FBPase.  The side chain of Asp
10
 
projects into the solvent, away from the hydrophobic surface against which Ile
10
 packs in the wild-type enzyme.  
Conformational differences are limited to those shown (helix H1 and the connecting element between helices 
H1 and H2).  Black lines represent the R-state of the wild-type enzyme (RCSB 1CNQ) and open lines represent 
R-state Asp
10
 FBPase.  This drawing was prepared with MOLSCIRPT (59). 
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Figure 2.  AMP/product complex of Asp
10
 FBPase.  Overview of the complex (left).  Subunits of the tetramer, 
labeled C1 through C4, have each one molecule of bound AMP, Fru-6-P (labeled F6P) and Pi, and three atoms 
of Zn
2+
.  Side chains of Asp
10
 from subunits C1 and C3 are omitted for clarity.  Residues 10–25 (helix H1, 
subunits C1 and C3), 187–195 (loop 190, subunits C1 and C3), 50–72 (dynamic loop, subunits C2 and C4), and 
264–274 (subunits C2 and C4) are in bold lines.  Rotation of the tetramer by 45° about the horizontal twofold 
axis (right).  IR-state subunits from Leu
54
 FBPase (red lines) are superimposed on the subunits of the IT-state 
Asp
10
 tetramer (black lines).  Shown only are Cα-atoms of the IR subunit that deviate from those of the IT 
structure by more than 0.5 Å.  This drawing was prepared with MOLSCIRPT (59). 
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Figure 3.  Stereoviews of tertiary conformational changes between the IR- and IT-states.  Dotted lines 
represent selected donor-acceptor interactions of 3.2 Å or less.  Double-headed arrows represent tight contacts 
less than 3 Å.  Superposition of the IR-state subunit from the AMP complex of Leu
54
 FBPase (red) onto each 
subunit of the AMP complex of Asp
10
 FBPase (black) reveals conformational change induced by a 9º subunit-
pair rotation.  Conformational changes at the AMP binding site (top),  conformational changes from helix H1 to 
loop 190 and then across a subunit interface to hinge residues of the dynamic loop (middle), and conformational 
changes in the hairpin turn of the dynamic loop, loop 264–274 and Arg313 (bottom) are shown.  This drawing 
was prepared with MOLSCIRPT (59). 
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Figure 4.  Molecular dynamic simulations of FBPase.  Time evolution of subunit-pair rotation angles (panel 
A) and root-mean-square (RMS) fluctuation as a function of residue index (panel B) from 15 ns simulations of 
the R-, IR-, IT- and T-state of FBPase.  Solid lines in panel B represent fluctuations averaged over all four 
subunits, whereas dashed curves for the IR- and IT-states are RMS fluctuations for subunits C3 and C4, 
respectively. 
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Figure 5.  PCA analysis of the dynamic loop.  A. Locations of segments 68-72 (red) and 264-274 (green) in 
the tertiary structure of the subunit along with correlated and anti-correlated motions of each segment shown by 
arrows.  Images are prepared with PYMOL (60).  B. Examples of high-amplitude correlated (upper) anti-
correlated (lower) modes from PCA analysis.  Blue off-diagonal elements represent strong anti-correlated 
motions between pairs of residues, whereas red off-diagonal elements represent correlated motions. 
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Figure 6.  Cumulative involvement coefficients of anti-correlated and correlated motions. Cumulative 
involvement coefficients of R-, IR-, IT- and T-state of FBPase were plotted against the principal component 
index (A).  Red lines indicate correlated motions between loop 58-72 and loop 264-274 and blue lines indicate 
the anti-correlated motions.  The cumulative involvement coefficients of subunit C3 in the IR-state and subunit 
C4 in IT-state are drawn in dotted lines (B).  In instances of loop displacement, the anti-correlated motions 
dominate the correlated motions. 
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Figure 7.  TMD simulation of the R- to T-state transition.  A. TMD simulations with different force 
constants.  Lines go from light grey to black with increasing force constant corresponding to k = 10, 100, 1000 
and 10000 kcal/mol/Å
2
.  B. TMD simulations with different time steps (light grey, 200 ps; grey, 500 ps; dark 
grey, 1000 ps; black, 2000 ps).  Panels on the left in A and B show subunit-pair rotation angle versus simulation 
time.  Those on the right show RMSD change for residues of the dynamic loops versus simulation time. 
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Figure 8.  Displacement of the dynamic loop.  A. TMD simulation (2000 ps) with force constant k=10000 
kcal/mol/Å
2
 reveals distinct steps in loop displacement (Stages I-IV).  Each curve tracks the RMSD of the loop 
for each subunit of the tetramer.  B.  Illustration of the dynamic loop at the onset of each stage.  This illustration 
was prepared with PYMOL (60).   
  
41 
 
 
Figure 9.  R- to T-state transition from TMD simulation. The TMD trajectories of the R- to T- transition are 
projected onto a two dimensional plane determined by the loop displacement (y-axis) and subunit-pair rotation 
angle (x-axis).  Data points provided by crystal structures are represented by tetramer icons.  The simulation 
indicates subunit-pair rotation beyond 15° followed by loop displacement and relaxation to the canonical T-state. 
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Abstract 
AMP transforms porcine fructose-1,6-bisphosphatase (FBPase) from an active R- to 
an inactive T-state.  Intermediate quaternary states (IR, IT and TF) lie on the transition 
pathway between the R- and T-state extremes, as revealed by crystal structures.  As many as 
48 ordered water molecules occupy the cavity at the center of the FBPase tetramer, and in the 
IR-state, water molecules define ordered clathrate-like structures.  Molecular dynamics 
simulations here of FBPase tetramers in R-, T- and intermediate quaternary states reveal 
water structures in the central cavity comparable to those observed in crystal structures.  The 
water structure has optimal stability in the cavities of intermediate quaternary states, and is a 
single stable cluster in the IR-state.  In order to determine whether water molecules of the 
central cavity influence functional properties and the quaternary state, aqueous/organic 
solvents were employed in kinetics and crystallization experiments.  In the presence of 1,2-
ethanediol, 1,2-propanediol, glycerol, xylitol, or sorbitol, Asp
10
 FBPase became 
progressively more active in the presence of saturating levels of AMP.  Under the same 
solvent conditions, crystal structures of Leu
54
 FBPase exhibited decreasing amounts of 
subunit-pair rotation relative to the R-state.  These results establish a correlation between 
AMP inhibition and the quaternary state of FBPase, and moreover implicate solvent 
organization in the central cavity as a determinant of FBPase function and conformation. 
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Introduction 
Fructose-1,6-bisphosphate (D-fructose-1,6-bisphosphate 1-phosphohydrolase; EC 3. 1. 
3; FBPase
1
) catalyzes a regulated step in gluconeogenesis, the degradation of fructose 1,6-
bisphosphate (Fru-1,6-P2) to fructose 6-phosphate (Fru-6-P) and phosphate (Pi) (1, 2).  
Divalent cations (Mg
2+
, Mn
2+
, or Zn
2+
) are essential for phosphatase activity.  Fructose 2,6-
bisphosphate (Fru-2,6-P2) and AMP are physiological inhibitors of eukaryotic FBPases.  The 
same effectors activate fructose-6-phosphate-1-kinase (the counterpart of FBPase in 
glycolysis) in the phosphorylation of Fru-6-P by ATP (3-8).  Fru-2,6-P2 binds to the active 
site of FBPase, competing with Fru-1,6-P2 (4, 5).  AMP is a non-competitive inhibitor with 
respect to substrate, and inhibits FBPase with positive cooperativity (3).  Fru-2,6-P2 enhances 
AMP inhibition in eukaryotic FBPases, a phenomenon called AMP/Fru-2,6-P2 synergism 
(4,5).  The concentration of AMP in vivo is relatively constant while that of Fru-2,6-P2 is 
dynamic and under hormone control (9,10).  Given the important regulatory role of FBPase 
in glucose metabolism, FBPase is a drug target for the treatment of type II diabetes (11-18).  
Understanding regulatory mechanisms of FBPase should facilitate the rational design of 
drugs. 
FBPase has been a subject of extensive structural studies (19-26).  Porcine FBPase, 
taken as a model for eukaryotic FBPases, is a homotetramer of 37 kDa subunits in a near 
square-planar arrangement.  Complexes of enzyme with products (Fru-6-P and Pi) and three 
divalent cations define the active R-state (20, 22).  In several complexes, the metal ion at site 
1 coordinates to the 1-OH group of Fru-6-P, whereas metals at sites 2 and 3 coordinate Pi and 
a loop (loop 50-72) essential for catalysis.  Such R-state complexes define the engaged 
conformation of loop 50-72 (22).  AMP binds to sites at least 30 Å from the nearest active 
site and transforms the tetramer into an inactive T-state (19, 23). 
T-state FBPase differs from the R-state by a 15° subunit-pair rotation and a 
disengaged conformation for loop 50-72 (23).  Competitive inhibition of AMP with respect 
to Mg
2+
 in kinetics is consistent with the absence of metals at sites 2 and 3 in AMP/product 
complexes (23).  Fru-2,6-P2 is a competitive inhibitor with respect to Fru-1,6-P2 (4, 5), and 
binds at the active site in crystallographic complexes causing a subunit-pair rotation (13°) 
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similar to that caused by AMP (24).  Moreover, loop 50-72 is in its disengaged conformation 
in Fru-2,6-P2 complexes of porcine FBPase, which is defined here as the TF-state.  The 
similar end-states induced by AMP and Fru-2,6-P2 is the likely basis of AMP/Fru-2,6-P2 
synergism (24). 
Intermediate states have been trapped by crystallizing mutant FBPases (Ala
54→Leu 
or Ile
10→Asp) that destabilize the disengaged conformation of loop 50-72 under conditions 
that favor the canonical T-state (25, 26).  Asp
10
 FBPase is subject to biphasic inhibition by 
AMP.  AMP causes maximal partial inhibition up to concentrations of 100 μM, but no 
additional inhibition until concentrations exceed 1 mM (27).  Biphasic inhibition indicates 
the presence of an intermediate quaternary state, and consistent with this hypothesis, the 
AMP complex of Asp
10
 FBPase is in a T-like quaternary state (IT, 12° subunit-pair rotation, 
engaged loop 50-72).  In contrast, Leu
54
 FBPase is relatively insensitive to AMP inhibition, 
and its AMP complexes define an R-like state (IR, 3° subunit-pair rotation, engaged loop 50-
72).  The tertiary conformations and quaternary states together define a transition pathway 
from R- to T-state, in which subunit-pair rotation precedes displacement of loop 50-72 (26). 
In all conformers of porcine FBPase there exists a water-filled cavity at the center of 
the tetramer.  The protein surface of the central cavity is largely hydrophobic.  The Type I 
FBPase from Escherichia coli has a 41% sequence identity to porcine FBPase; however, the 
regulatory mechanism of E coli FBPase is distinct from its mammalian counterparts (28, 29), 
lacking AMP coopertivity and AMP/Fru-2,6-P2 synergism (24, 28).  Hydrophilic side chains 
fill the central cavity in E coli FBPase.  Many examples are in the literature of essential roles 
for buried waters molecules in protein folding, stability, flexibility, catalysis and ligand 
binding (30-34); however, a role for water molecules in the central cavity of mammalian 
FBPase is undetermined. 
Presented here is an analysis of the stability of water molecules in the central cavity 
of porcine FBPase and the potential structural and functional roles of such water molecules.  
Molecular dynamics (MD) simulations reveal sites of water localization and stability that are 
in agreement with crystallographic investigations.  Water stability is greatest in intermediate 
quaternary states with the dynamic loops in the engaged conformation, suggesting that the 
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formation of highly-ordered water structures in the central cavity may be linked to the 
quaternary state of FBPase.  Different aqueous/organic solvents were introduced to FBPase 
kinetics and crystallization experiments in order to modulate the structure of water in the 
central cavity.  The activity of FBPase in the presence of saturating AMP varies with the 
solvent system as does the quaternary state of FBPase crystallized from the same solvent 
system.  The level of inhibition by saturating AMP correlates well with the quaternary state 
observed in crystal structures, suggesting that changes in water structure within the central 
cavity could influence FBPase conformation and function. 
 
Experimental procedures 
Materials— Fru-1,6-P2, NADP, AMP, 1,2-ethandiol (ED), 1,2-propanediol (PD), xylitol and 
sorbitol were purchased from Sigma.  Glucose-6-phophate dehydrogenase and 
phosphoglucose isomerase were from Roche Applied Sciences.  FBPase-deficient E. coli 
strain DF 657 came from the Genetic Stock Center at Yale University.  Other chemicals were 
of reagent grade or equivalent. 
Expression and purification of FBPase— Asp10 and Leu54 mutations were the results of 
previous work (25, 27).  DNA sequencing done by Iowa State University sequencing facility, 
using the fluorescent dye-dideoxy terminator method, confirmed the constructs.  E. coli DF 
657 was used for the expression of FBPase.  After cell breakage and centrifugation, the 
supernatant was loaded onto a Cibracon Blue-Sepharose column equilibrated with 5 mM 
MgCl and 20 mM Tris-HCl, pH 7.5.  Enzyme was eluted with 5 mM AMP and 20 mM Tris-
HCl, pH 7.5.  The eluted protein sample was then loaded onto a DEAE-Sepharose column 
equilibrated with 20 mM Tris-HCl, pH 8.3.  Purified enzyme was eluted with a NaCl gradient 
(0–0.5 M) in 20 mM Tris-HCl, pH 8.3.  Enzyme was subjected to extensive dialysis against 
50 mM Hepes, pH 7.5, before kinetics or crystallization experiments.  Purity and protein 
concentrations of FBPase were confirmed by SDS-polyacrylamide gel electrophoresis (35) 
and the Bradford assay (36), respectively. 
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Kinetics— AMP inhibition assays employed the coupling enzymes, phosphoglucose 
isomerase, and glucose-6-phosphate dehydrogenase (1).  The reduction of NADP to NADPH 
was monitored by absorbance at 340 nm.  Assays were performed at 22 °C in 50 mM Hepes, 
pH 7.5.  Assay solutions contained EDTA and KCl at concentrations of 10 μM and 150 mM, 
respectively, and saturating levels of Fru-1,6-P2 (20 μM) and MgCl2 (5 mM). 
Crystallization of product complexes— Crystals of Leu54 FBPase in ED or PD were grown by 
the hanging drop method.  2 μl of protein solution and 2 μl of precipitant solution were 
combined in a droplet.  Wells contained 500 μl of the precipitant solution.  Crystals grew 
from a protein solution with Leu
54
 FBPase (10 mg/ml), Hepes (50 mM, pH 7.5), MnCl2 (5 
mM), Fru-1,6-P2 (5 mM), and AMP (5 mM) combined with a precipitant solution with Hepes 
(100 mM, pH 7.5), polyethylene glycol 3350 (12%, w/v), t-butyl alcohol (5%, v/v) and ED 
(25%, v/v) or PD (25%. v/v).  Crystals were of equal dimensions (0.2–0.4 mm), growing in 
approximately 3 days at 20 °C.  Crystals can be transferred directly from droplet to liquid 
nitrogen as conditions of crystallization include cryo-protectants. 
X-ray data collection, structure determination, and refinement— Data were collected at Iowa 
State University from single crystals on a Rigaku R-AXIS IV++ rotating anode/image plate 
system using CuKα radiation from an Osmic confocal optics system and a temperature of 110 
K.  Data were reduced with the program package d*trek (37). 
IR-state FBPase (PDBID: 1YYZ) was used in generating the initial structures by 
molecular replacement and electron density maps.  The resulting models underwent 
refinement using CNS (38) with force constants and parameters of stereochemistry from 
Engh and Huber (39).  A cycle of refinement consisted of slow cooling from 1000 to 300 K 
in steps of 25 K followed by 120 cycles of conjugate gradient minimization and concluded 
by the refinement of individual thermal parameters.  Restraints of 1.5 Å
2
 on nearest neighbor 
and next-to-nearest neighbor main chain atoms, 2.0 Å
2
 on nearest neighbor side chain atoms, 
and 2.5 Å
2
 on next-to-nearest neighbor side chain atoms were employed in thermal parameter 
refinement.  Water molecules were added to difference electron density of 2.5σ or better until 
no significant decrease was evident in the Rfree value.  Water molecules in the final models 
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fell within the allowed range for donor-acceptor distances and have thermal parameters under 
60 Å
2
.  Stereochemistry of the models was examined by the program PROCHECK (40). 
Analysis of central cavity— Surface area was measured by the rolling probe method with a 
probe radius of 1.4 Å (41).  Hydrophobicity of the central cavity was calculated as the 
fraction of total surface area of the cavity associated with carbon and sulfur atoms.  The 
volume of the central cavity was estimated by the summation of 0.1 Å cells contained within 
the cavity. 
Molecular dynamics (MD) simulations— MD simulations employed NAMD (42) with the 
CHARMM 27 force field (43).  The initial coordinates for R- IR-, and IT-, TF- and T-states 
came from RCSB database entries 1NUY, 1YYZ, 2F3D, 2QVV and 1EYK, respectively.  
The system included an entire tetramer of FBPase and approximately 30,000 TIP3P water 
molecules (44) in a rectangular water box with a buffering distance of 15 Å.  Sodium and 
chloride ions were added to neutralize the net charge of system.  Periodic boundary 
conditions were applied and the particle mesh Ewald algorithm (45) was used for the 
calculation of long-range electrostatic interactions.  The cutoff was set to 12 Å for non-
bonded Van der Waals interactions, and the integration time step was 2.0 fs.  All models 
were energy-minimized for 10 ps and gradually heated to 310 K to relax unfavorable contacts 
(if any), followed by another 10 ps simulation to equilibrate the system.  Protein backbone 
atoms were fixed in simulations to retain starting quaternary states and facilitate the analysis 
of the solvent structure.  Finally, simulations of 10 ns were carried out with constant pressure 
and temperature (1.01325 bar at 310 K). 
Structural clustering analysis— Fixed backbone atoms eliminated rigid-body motions over 
the simulation, allowing the direct comparison of water structure by structural clustering 
analysis.  Coordinates of water molecules within the cavity were recorded at 5 ps intervals 
during the last 5 ns of simulations (a total of 1000 sets).  Root mean square deviations 
(RMSD) between all pair wise combinations of coordinate sets were determined through an 
iterative process that began with the closest pair of water molecules, one molecule from each 
set.  The distance between matched water molecules separated by 3 Å or less contributed 
directly to the calculation of RMSD.  Otherwise a limiting value of 3 Å was used, reflecting a 
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match to a dummy water molecule.  The process resulted in the one-to-one mapping of water 
molecules from any given set onto water molecules or dummy water molecules of all other 
sets.  A 1000 by 1000 matrix, in which each element is a RMSD, resulted from the mappings.  
The structural clustering analysis followed the procedure described in ref 46.  The coordinate 
set which gave the most RMSD values below an arbitrary threshold of 1 Å was taken as the 
representative of the most prevalent water cluster. 
 
Results 
Central cavity of FBPase— The quaternary state of the protein largely defines the boundaries 
of central cavities; however, two channels connect the cavity to the bulk solvent.  These 
cavity openings, as well as the entire cavity, obey mutually intersecting twofold axes of 
symmetry of the tetramer.  The channels are roughly parallel to the symmetry axis extending 
from square-planar face of the tetramer (the ±x-direction of Fig. 1), and x-coordinates of 
minimum cavity surface (±6 Å) marks the boundaries between cavity and bulk solvent.  
Measured from its center, the cavity has dimensions of approximately 6, 10, and 12 Å on x, y, 
and z axes, respectively. 
Residues 44-49 from the C-terminus of helix H2, loop 186-192, and the beginning of 
loop 50-72 define the largely hydrophobic surface of the central cavity, with 70% of the 
surface formed by atoms of carbon and sulfur (Table 1).  Water molecules occupy the cavity, 
approximately 30 of which are ordered in crystal structures of the R- and T-states and 48 in 
the IR-state.  All water molecules in the central cavity of IR-state are within hydrogen bonding 
distance with at least one other water molecule in the cavity (Fig. 1, C).  The hydrogen bond 
network expands throughout the cavity, defining a clathrate-like structure. 
The AMP induced subunit-pair rotation from the R- to the IT-state reduces the size of 
cavity and increases the hydrophobicity of the cavity surface (Table 1).  When loop 50-72 is 
in its disengaged conformation, however, further rotation from the TF- to T-state enlarges the 
cavity.  As residues 49-51, (the N-terminal hinge of loop 50-72) are part of the cavity surface, 
the movement of loop 50-72 from engaged to disengaged conformation (IT- to TF-) induces 
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extensive conformational change in the protein (47), enlarges the cavity volume, but 
decreases the cavity surface area. 
Molecular dynamics simulations— Water molecules can diffuse into or out of the central 
cavity through the channels during simulations.  The number of water molecules in the 
central cavity stabilizes within the first 2 ns.  (The number of water molecules in the central 
cavity and hydrogen bonds between them were recorded every 2 ps over the simulation).  
The IR-state has the maximum number of water molecules in the central cavity, whereas the 
TF-state has the fewest (Table 2).  R- and T-states contain similar numbers of water 
molecules.  Water molecules in the IR- and IT-states pack more densely than in other states.  
Water molecules interchange positions during the simulations.  The average dwell time for a 
water molecule at a cavity site is longest in the IR- and IT-states, and shortest in the TF-state. 
The sites for water molecules defined by simulations are consistent with those 
determined by crystallography.  Indeed, agreement between simulations and crystal structure 
is optimal for the IR-state where the water structure is large and maximally stable (Fig. 2).  A 
single dominant cluster of water molecules in the IR-state appears in over 90% of frames 
from the simulation.  The water organization in the cavity of the IT-state is also relatively 
stable, with 50% of frames contributing to one cluster; however, the IT-state from simulation 
identifies more water molecules than does the crystallographic structure (Table 1 versus 
Table 2).  For the R-, TF- and T-states, no cluster of water molecules dominates. 
AMP inhibition of Asp
10
 FBPase in different co-solvents— For each of Leu54 and Asp10 
FBPases, three crystal structures have been reported (25, 26).  R-state crystals grow in the 
absence of AMP and I- and T-states both appear in the presence of AMP.  The appearance of 
different quaternary states in the presence of AMP is a result of different cyro-protectants 
(glycerol for I-state versus 2-methyl-2,4-pentanediol (MPD) for T-state).  Changes in 
quaternary state in response to cyro-protectant suggest the possibility of the systematic 
manipulation of the quaternary state of FBPase by variations in the solvent system. 
The biphasic inhibition of Asp
10
 FBPase by AMP (27) offers the possibility of 
activity assays as a means of probing the effects of solvent systems on the quaternary state.  
56 
 
The partially active state of Asp
10
 FBPase observed in the presence of saturating AMP is due 
presumably to an intermediate quaternary state that lies between the fully active R-state and 
the inactive T-state.  (The latter is made energetically inaccessible by the mutation).  Indeed, 
crystallographic studies have identified an intermediate quaternary state in the presence of 
AMP that can have an engaged loop 50-72 (the IT-state) (26). 
Glycerol reduces Asp
10
 FBPase activity (the enzyme in 25% glycerol has 40% of the 
specific activity in water), but also significantly reduces partial AMP inhibition (Table 3).  In 
order to focus on the effect of different solvent systems on AMP inhibition, results are 
presented as velocities relative to that of Asp
10
 FBPase in a particular solvent system in the 
absence of AMP.  Biphasic inhibition curves employ the following empirical relationship in 
data fitting: 
 =
1  plateau
1 (
 
 Chigh
)
nhigh  
 plateau
1 (
 
 Clow
)
nlow 
where V, Vplateau, I, IChigh, nhigh, IClow and nlow indicate relative velocity, relative 
velocity at the plateau, AMP concentration, IC50 for the high affinity binding site, Hill 
coefficient for the high affinity binding site, IC50 for low affinity binding site, and Hill 
coefficient for the low affinity binding site, respectively.  Activity assays using different 
concentrations of AMP in different glycerol/water solvent systems reveal a systematic 
increase in the relative activity of Asp
10
 FBPase as glycerol concentrations increase (Fig. 3).  
IC50 values for the high and low affinity interactions increase 3- and 5-fold, respectively, as 
glycerol concentrations increase (Table 3).  Under all conditions, the Hill coefficient for the 
high affinity site is near 2, whereas that for low affinity site is approximately unity.  Most 
notably, the effect of glycerol in diminishing AMP inhibition reaches a maximum at 30% 
(v/v) glycerol, and that the dependence of plateau velocity on glycerol concentration is 
sigmoidal (Fig. 3). 
Other solvents systems have similar effects to that of glycerol (Fig. 4; Table 3).  
Asp
10
 FBPase is inactive in 25% (v/v) ethanol, 1-propanol, 2-propanol or MPD, and in 25% 
(v/v) 1,3-propanediol, the enzyme retains less than 10% of its activity.  Asp
10
 FBPase, 
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however, is active in solvent systems with ED, PD, xylitol or sorbitol.  Relative velocities as 
a function of AMP concentration in 25% (v/v or w/v) ED, PD, xylitol and sorbitol (Fig. 4) 
define plateau relative velocities below (as for xylitol and sorbitol), equal to (ED) and above 
(as for PD) those determined in the presence of 25% v/v glycerol.  In PD, the enzyme is 
barely inhibited by millimolar levels of AMP, retaining a plateau activity of 80%.  The high 
affinity AMP site exhibits cooperativity in all solvent systems, whereas the low affinity site 
has a Hill coefficient of unity (Table 3). 
Crystal structures of Leu
54
 FBPase in different co-solvents (Protein Data Bank code 4GBV in 
ED and 4GBW in PD)— Leu54 FBPase crystallized under a great variety of solvent systems, 
and hence served as a surrogate for Asp
10
 FBPase in probing quaternary states of FBPase.  
Crystals grown in the presence 10 mM AMP and 5 mM of substrate diffract to a resolution 
equal to or higher than 3 Å in ED and PD solvent systems.  Mn
2+
 is used as a divalent cation, 
which stabilizes engaged loop more than does Mg
2+
 and does not precipitate at high 
concentrations at neutral pH as does Zn
2+
 (48).  Crystals from ED and PD systems are in 
space group I222, isomorphous with R- and IR-state crystals of Leu
54
 FBPase in glycerol.  
Space group parameters for crystals grown from ED (a = 53.69, b = 82.51, c = 166.28 Å) are 
essentially identical to those grown from PD (a = 53.38, b = 82.72, c = 165.17 Å).  The 
statistics of data collection and refinement are in Table 4.  Both models begin with residue 10.  
Electron density for AMP molecules in both models is weak, reflecting weak binding of 
AMP. 
Comparison of the ED and PD structures to the R-, IR- and T-structures of Leu
54
 
FBPase reveals no significant differences at the level of the C1-C2 subunit pair; however, 
whole-tetramer alignments reveal distinct differences in subunit-pair rotations.  The rotation 
angles for Leu
54
 FBPase in PD, glycerol, ED, and MPD (T-state) in the presence of AMP are 
1, 3, 4, and 15°, respectively (Fig. 5). 
Correlation of FBPase activity and subunit-pair rotation— PD exhibits the strongest 
stabilization effect on the I-state of Asp
10
 FBPase, whereas xylitol and sorbitol show the least 
effects.  Leu
54
 FBPase show different levels of conformational change in different co-solvent 
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systems.  A plot of plateau velocity of Asp
10
 FBPase against subunit-pair rotation (Fig. 6) 
reveals a correlation between activity and subunit-pair rotation toward the R-state. 
 
Discussion 
MD simulations of water molecules in protein cavities are in the literature (49-52).  
The investigation here identified approximately 45-50 well-ordered water molecules in the 
central cavity of the IR-state, on the basis of simulations and crystal structures.  To our 
knowledge, waters in the FBPase central cavity represent the largest cluster of water 
molecules found inside a protein.  Water molecules in the central cavity are well-ordered and 
resist exchange with the bulk solvent.  In both crystal structure and simulation, similar 
hydrogen bond networks interconnect all water molecules in the cavity.  Rings of five water 
molecules are a clear feature of the hydrogen bond network.  Cluster analysis, indicates a 
stable structure that persists throughout 10 ns of simulation (Fig. 2). 
Hydrophilic surfaces directly provide hydrogen bonding sites for water molecules, 
whereas hydrophobic surfaces enhance water-water interactions (53).  Small apolar cavities, 
therefore, usually remain dehydrated due to the dearth of water-water interactions (54).  
Nonetheless, hydration of sufficiently large apolar cavities can be favorable energetically 
(55).  Clathrate-like arrangements of water molecules cover hydrophobic surfaces of crambin 
in crystal structures (56).  The cavity in FBPase is large but not entirely hydrophobic.  
Hydrophilic surfaces may provide hydrogen bonds to water molecules, which in turn become 
seeds for extended networks of hydrogen-bonded water molecules that span the entire cavity.  
The hydrophobic surface of the cavity would enhance water-water interactions and stabilize 
water networks. 
The central cavity of FBPase undergoes changes in volume, shape and surface 
structure due to the subunit-pair rotation and conformational changes in loop 50-72 (Table 1).  
In the transition from R- to IT-state, the cavity becomes smaller and more hydrophobic; 
however, in the transition from IT- to T-state, the cavity increases in size and becomes less 
hydrophobic.  On the basis of simulations, water clusters are more stable and extensive in the 
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in IR- and IT-states and least stable in the TF-state (Fig. 2; Table 2).  The extra stability of 
water in IR- and IT-state may be due due to elevated hydrophobicity and/or to a more 
complementary fit of the water network to the central cavity. 
The thermodynamic contribution of the water structure could be a significant factor in 
a conformational transition from the IT- to TF-state (movement of the dynamic loop from an 
engaged to disengaged conformation).  The movement of loop 50-72 has been linked to 
dynamic modes that exacerbate unfavorable steric contacts involving the loop in its engaged 
conformation (26).  The order-to-disorder transition of water structure in the cavity could be 
a significant free-energy factor in support of conformational change of the dynamic loop to 
its disengaged conformation. 
Polyols like glycerol are chemical chaperones that stabilize proteins from unfolding 
or aggregation (57).  Glycerol may enhance protein stability through the ordering of water 
molecules on the protein surface (58-60).  The correlation between subunit-pair rotation and 
activity (Fig. 6) may be linked to the ordering of water molecules in the central cavity.  If in 
the absence of glycerol the AMP/FBPase complex is in the IT-state, then as the concentration 
of glycerol increases, so too does the order of water structure in the central cavity.  Enhanced 
order of the water structure in turn favors the more active IR-state of the tetramer.  The plot of 
plateau activity against glycerol concentration (Fig. 3) is sigmoidal, implying a cooperative 
phenomenon, as would be anticipated for the ordering of water molecules in a symmetric 
cavity. 
The effects of chemical chaperones on FBPase activity suggest that the crowded 
environment within the cell would favor the ordering of water molecules in the central cavity.  
Although such an effect may occur, its impact on wild-type FBPase likely would not offset 
the influence of AMP.  A significant chaperone effect occurs only in mutant forms of FBPase 
which cannot stabilize a disengaged conformation of loop 50-72.  The T- and TF-states of 
these mutant FBPases are energetically unfavorable and hence these systems exist primarily 
in energy accessible R-states and/or intermediate quaternary states. 
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Human FBPase is a drug target for the treatment of Type II diabetes (11-18).  
Screening efforts usually identify molecules that bind to the AMP pocket (13-18), but at least 
two different classes of inhibitor bind to the center of FBPase (11-12).  OC252 binds to the 
outside surface of the central cavity channel, and induces a conformational change from R-
state to a state that we call here TF (subunit-pair rotation of 11-13° with a disengaged loop 
50-72) (12).  OC252 inhibits synergistically with AMP and uncompetitively with respect to 
substrate.  The uncompetitive mechanism indicates that OC252 binds to the R-state in the 
presence of substrate with loop 50-72 in its engaged conformation.  Indeed, loop 50-72 in the 
disengaged conformation of the OC252 complex, wraps over the bound OC252 molecule, 
consistent with an OC252 binding event that precedes the loop conformational change. 
The basis for synergism between AMP and OC252 may in fact be linked to structural 
modulation of water molecules in the central cavity.  An engaged loop 50-72 persists up to at 
least the IT-state (11-13° subunit-pair rotation).  AMP binding energy would go in part 
toward the generation of ordered water molecules in the central cavity as the tetramer 
transitions from the R- to the IT-state.  The ordered solvent represents a source of “stored” 
energy, and any mechanism that releases that energy would act synergistically with AMP in 
the inhibition of FBPase.  By binding to the center of FBPase in its IR- and/or IT-state, OC252 
could eliminate solvent ordering.  Fru-2,6-P2 displaces loop 50-72 from the active site, and 
also causes the loss of order water structure in the central cavity.  Binding synergism between 
OC252 and AMP, as well as Fru-2,6-P2 and AMP then could arise through ligand induced 
order-to-disorder transition of water molecules in the central cavity. 
Water molecules are also important in allosteric effects in mammalian hemoglobin 
(61-65).  Hemoglobin is a hetero-tetramer.  Oxygen binds to hemoglobin cooperatively and 
induces global structural reorganization from T- to R-state.  Global conformational change in 
hemoglobin is coupled to protein hydration (61-62).  Oxygen affinity towards hemoglobin 
can be enhanced by mixed solvent systems (61, 63-65).  Effectors such as Cl
–
 and 2,3-
bisphosphoglyceric acid reduce the hydration level of hemoglobin, favoring the T-state (64).  
The effects of water organization in allosteric transition in both tetrameric FBPase and 
hemoglobin may imply a general design principle in regulation of oligomeric proteins. 
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Table 1.  Central cavities from crystal structures of FBPase. 
 
Quaternary 
state 
Subunit-
pair 
rotation 
(°) 
Loop 
50-72 
Volume 
(Å
3
) 
Surface 
area 
(Å
2
) 
Surface 
fraction 
as C 
and S 
Number 
of water 
molecules 
R 0 Engaged 316 932 0.70 27 
IR 3 Engaged 259 877 0.73 48 
IT 12 Engaged 235 831 0.74 28 
TF 13 Disengaged 291 765 0.71 35 
T 15 Disengaged 385 793 0.72 33 
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Table 2.  Water molecule populations of central cavities from MD simulations. 
Quaternary 
state 
Average 
number of 
water 
molecules 
Average 
number of 
hydrogen 
bonds 
Density 
(Å
-3
) 
Average 
dwell time 
(ps) 
R 42.3 67.0 0.133 20.5 
IR 45.4 74.7 0.175 33.7 
IT 42.3 68.1 0.180 26.0 
TF 37.7 60.0 0.130 18.1 
T 43.6 68.0 0.113 20.8 
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Table 3.  AMP inhibition of Asp
10
 FBPase in mixed solvent systems. 
Uncertainty in the last significant digit is given parenthetically. 
Solvent 
system 
IC50 (high-
affinity 
site) (μM) 
Hill coefficient 
(high-affinity 
site) 
IC50 (low-
affinity 
site) (mM) 
Hill coefficient 
(low-affinity 
site) 
Relative 
plateau 
velocity 
Water 4.3(2) 2.1 (1) 3.5 (5) 0.9 (1) 0.28 (1) 
Glycerol (5% v/v) 5.8 (3) 2.4 (2) 5.7 (9) 1.1 (1) 0.32 (1) 
Glycerol (10% v/v) 7.0 (3) 2.3 (2) 7.5 (7) 1.2 (1) 0.394 (9) 
Glycerol (15% v/v) 7.5 (4) 2.2 (2) 9.2 (8) 0.98 (8) 0.46 (1) 
Glycerol (20% v/v) 7.4 (6) 2.0 (3) 12 (1) 1.3 (2) 0.52 (1) 
Glycerol (25% v/v) 10.6 (9) 2.4 (4) 14 (1) 1.2 (1) 0.55 (1) 
Glycerol (30% v/v) 11.3 (4) 1.9 (1) 18.1 (7) 1.04 (5) 0.567 (8) 
ED          (25% v/v) 8.1 (3) 1.8 (1) 13.6 (6) 1.10 (5) 0.518 (9) 
PD          (25% v/v) 7.2 (9) 3.2 (9) 21 (1) 1.03 (7) 0.820 (8) 
Xilitol     (25% v/v) 9.1 (3) 1.8 (1) 11 (1) 1.2 (1) 0.352 (7) 
Sorbitol   (25% v/v) 9.9 (1) 2.0 (1) 13.1 (2) 1.22 (2) 0.41 (1) 
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Table 4.  Statistics of data collection and refinement for Leu
54
 FBPase. 
Crystalline complex
a
 ED PD 
Resolution limit (Å) 2.90 2.00 
Number of measurements 23,686 74,692 
Number of unique reflections 8,010 20,855 
Completeness of data (%):   
    Overall 93.7 82.8 
    Last shell/resolution-range (Å) 96.8/3.00-2.90 56.5/2.07-2.00 
Rsym
b
   
    Overall 0.122 0.065 
    Last shell/resolution-range (Å) 0.295/3.00-2.90 0.277/2.07-2.00 
Number of reflections in refinement 7,635 19,759 
Number of atoms 2,601 2,767 
Number of solvent sites 103 228 
Rfactor
c
 0.180 0.195 
Rfree
d
 0.243 0.241 
Mean B (Å
2
) overall/protein 36/35 31/32 
Mean B (Å
2
) for AMP 67 97 
Root mean square deviations (deg):   
    Bond lengths (Å) 0.012 0.024 
    Bond angles 1.5 2.0 
 
a
Unit cell lengths (a, b, c) in Å for the FBPase AMP complexes in ED and PD are (53.69, 82.51, 166.28), and 
(53.38, 82.72, 165.17), respectively.  Unit cell angles (, , ) are 90 for space groups I222. 
b
Rsym = ji | Iij - <Ij> | /ijIij, where i runs over multiple observations of the same intensity, and j runs over all 
crystallographically unique intensities. 
c
Rfactor =  || Fobs | - | Fcalc || / | Fobs |, where | Fobs | > 0. 
d 
Rfree based upon 10% of the data randomly culled and not used in the refinement. 
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Figure 1.  FBPase central cavity and water molecules.  A. Central cavity of FBPase in the IR-state as viewed 
down the symmetry axis that separates the C1-C2 subunit pair from the C3-C4 subunit pair.  Carbon, nitrogen 
and oxygen atoms are in white, blue and red, respectively.  Interior water molecules are represented by red 
spheres.  B. Surface area of the central cavity plotted along the symmetry axis directed from the square-planar 
face of the tetramer (x-direction).  Surface areas from R-, IR- IT-, TF- and T-state cavities are represented by 
dark blue, purple, green, magenta, and light blue, respectively.  Central cavity is defined as shaded region.  C.  
Water molecules from central cavity of IR-state FBPase are plotted as red spheres connected by possible 
hydrogen bonds. Figures were prepared with pymol (66). 
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Figure 2.  Structural clustering of waters in FBPase central cavity.  Fractions of the ten most prevalent 
clusters are indicated by bars on the left side of the figure for the R, IR-, IT-, TF, and T-states.  On the right side 
is the dominant cluster for each quaternary state aligned with water sites from crystal structures.  Blue spheres 
indicates shared positions from simulation and crystal structure, and red spheres represent sites observed only 
from structural clustering analysis and green spheres only from crystallographic studies. 
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Figure 3.  AMP inhibition of Asp
10
 FBPase in the presence of glycerol.  Relative velocities (velocities 
relative to those in the absence of AMP under the specified solvent systems) are plotted against AMP 
concentration ranging from 1 μM to 40 mM (top panel).  Percent (v/v) glycerol-aqueous buffer systems for 
assays of Asp
10
 FBPase are as follows: 0 ( ), 5 (□), 10 ( ), 15 (◊), 20 (●), 25 (○) and 30 (∆).  The relative 
velocity of wild type FBPase in aqueous buffer (+) is presented as a reference curve using a fitting relationship 
with only high-affinity parameters.  Relative activity at the plateau (Vplateau) as a function of percent (v/v) 
glycerol is plotted (bottom panel).   
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Figure 4.  AMP inhibition of Asp
10
 FBPase in the presence of different co-solvent systems.  Relative 
activities are plotted against AMP concentrations ranging from 1 μM to 40 mM.  Organic-aqueous buffer 
systems (the organic component at 25% (v/v)) for assays of Asp
10
 FBPase are as follows: no organic component 
( ) xylitol, (□) sorbitol, ( ) ED, (◊) glycerol (●) and PD (○).  The relative velocity of wild type FBPase in 
aqueous buffer (+) is presented as a reference curve using a fitting relationship with only high-affinity 
parameters.   
  
69 
 
 
Figure 5. Crystal structures of AMP complexes of Leu
54
 FBPase.  AMP complexes of Leu
54
 FBPase in PD 
(cyan), glycerol (magenta), ED (green) and MPD (black) are aligned to R-state Leu
54
 FBPase (grey).  The 
viewing direction and region of the tetramer shown is indicated by the FBPase icon.  C1-C2 subunit-pairs of all 
structures are aligned, and different subunit-pair rotations are represented by residues 10-120 of the C3-C4 
subunit-pair.  The rotational angles and the conformation of loop 50-72 are indicated. Figures were prepared 
with pymol (66). 
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Figure 6.  Correlation between subunit-pair rotation and plateau velocity.  Subunit-pair rotation 
angles come from structure of Leu
54
 FBPase crystallized in different solvent systems (see methods 
section and reference 25).  The R-state represents 0° subunit-pair rotation and the T-state a 15º 
subunit-pair rotation.  Plateau activities are from activity assays of Asp
10
 FBPase taken under solvent 
conditions used in the crystallization of Leu
54
 FBPase.  The subunit-pair rotational, relative plateau 
velocity in PD, glycerol, ED and MPD are as follows: (1°, 0.82), (3°, 0.55), (4°, 0.52) and (15°, 0.00), 
respectively.   
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Abstract 
AMP and fructose 2,6-bisphosphate (Fru-2,6-P2) synergistically inhibit porcine 
fructose-1,6-bisphosphatase (pFBPase); whereas for Escherichia coli FBPase (eFBPase) 
synergism is absent even though AMP and Fru-2,6-P2 are potent inhibitors.  AMP and Fru-
2,6-P2 induce 15° and 13° subunit-pair rotations, respectively, in porcine FBPase; however, 
the corresponding values in eFBPase are 9° and 0°, respectively.  A hydrophobic central 
cavity in pFBPase, populated by water molecules, is filled with hydrophilic side chains in 
eFBPase.  Explored here is the linkage of AMP/Fru-2,6-P2 synergism to the central cavity in 
FBPases.  The single mutation Ser
45→His substantially fills the central cavity of pFBPase, 
and the triple mutation, Ser
45→His, Thr46→Arg and Leu186→Tyr, replaces porcine with E. 
coli-type side chains.  Both single and triple mutations significantly reduce synergism, while 
retaining other wild-type kinetic properties.  Similar to the effect of Fru-2,6-P2 on eFBPase, 
the triple mutant of pFBPase with bound Fru-2,6-P2 exhibits only a 2° subunit-pair rotation 
as opposed to the 13° rotation exhibited by the Fru-2,6-P2 complex of wild-type pFBPase.  
The side chain at position 45 is small in all available eukaryotic FBPases, but large and 
hydrophilic in bacterial FBPases similar to eFBPase.  Analysis of signature residues indicates 
the likelihood of FBPases in specific bacterial organisms that exhibit AMP/Fru-2,6-P2 
synergism.  These FBPases may be models for an evolutionary precursor of eukaryotic 
FBPase.  
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Introduction 
Fructose-1,6-bisphosphatase (D-fructose-1,6-bisphosphate 1-phosphohydrolase; EC 3. 
1. 3; FBPase
1
) catalyzes the penultimate step in gluconeogenesis, hydrolyzing fructose 1,6-
bisphosphate (Fru-1,6-P2) to fructose 6-phosphate (Fru-6-P) and phosphate (Pi) (1, 2).  
Frutose-6-phosphate-1-kinase (PFK-1) in glycolysis opposes the action of FBPase by the 
ATP-dependent phosphorylation of Fru-6-P (3).  The coordinated regulation of FBPase and 
PFK-1 limits futile cycling in vivo.  In mammals and presumably other eukaryotes, fructose 
2,6-bisphosphate (Fru-2,6-P2) and AMP inhibit FBPase while activating PFK-1 (3-10).  In 
vivo AMP concentrations are nearly constant due to the action of adenylate kinase (11), 
whereas the level of Fru-2,6-P2 varies in response to changing nutritional states (10).  
AMP/Fru-2,6-P2 synergism in the inhibition of eukaryotic FBPases (5, 6, 12, 13), however, 
lowers the apparent Ki of AMP as concentrations of Fru-2,6-P2 increase, making both AMP 
and Fru-2,6-P2 dynamic physiological regulators. 
Porcine liver FBPase (hereafter pFBPase) is a model for eukaryotic FBPases (14).  
Four identical subunits (molecular weight of 37 kDa) form an approximate square-planar 
arrangement with D2 symmetry.  AMP, which binds 28 Å away from the active site (15, 16), 
is a non-competitive inhibitor with respect to Fru-1,6-P2, but a competitive inhibitor with 
respect to catalytically essential divalent cations (Mg
2+
, Mn
2+
, or Zn
2+
) (13, 17, 18).  Binding 
of AMP induces a conformational transition from active R-state to inactive T-state (16, 19).  
The R- and T-states differ principally by a 15° rotation of upper relative to the lower subunit 
pair of the tetramer, and by the displacement of loop 50-72 from an active-site engaged 
conformation to disengaged conformation (16).  At least two AMP molecules are required for 
the R- to T-state transition (20).  The dimer-dimer interface is the origin of AMP 
cooperativity (20).  Mutations that disrupt interactions between subunit pairs eliminate the 
cooperative binding of AMP (21, 22).  Two AMP-bound intermediate states (IR-state and IT-
state) have been identified, both of which have engaged loop 50-72 and subunit-pair rotations 
of 3° and 11°, respectively (23, 24). 
Fru-2,6-P2 is a competitive inhibitor with respect to Fru-1,6-P2 (5, 6).  Chemical 
modification, NMR, mutagenesis and crystallographic studies consistently indicate Fru-2,6-
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P2 binding to the active site (14, 25-28).  In the presence of Fru-2,6-P2, the Ki for AMP falls 
10 fold (AMP/Fru-2,6-P2 synergism) (5, 6, 29).  Hines et al. (14) suggest AMP/Fru-2,6-P2 
synergism arises from a similar end-state induced independently by AMP and Fru-2,6-P2, and 
indeed, Fru-2,6-P2 and AMP cause comparable subunit-pair rotations in pFBPase.  Moreover, 
the crystallographic work is in harmony with similar UV spectra of FBPase in complexes 
with Fru-2,6-P2 and AMP (14). 
Esherichia coli FBPase (eFBPase) has 41% sequence identity with pFBPase, but a 
fundamentally different mechanism of regulation (30-32).  eFBPase is subject to feed-
forward activation by phosphoenolpyruvate, the binding of which favors an active tetramer 
over an inactive or less active dimer (30-31).  AMP and glucose 6-phosphate (Glc-6-P) are 
synergistic inhibitors that together drive the enzyme to a T-like state (32).  Fru-2,6-P2, 
although not present in E. coli, is a potent inhibitor of eFBPase (14).  Unlike pFBPase, there 
is no Fru-2,6-P2/AMP synergism for eFBPase and, consistent with the hypothesis of Hines et 
al. (14), eFBPase remains in the R-state in the presence of Fru-2,6-P2. 
The foregoing begs the question: If subunit-pair rotation in response to Fru-2,6-P2 is 
necessary for synergism, then why do subunit pairs rotate in pFBPase and not eFBPase?  A 
large cavity is present at the center of the pFBPase tetramer.  The cavity has ordered water 
molecules, which collectively influence the quaternary conformation of the porcine enzyme 
(33).  In eFBPase, however, hydrophilic side chains fill the corresponding region.  Shown 
here by directed mutation, kinetics and structure determinations, the central cavity of 
pFBPase enables the subunit-pair rotation of the tetramer in response to Fru-2,6-P2.  
Moreover, analysis of sequences infers the existence of bacterial FBPases that likely exhibit 
AMP/Fru-2,6-P2 synergism, even though these organisms are unlikely to produce Fru-2,6-P2.  
Hence, the evolution of Fru-2,6-P2 as a dynamic regulator of FBPase in eukaryotic systems 
probably evolved from a primordial FBPase possessing a stable tetrameric assembly with a 
water-filled central cavity. 
 
Experimental procedures 
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Materials—Fru-1,6-P2, NADP
+
 and AMP came from Sigma.   Fru-2,6-P2 was prepared 
according to ref 34.  Glucose-6-phophate dehydrogenase and phosphoglucose isomerase 
were purchased from Roche Applied Sciences.  The FBPase-deficient E. coli strain DF 657 
was from the Genetic Stock Center at Yale University.  Other chemicals were of reagent 
grade or equivalent. 
Directed mutations of pFBPase— Mutations were accomplished by specific base changes 
utilizing the Transformer
TM
 site-directed mutagenesis kit (Clontech).  The mutagenic primers 
were as follows: Ser
45→His, 5’-CAAGGCCATCCACACCGCAGTC-3’; Thr46→Arg, 5’-
CAAGGCCATCTCCCGCGCAGTCCGCAAG-3’; Leu186→Tyr, TGCTTCATGTATGA 
CCCGGCCATC; Ser
45→His/Thr46→Arg, 5’-CAAGGCCATCCACCGCGCAGTCCGCAA 
G-3’ (codons for point mutations are underlined in bold typeface).  The constructs were 
confirmed by sequencing the promoter region and the entire open reading frame.  The Iowa 
State University sequencing facility provided DNA sequences using the fluorescent dye-
dideoxy terminator method. 
Expression and purification of wild-type and mutant pFBPases— The supernatant solution of 
a cell free extract was loaded onto a Cibracon Blue-Sepharose column previously 
equilibrated with 20 mM Tris-HCl, pH 7.5, 5 mM MgCl2.  The column was washed with 20 
mM Tris-HCl, pH 7.5.  Enzyme was eluted with 5 mM AMP and 20 mM Tris-HCl, pH 7.5.  
The pH of eluted protein solution was adjusted to 8.5 before loading onto a DEAE-Sepharose 
column equilibrated with 20 mM Tris-HCl, pH 8.3.  Purified enzyme was eluted with a NaCl 
gradient (0–0.5 M) in 10 mM Tris-HCl, pH 8.3, and then dialyzed extensively against 50 mM 
Hepes, pH 7.4, for kinetic investigations and for crystallization experiments.  Purity and 
protein concentrations of FBPase preparations were confirmed by SDS-polyacrylamide gel 
electrophoresis (35) and the Bradford assay (36), respectively. 
Kinetics— Phosphoglucose isomerase, and glucose-6-phosphate dehydrogenase were used as 
coupling enzymes in assays for FBPase (1).  For specific activity measurements, reduction of 
NADP to NADPH was monitored by absorbance at 340 nm.  Other assays used the same 
coupling enzymes but monitored the formation of NADPH by its fluorescence emission at 
470 nm using an excitation wavelength of 340 nm.  Assays were performed at 22 °C in 50 
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mM Hepes, pH 7.5.  Assay solutions contained EDTA and KCl at concentrations of 10 μM 
and 150 mM, respectively.  Data for AMP inhibition with respect to Mg
2+
 and Fru-2,6-P2 
inhibition with respect to Fru-1,6-P2 were fit to several models using Grafit (37), with best 
fits of data to model reported here. 
Crystallization cavity-filled pFBPase— The method of hanging drops was used in 
crystallizing Ser
45→His/Thr46→Arg/Leu186→Tyr pFBPase (hereafter Cav– FBPase).  2 μl of 
protein solution was mixed with 2 μl of precipitant solution.  Wells contained 500 μl of the 
precipitant solution.  Crystals of the Fru-2,6-P2 complex grew from a protein solution (10 
mg/ml Cav
–
 FBPase, 25 mM Hepes, pH 7.4, 5 mM MgCl2, and 5 mM Fru-2,6-P2) combined 
with a precipitant solution (100 mM Hepes, pH 7.4, 8% (w/v) polyethylene glycol 3350, 27% 
(v/v) glycerol, and 5% (v/v) t-butyl alcohol).  Crystals of AMP complex grew from a protein 
solution (10 mg/ml Cav
–
 FBPase, 25 mM Hepes, pH 7.4, 5 mM MgCl2, and 5 mM AMP) 
combined with a precipitant solution (100 mM Hepes, pH 7.4, 12% (w/v) polyethylene 
glycol 3350, 23% (v/v) glycerol, and 5% (v/v) t-butyl alcohol).  Crystals were of equal 
dimensions (0.2–0.4 mm), growing in approximately 3 days at 20 °C, and were transferred 
directly from droplet to liquid nitrogen as cryo-protectants were included in the conditions of 
crystallization. 
X-ray data collection, structure determination, and refinement— Data were collected at Iowa 
State University from single crystals on a Rigaku R-AXIS IV++ rotating anode/image plate 
system using CuKα radiation from an Osmic confocal optics system and a temperature of 110 
K.  Program d*trek (38) was used in reducing data. 
Cav
–
 FBPase with Fru-2,6-P2 and AMP are isomorphous to R- and T-state FBPase 
complexes, respectively.  R-state FBPase (PDBID: 1CNQ) and T-state FBPase 
(PDBID:1EYJ) were used as initial models for molecular replacement.  The resulting models 
underwent refinement using CNS (39) with force constants and parameters of 
stereochemistry from Engh and Huber (40).  A cycle of refinement consisted of slow cooling 
from 1000 to 300 K in steps of 25 K followed by 100 cycles of conjugate gradient 
minimization and concluded by the refinement of individual thermal parameters.  Restraints 
of 1.5 Å
2
 on nearest neighbor and next-to-nearest neighbor main chain atoms, 2.0 Å
2
 on 
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nearest neighbor side chain atoms, and 2.5 Å
2
 on next-to-nearest neighbor side chain atoms 
were employed in thermal parameter refinement.  Water molecules were added to difference 
electron density of 2.5σ or better until no significant decrease was evident in the Rfree value.  
Water molecules in the final models were within acceptable donor-acceptor distances to each 
other and/or a polar group of the protein. Stereochemistry of the models was analyzed by use 
of PROCHECK (41). 
 
Results 
Rationale for directed mutations— Directed mutations have identified residues essential for 
AMP binding (20, 42), regulation (43-45), and cooperativity (21-22, 46), and Fru-2,6-P2 
binding (47); however, no mutation eliminates AMP/Fru-2,6-P2 synergism while retaining 
potent AMP and Fru-2,6-P2 inhibition.  As eFBPase shares 41% identity with pFBPase but 
lacks AMP/Fru-2,6-P2 synergism, some subset of residues that differ must be responsible.  
The water-filled central cavity of pFBPase, absent in eFBPase, can influence the quaternary 
state of specific mutants of pFBPase (33).  Gao et al. (33) have hypothesized that the central 
cavity enables AMP/inhibitor synergism through water structure reorganization (33).  Only 
three positions in or near the central cavity differ in residue type between eFBPase and 
pFBPase.  Ser
45
, Thr
46
 and Leu
186
 in the porcine enzyme are large hydrophilic residues, His
37
, 
Arg
38
 and Tyr
180
, respectively, in eFBPase (Fig. 1).  Side chains of Ser
45
/His
37
 point into the 
central cavity, whereas side chains of Thr
46
/Arg
38
 and Leu
186
/Tyr
180
 are at the edge of the 
cavity.  If the central cavity is essential to synergism, then mutations that replace residues of 
pFBPase with those of eFBPase should significantly reduce AMP/Fru-2,6-P2 synergism. 
Expression and purification of wild-type and mutant pFBPase— Wild type and mutant 
pFBPases were at least 95% pure on the basis of sodium dodecylsulfate-polyacrylamide gel 
electrophoresis (data not shown).  Gels indicated no proteolysis of the purified enzymes. 
Kinetics— His45, Arg46 and Cav– FBPase have substantial activity (50%) relative to wild type 
enzyme (Table 1).  The Km for substrate for Tyr
186
 FBPase is 2-fold greater that for wild-type 
enzyme.  Mutations cause only minor changes in the Ka for Mg
2+
.  AMP is a competitive 
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inhibitor with respect to Mg
2+
 for all mutants.  Hill coefficients of approximately 2 indicate 
positive coopertivity in AMP binding.  The Ki of AMP for Arg
46
 FBPase deceases 6-fold, 
whereas for other mutants, the Ki for AMP inhibition is comparable to that of wild-type 
enzyme.  Fru-2,6-P2 is a potent inhibitor, competitive with respect to Fru-1,6-P2 for all 
mutants.  The Ki for Fru-2,6-P2 ranges from 0.05 μM for His
45
 FBPase to 0.27 μM for Arg46 
FBPase.  Mutantions here evidently have relatively minor effects on activity and binding 
affinities of inhibitors. 
Saturating concentration of Mg
2+
 (10 mM) and Fru-1,6-P2 (20 μM) were employed in 
the measurement of Fru-2,6-P2/AMP synergism.  AMP titrations were done at six 
concentrations of Fru-2,6-P2 (0, 0.1, 0.3, 1, 3, and 10 μM) (Fig. 2).  Each titration curve is fit 
to Eqn 1: 
   
  
   
 
    
  
    (Eqn 1) 
where v, VM, I, I0.5 and n are velocity, maximum velocity, AMP concentration, AMP 
concentration that gives 50% inhibition and the Hill coefficient for AMP, respectively.  For 
wild-type, Arg
46
 and Tyr
186
 pFBPase, I0.5 of AMP inhibition decreases significantly as Fru-
2,6-P2 concentration increases (indicative of Fru-2,6-P2/AMP synergism).  On the other hand, 
His
45
 and Cav
–
 pFBPase show little change.  For all enzymes, AMP cooperativity decreases 
as Fru-2,6-P2 concentrations increase.  Hill coefficients for AMP binding are close to 2 at 
low Fru-2,6-P2 concentration but fall to unity at high Fru-2,6-P2 concentration.  I0.5 at 
different Fru-2,6-P2 concentrations can be fit to Eqn 2 (14): 
          
      
     
         
    
   
  
  
  (Eqn 2) 
where I0.5 is the AMP concentration that causes 50% inhibition,     
    
 is the AMP 
concentration that causes 50% inhibition in the presence of an infinite concentration of Fru-
2,6-P2,     
    is the AMP concentration that causes 50% inhibition in the absence of Fru-2,6-P2, 
Ib is the concentration of Fru-2,6-P2, αb is the concentration of Fru-2,6-P2 that produces a 50% 
synergistic effect.  The value of (    
   /    
    
) is a measure of Fru-2,6-P2/AMP synergism.  
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Fitted values for Fru-2,6-P2/AMP synergism are in Table 2.  For wild-type pFBPase, Fru-2,6-
P2 enhances AMP inhibition by ~8-fold, whereas for His
45
 and Cav
–
 pFBPase     
   /    
    
 
values are approximately 3 and 2, respectively. 
AMP complex of Cav
–
 FBPase (Protein Data Bank code 4GWS)— Crystals of the AMP 
complex of Cav
–
 pFBPase are in space group P21212 (a=60.78 Å, b=166.54 Å and c=79.21 
Å), isomorphous to crystals of canonical T-state pFBPase.  A C1-C2 dimer exists in the 
asymmetric unit.  Both monomers in the model start from residue 9.  Electron density for 
residues 60-72 in the dynamic loop is weak, and associated with high B-parameters.  
Statistics for data collection and refinement are in Table 3. 
The AMP complex of Cav
–
 pFBPase is T-state, with a 15° subunit-pair rotation and a 
disengaged loop 50-72.  The root-mean-squared deviation (RMSD) in Cα carbons between 
AMP complexes of Cav
–
 and wild-type pFBPase (both in the T-state) is 0.3 Å.  One molecule 
each of Fru-6-P, Mg
2+
, Pi, and AMP binds to each subunit.  Side chains of His
45
 and Tyr
186
 in 
Cav
–
 pFBPase are clear in the electron density map; however, the side chain of Arg
46
 is 
disordered.  Further details regarding the structure of the AMP complex of pFBPase is in the 
literature (16). 
Fru-2,6-P2 Complex of Cav
–
 FBPase (Protein Data Bank code 4GWU)— Crystals of Fru-2,6-
P2 complexes of Cav
–
 pFBPase belong to space group I222 (a=54.00 Å, b=81.22 Å, and 
c=165.06 Å) and are isomorphous to crystals of wild-type pFBPase in its R-state (PDB code 
1CNQ).  The asymmetric unit is a monomer.  Electron density for residues 1-6 and 50-70 is 
absent.  Electron density for residues 22-27 at the AMP binding site is weak and with high B 
values, consistent with previously reported R-state structures (48).  Side chains of His
45
 and 
Tyr
186
 are clear in electron density maps whereas the side chain of Arg
46
 is disordered (Fig. 
1).  Electron density confirms the presence of bound Fru-2,6-P2.  Mg
2+
 at metal site-1 is in 
contact with the 1-hydroxyl group and 2-phosphoryl group of Fru-2,6-P2. 
Superposition of the entire tetramer of the Fru-2,6-P2 complex of Cav
–
 pFBPase onto 
the wild-type R-state, wild-type Fru-2,6-P2 complex and wild-type T-state yields root-mean-
square deviations in Cα coordinates of 0.75, 2.3 and 2.5 Å, respectively.  The Fru-2,6-P2 
85 
 
complex of Cav
–
 pFBPase is near the canonical R-state, exhibiting a 2° subunit-pair rotation 
as opposed to the 13° rotation of the Fru-2,6-P2 complex of wild-type pFBPase (14).  The 2° 
rotation in Fru-2,6-P2 complex of Cav
–
 pFBPase is similar to the 3° rotation of the IR-state 
induced by AMP in Leu
54
 pFBPase (23).  The shearing of helices H1 and H2 observed in the 
AMP complex of Leu
54
 pFBPase is evident in the Fru-2,6-P2 complex of Cav
–
 pFBPase, as is 
the loss of the hydrogen bond between Asn
35
 and Thr
14
 and the movement of Ile
10
 moves 
from its hydrophobic pocket (Fig. 3). 
Fru-2,6-P2 induces local conformational change in Cav
–
 pFBPase similar to that 
induced in wild-type pFBPase (14).  Loop 121-126 moves towards Fru-2,6-P2 probably in 
response to hydrogen bonds formed between backbone amide groups of Ser
123
 and Ser
124
 and 
the 2-phosphoryl group of Fru-2,6-P2.  α-Carbons of Glu
97
 and Glu
98
 move toward the Mg
2+
 
at site-1, most likely a consequence of altered metal coordination due to the absence of metal 
at site-2.  Movements in residues 97-98 and 121-126 may block Asp
74
 from forming a 
functionally essential hydrogen bond with the C-terminal end of loop 50-72.  Loop 50-72 
itself is disordered, and metal cations are absent from sites 2 and 3.  The conformation of 
loop 264-274 in the Fru-2,6-P2 complex of Cav
–
 pFBPase is nearly identical to that of the 
product complex of wild-type pFBPase (R-state), having not undergone the conformational 
change observed in the R- to T-state transition. 
Sequence Analysis of Type-I FBPases— The alignment and hierarchical clustering of 307 
Type I FBPase sequences from the uniprot database (49) employed the ClustalW web server 
(www.genome.jp/tools/clustalw).  Comparison of sequence positions occupied by signature 
residues responsible for AMP inhibition, tetramer stability, Glc-6-P inhibition, 
phosphoenolpyruvate activation, and cavity formation segregate FBPases into groups with 
mutually exclusive regulatory mechanisms.  Position 45, for instance, is a small side-chain 
residue in eukaryotic FBPases, but large and hydrophilic in E. coli-like FBPases (Fig. 5).  
Residue 112 is critical for AMP inhibition (42) and is lysine in the vast majority of 
eukaryotic and E. coli-like FBPases.  The salt link between Lys
42
 and Glu
192
 is essential to 
tetramer stability, and position 192 is glutamate in eukaryotic FBPase, but a non-charged 
residue type in E. coli-like FBPases (30, 31).  Positive charges at positions 228 and 38 are 
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important for Glu-6-P inhibition and anion activation in eFBPase, respectively, both of which 
are absent in eukaryotic FBPases (30-32). 
Signature residue information applied to sequences of 307 Type I FBPase leads to 
predictions of regulatory properties (Fig. 6).  Sequences of eukaryotic FBPases fall into 
blocks of relatively high similarity corresponding to fungi, mammalian muscle, mammalian 
liver, and plants.  The eukaryotic FBPases should be stable tetramers subject to synergistic 
inhibition by AMP and Fru-2,6-P2 (signature residues for the AMP site, tetramer stability and 
central cavity are present).  Plant chloroplasts have a distinct AMP-independent regulatory 
mechanism (52, 53), and define a block separate from eukaryotic FBPases.  A block with 64 
sequences in the middle of the similarity matrix includes E. coli FBPase.  These E. coli-like 
FBPases have residue types associated with phosphoenolpyruvate activation, a dynamic 
equilibrium between dimer and tetramer forms, AMP inhibition, no central cavity and hence, 
no AMP/Fru-2,6-P2 synergism.  More than half of all similarity blocks have scant or no 
experimental data regarding regulatory properties.  FBPases in the large block at the top right 
of the similarity matrix, for instance, should lack all known mechanisms of FBPase inhibition 
(AMP and/or Glc-6-P inhibition or reversible disulfide bond formation) and yet be stable 
tetramers. 
 
Discussion 
Ser
45→His and Cav– mutations of pFBPase represent first instances of mutant 
pFBPases that retain potent AMP and Fru-2,6-P2 inhibition with greatly reduced AMP/Fru-
2,6-P2 synergism.  Kinetic parameters for catalysis, Mg
2+
 activation, AMP inhibition and 
Fru-2,6-P2 inhibition of all cavity mutants of pFBPase investigated here are similar to those 
of the wild-type enzyme.  Reduced Fru-2,6-P2/AMP synergism in Cav
–
 pFBPase is not due to 
the disruption of the active or allosteric binding sites, but rather to an impaired quaternary 
response: Cav
–
 pFBPase exhibits only a 2° subunit-pair rotation and disordered loop 50-72 in 
its Fru-2,6-P2 complex, in contrast to the 13° subunit-pair rotation and disengaged loop 50-72 
for wild-type pFBPase.  Reduced synergism in Cav
–
 pFBPase arises arguably from the failure 
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of loop 50-72 to achieve its disengaged conformation in response to bound Fru-2,6-P2 and 
the loss of water molecules at the center of the tetramer. 
The effect of AMP on Leu
54
 pFBPase provides insights as to how mechanical 
processes of the protein contribute to Fru-2,6-P2/AMP synergism.  The binding of AMP to 
Leu
54
 pFBPase shears helices H1 and H2, disrupting hydrogen bonds at the C1-C4 interface 
(23).  Subunit-pair rotation to the T-state re-establishes disrupted hydrogen bonds and also 
squeezes the loop 50-72 out of its engaged conformation (24).  Once displaced from the 
active site loop 50-72 acquires its disengaged conformation in the case of wild-type pFBPase, 
but the Ala
54→Leu mutation blocks the disengaged conformation of loop 50-72. 
Now the binding of Fru-2,6-P2 to Cav
–
 pFBPase displaces the engaged loop directly, 
and helices H1 and H2 exhibit a shear virtually identical to that caused by AMP in its 
complex with Leu
54
 pFBPase (Fig. 3).  Cav
–
 pFBPase simply traps the Fru-2,6-P2-bound 
tetramer early in the R- to T-state transition much like the Leu
54
 pFPBase traps an AMP-
bound tetramer (23); however, Cav
–
 pFBPase differs in that a disengaged conformation for 
loop 50-72 (and a canonical T-state) is still possible.  (Note, the AMP complex of Cav
–
 
pFBPase is in the canconical T-state).  The Fru-2,6-P2 complex of Cav
–
 pFBPase does not 
form the disengaged conformation of loop 50-72 because of structural changes to the center 
or the tetramer.  Those changes impact solvent structure (Fig. 1).  The side chain of His
45
 
does not cause steric conflict in eFBPase or Cav
–
 pFBPase.  Ser
45→His does not interfere 
directly with the R- to T-state transition.  On the other hand, His
45
 may disrupt the hydrogen 
bonding network associated with ordered water molecules at the central cavity of pFBPase.  
The Van der Waals volume is 137 Å
3
 for His and 89 Å
3 
for Ser (50).  Replacement of Ser by 
His disrupts the clathrate-like structures of 48 water molecules in the central cavity, observed 
in IR-state. 
Order/disorder phenomena involving water molecules of the central cavity of wild-
type pFBPase are factors in the quaternary transition (33).  The binding of AMP to wild-type 
pFBPase pushes the tetramer into an intermediate quaternary state, which on the basis of 
crystal structures and molecular dynamics simulations enhances the structure and stability of 
water in the central cavity (33).  The movement of the loop 50-72 from the engaged to 
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disengaged conformation, causes an order-to-disorder transition in water molecules of the 
central cavity and contributes a favorable contribution to the overall free energy change of 
the R- to T-state transition.  In the absence of a hydrated central cavity (as is the case for 
Cav
–
 pFBPase) this favorable contribution to the overall free energy balance disappears, and 
hence, the binding of Fru-2,6-P2, which displaces the engaged conformation of loop 50-72, 
has a diminished effect on AMP binding. 
Fru-2,6-P2/AMP synergism, although reduced, is still present in His
45
 and Cav
–
 
pFBPase.  The 2° subunit-pair rotation caused by Fru-2,6-P2 in Cav
–
 pFBPase is similar to 
changes induced by AMP in Leu
54
 pFBPase (IR-state, 3° subunit-pair rotation).  Structural 
changes at C1-C4 interface due to small subunit-pair rotations could be the structural basis 
for the weak synergism that remains in Cav
–
 pFBPase.  Indeed, wild-type and pFBPase 
mutant enzymes here exhibit reduced AMP cooperativity in the presence of Fru-2,6-P2, 
which may come from conformational changes at the C1-C4 interface (such as the 
weakening of the hydrogen bond between Glu
192
 and Thr
39
) within the first few degrees of 
subunit-pair rotation.  The model above predicts that an engaged dynamic loop in the 
presence of bound Fru-2,6-P2 would eliminate Fru-2,6-P2/AMP synergism altogether, and in 
fact, such is the case for eFBPase: no Fru-2,6-P2/AMP synergism and the complex of Fru-
2,6-P2 with wild-type eFBPase reveals a dynamic loop in its engaged conformation (14). 
The failure of the loop 50-72 to achieve a disengaged conformation in its Fru-2,6-P2 
complex of Cav
–
 pFBPase is also consistent with the results of targeted molecular dynamics 
simulations which indicate the transition of loop 50-72 from an engaged to disengaged 
conformation comes late in the R- to T-state transition (24).  Moreover, previous work ties 
the conformational change in loop 264-274 to subunit-pair rotation from the IR- to IT-state 
(from 3° to 12°, respectively) (23).  A comparison of the Fru-2,6-P2 complexes of Cav
–
 and 
wild-type pFBPases reaffirms the correlation between movement of loop 264-274 and a 
subunit-pair rotation from a near R-state to a near T-state tetramer. 
On the basis of molecular dynamics simulations, the stability of waters in the central 
cavity is related to quaternary changes in FBPase (33).  Indeed, for specific mutant forms of 
pFBPase, water molecules adopt stable and well ordered clusters.  Moreover, FBPase activity 
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in the presence of AMP is dependent on organic solvents that cause change in the properties 
of bulk water, suggesting the structure of water molecules in the central cavity is on par with 
the effects caused by AMP or Fru-2,6-P2 on the quaternary state of FBPase. 
AMP and Fru-2,6-P2 work synergistically in inhibiting mammalian FBPases.  
Observations here suggest that any tetrameric FBPase with a signature residues of a central 
cavity should exhibit AMP/Fru-2,6-P2 synergism.  Hence, all eukaryotic organisms for which 
sequences of FBPase are known should exhibit AMP/Fru-2,6-P2 synergism, and to the best of 
our, knowledge all eukaryotic organisms make Fru-2,6-P2. 
Fru-2,6-P2, however, is not present in bacteria systems (51).  Instead, E. coli employs 
Glc-6-P as a synergistic inhibitor with respect to AMP (32).  Unlike Fru-2,6-P2, Glc-6-P is an 
allosteric non-competitive inhibitor with respect to substrate.  Vastly different kinetic 
properties and a distinct allosteric binding site for Glc-6-P in eFBPase makes Glc-6-P an 
unlikely direct precursor of Fru-2,6-P2 through evolution.  In our predictions (Fig. 6), 
FBPases from Leptospira, which lies between eukaryotic FBPases and E. coli-like FBPases 
in the similarity matrix, are most similar to eukaryotic FBPases, having key residues for 
AMP inhibition, tetramer formation and AMP/Fru-2,6-P2 synergism.  Characterization of one 
of the Leptospira FBPases may extend our understanding of evolution of AMP/Fru-2,6-P2 
synergism in eukaryotic FBPases.  Moreover, the sequence analysis also indicates a large 
block of FBPases (top right corner of the similarity matrix) that have neither AMP nor Glu-6-
P inhibition.  A novel inhibitory mechanism may be present in this group of FBPases. 
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TABLE 1.  Parameters from the kinetics of wild type and mutant forms of pFBPase. 
Assay conditions are 50 mM Hepes, pH 7.5, 150 mM KCl and 10 μM EDTA.  Values in parenthesis 
are standard deviations in the last significant digit. 
pFBPase 
Specific 
activity 
(μmol s–1mg–1)a 
KM 
Fru-1,6-P2 
(μM)b 
Hill 
coef. 
Mg
2+ c
 
Ka 
Mg
2+
 
(mM)
2 d
 
Hill 
coef. 
AMP 
e
 
Ki 
AMP 
(μM)2 f 
Ki 
Fru-2,6-P2 
(μM) g 
WT 25 (1) 1.47 (7) 1.7 (1) 0.70 (5) 2.2 (1) 0.76 (8) 0.14 (1) 
S45H 11.9 (7) 1.07 (7) 1.6 (1) 1.0 (1) 1.8 (1) 0.35 (5) 0.053 (9) 
T46R 12.3 (9) 0.68 (8) 1.8 (2) 0.93 (9) 2.4 (2) 4.8 (2) 0.27 (5) 
L186Y 21.0 (7) 1.1 (1) 1.6 (1) 0.68 (4) 1.7 (2) 0.58 (9) 0.16 (1) 
Cav
–
 15.2 (9) 1.1 (2) 1.8 (1) 0.82 (6) 2.2 (2) 0.56 (4) 0.14 (1) 
a
Determined at saturating Fru-1,6-P2 (20 µM) and Mg
2+
 (5 mM for wild-type and 10 mM for mutant 
FBPases).  Reported values come from five repetitions. 
b
Determined at saturating Mg
2+
 (5 mM for wild-type and 10 mM for mutant FBPases).  The 
concentrations of Fru-1,6-P2 varies from 0.3 to 20 µM. 
c
Hill coefficient for Mg
2+
 employed 0.2 to 20 mM Mg
2+
 and saturating Fru-1,6-P2 (20 µM). 
d
Determined by using concentrations in Mg
2+
 from 0.5–5 mM and Fru-1,6-P2 from 0.5–10 µM. 
e
Determined by using concentrations in AMP from 0.1–100 µM and saturating Fru-1,6-P2 (20 µM) 
and Mg
2+
 (10 mM). 
f
Determined by using concentrations in Mg
2+
 from 0.5–5 mM with saturating Fru-1,6-P2 (20 µM).  
AMP concentrations range from 0–5 µM for wild-type FBPase, 0–3 µM for His45 FBPase, 0–20 µM 
for Arg
46
 FBPase, 0–5 µM for Tyr186 and Cav– FBPases. 
g
Determined by using Mg
2+
 (5 mM for wild-type and 10 mM for mutant FBPases) and Fru-1,6-P2 
concentrations from 0.5–10 µM.  Concentrations of Fru-2,6-P2 range from 0–1 µM for wild-type 
FBPase, 0–0.5 µM for His45 FBPase, 0–1 µM for Arg46 FBPase, and 0–1 µM for Tyr186 FBPase and 
Cav
–
 FBPases. 
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TABLE 2.  Fru-2,6-P2/AMP synergism for wild type and mutant forms of pFBPase. 
Quantities     
    
 and     
    are defined in the results section.   
Value in parentheses are uncertainties in the last significant digit. 
 
 Wild-type Ser
45→His Thr46→Arg Leu186→Tyr Cav– 
    
    
 
a(μM) 0.6 (1) 0.6 (1) 1.9±0.4 0.53 (9) 0.8 (1) 
    
    
a(μM) 4.4 (2) 1.87 (6) 11.6±0.5 2.77 (9) 2.0 (1) 
    
   /    
    
 7 (2) 3.1 (7) 6 (2) 5 (1) 2.5 (5) 
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TABLE 3.  Statistics of data collection and refinement for Cav
–
 FBPase. 
 Fru-2,6-P2 complex
a
 AMP complex
a
 
Resolution limit (Å) 3.00 2.75 
Number of measurements 26,045 50,125 
Number of unique reflections 7,478 17,334 
Completeness of data (%): 
   Overall 98.4 82.0 
   Last shell/resolution-range (Å) 99.9/3.11-3.00 85.5/2.85-2.75 
Rsym
b
 
   Overall 0.163 0.100 
   Last shell/resolution-range (Å) 0.516/3.11-3.00 0.272/2.85-2.75 
Number of reflections in refinement 7,104 16,412 
Number of atoms 2,489 5,399 
Number of solvent sites 88 281 
Rfactor
c
 0.211 0.198 
Rfree
d
 0.283 0.247 
Mean B (Å
2
) overall/protein 55/55 24/24 
Mean B (Å
2
) for Fru-2,6-P2 49 — 
Mean B (Å
2
) for AMP — 29 
Root mean square deviations: 
   Bond lengths (Å) 0.014 0.012 
   Bond angles (deg.) 1.6 1.7 
a
Unit cell lengths (a, b, c) in Å for the Fru-2,6-P2 and AMP complexes are (54.00, 81.22, 165.06), and 
(60.24, 164.28, 79.14), respectively.  Unit cell angles (, , ) are 90 for space groups I222 and 
P21212. 
b
Rsym = ji | Iij - <Ij> | /ijIij, where i runs over multiple observations of the same intensity, and j 
runs over all crystallographically unique intensities. 
c
Rfactor =  || Fobs | - | Fcalc || / | Fobs |, where | Fobs | > 0. 
d
Rfree based upon 10% of the data randomly culled and not used in the refinement. 
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Figure 1.  Central cavity regions of FBPases.  Leu
54
 pFBPase (IR-state, AMP complex, panel A) and eFBPase 
(R-state, phosphoenolpyruvate complex, panel B) exhibit significant differences in hydration levels at the center 
of the tetramer.  Mutation of positions 45, 46 and 186 to E. coli type residues (Cav
–
 FBPase) has hydration 
levels comparable to eFBPase (Fru-2,6-P2 complex of Cav
–
 pFBPase, near R-state, panel C).  Electron density 
covering positions 45, 46 and 186 (Fru-2,6-P2 complex of Cav
–
 pFBPase, panel D).  The surface renderings are 
of subunits C1 and C4 of the tetramer, with ball-and-stick models representing selected residues from subunits 
C2 and C3 and water molecules (red spheres).  The icon at the center with associated arrow indicates the region 
viewed and viewing direction, respectively.  Image generated with Pymol (54). 
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Figure 2.  AMP/Fru-2,6-P2 synergism for wild-type and mutant FBPases.  Panels A-E come from assays 
using wild-type, His
45
, Arg
46
, Tyr
186
 and Cav
–
 pFBPases, respectively.  Reaction velocities as a function of 
AMP concentration (left) are taken at 0 (○), 0.1 (□), 0.3 ( ), 1 (●), 3 ( ), and 10 μM ( ) Fru-2,6-P2.  I0.5 values 
from the curves on the left are plotted against Fru-2,6-P2 concentrations (right). 
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Figure 3.  Conformation changes at the C1-C4 interface.  Subunits are aligned for the Fru-2,6-P2 complex of 
Cav
–
 pFBPase (magenta), the AMP complex of Leu
54
 pFBPase (cyan) and the product complex of wild-type 
pFBPase (green).  Dotted lines indicate hydrogen bonds.  The relative positions of helices H1 and H2 are 
similar in the Fru-2,6-P2 complex of Cav
–
 pFBPase and AMP complex of Leu
54
 pFBPase, which have subunit-
pair rotations of 2° and 3°, respectively, relative to the R-state product complex of wild-type pFBPase. 
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Figure 4.  Conservation of selected signature residues associate with regulatory mechanisms of FBPase.  
Amino acid types associated with sequence positions essential for AMP inhibition (residue 112), tetramer 
formation (residue 192), Glc-6-P inhibition (residue 228), anion activation (residue 38), and central cavity 
formation (residue 45) are presented from top to bottom.  Grey, red and green columns represent the amino acid 
type for all FBPases, eukaryotic FBPases and E. coli-like FBPases, respectively. 
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Figure 5.  Similarity matrix of Type-I FBPase sequences and the prediction of structural and regulatory 
properties.  The fraction of identical residues in sequence pairs are represented by color according to the scale 
on the right-hand side of the similarity matrix.  The positions of eFBPase, pFBPase and the FBPase from 
Leptospira interogans are marked by vertical and horizontal dotted lines.  FBPases from eukaryotic systems and 
E. coli-like are indicated by brackets.  Regulatory properties are predicted (gray bar) according to residue types 
associated with key positions in the amino acid sequence.  AMP inhibition, requires serine or threonine for 
residue 31, lysine or arginine for residue 112, and tyrosine for residue 113.  Tetramer stability requires lysine or 
arginine for residue 42, and glutamate for residue 192.  Glc-6-P inhibition requires tyrosine for residue 216, 
lysine or arginine for residue 228, and glutamine for residue 231.  Anion activation requires glycine for residue 
14, lysine or arginine for residue 38, lysine or arginine for residue 88, and not glutamate for residue 192.  
Presence of a central cavity (AMP/Fru-2,6-P2 synergism) requires small side chains (glycine, alanine, cysteine, 
serine, or gap) for residue 45. 
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CHAPTER V.  RELEVANCE OF THE DIMER-DIMER INTERFACE IN 
PORCINE LIVER FRUCTOSE-1,6-BISPHOSPHATASE TO AMP 
INHIBITION AND COOPERATIVITY 
A paper to be submitted to Biochemistry 
Yang Gao and Richard B. Honzatko 
Roy J. Carver Department of Biochemistry, Biophysics, and Molecular Biology,  
Iowa State University, Ames, IA 50011 
Abstract 
The hydrolysis of fructose 1,6-bisphosphate by fructose-1,6-bisphosphatase (FBPase) 
is a highly regulated reaction in most organisms.  In mammals, FBPase is stable tetramer 
subject to cooperative allosteric inhibition by AMP coupled with synergistic inhibition by 
fructose-2,6-bisphosphate.  Positive cooperativity in AMP binding arises from the interaction 
of allosteric sites across a specific dimer-dimer interface of the mammalian tetramer.  Point 
mutations at that interface (targeting Arg
22
, Thr
39
, Lys
42
, Ile
190
, Gly
191
 and Glu
192
) exhibit a 
range of effects on AMP cooperativity and tetramer stability; however, functional changes 
due to mutations have not been correlated with conformational changes because of 
insufficient structural information.  Point mutations at positions 39, 42, 190, 191 and 192 
resulted in the formation of FBPase dimmers on the basis of significant shifts in mobility in 
nondenaturing gel electrophoresis and determinations of mass by equilibrium analytical 
sedimentation.  Met
22
 FBPase, however, has mass determinations identical to the wild-type 
tetramer.  Met
22
 and Gln
192
 FBPases were crystallized in the absence/presence of AMP, as 
well as products and divalent cations.  Crystal structures with AMP are similar to that of the 
wild-type enzyme, exhibiting a 15° dimer-dimer rotation relative to the wild-type structure in 
the absence of AMP (R-state).  Crystal structures of Gln
192
 and Met
22
 FBPases with no AMP, 
however, exhibit 2 and 14° dimer-dimer rotations, respectively.  Moreover, AMP binding 
sites in the absence of AMP assume conformations similar to AMP-bound conformations of 
the wild-type enzyme.  Loss of cooperativity in AMP inhibition then arises from two 
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mechanisms: dissociation of tetramers into stable dimers and the dominance of a T-like 
quaternary state in the absence of bound AMP. 
 
Introduction 
Fructose-1,6-bisphosphate (D-fructose-1, 6-bisphosphate 1-phosphohydrolase; EC 3. 
1. 3; FBPase) governs a key step in gluconeogenesis.  In the presence of divalent cations 
(Mg
2+
, Mn
2+
, or Zn
2+
), FBPase hydrolyzes fructose 1,6-bisphosphate (Fru-1,6-P2) to fructose 
6-phosphate (Fru-6-P) and inorganic phosphate (Pi) (1-2).  FBPase and fructose-6-phosphate-
1-kinase (PFK-1) define a futile cycle, which in mammalian systems is coordinately 
regulated by adenine nucleotides and fructose 2,6-bisphosphate (Fru-2,6-P2) (3-8).  AMP 
allosterically inhibits FBPase with positive cooperativity (9-10) and Fru-2,6-P2 is a potent 
active-site inhibitor that enhances AMP inhibition, a phenomenon called AMP/Fru-2,6-P2 
synergism (4-5).  Levels of Fru-2,6-P2 are under hormonal control, ensuring regulation of 
FBPase in response to the nutritional status of the organism. 
In eukaryotic systems, FBPase is a homotetramer of 37 kDa monomers.  The four 
subunits are arranged in D2 symmetry and named clockwise from C1 to C4, with C1 
representing the upper left subunit (11).  The tetramer reversibly dissociates into dimers (C1-
C2 or C3-C4) and then into monomers (12-13).  Matrix-bound monomers of FBPase are 
inactive, whereas matrix-bound dimers exhibit reduced activity compared to tetramer (14).  
Structurally distinct interfaces lie between subunits C1-C2 and C1-C4.  Active sites of 
FBPase require residues from both subunits C1 and C2 (15).  Conformational changes at the 
C1-C4 interface influence FBPase activity and determine the quaternary state of the tetramer 
(18). 
AMP inhibits FBPase competitively with respect to Mg
2+
 and non-competitively with 
respect to Fru-1,6-P2 (9).  AMP binding sites are near each other at the C1-C4 interface (16).  
Ligation by AMP induces a transition from an active R- to inactive T-state (16).  The C1-C2 
dimer rotates 15° relative to the C3-C4 dimer and displaces catalytically essential loops 50-
72 from active sites (17-18).  (Conformations of loop 50-72 associated with active and 
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inhibited states of the enzyme are called “engaged” and “disengaged”, respectively).  Two 
AMP-bound intermediate states (IR and IT) have been observed in crystal structures of mutant 
FBPases.  Both intermediate states have engaged loops 50-72 and intermediate dimer-dimer 
rotations of 3 and 12°, respectively for the IR- and IT-states (19-20).  Fru-2,6-P2 binds to the 
active site of FBPase and stabilizes a conformation comparable to that of AMP-bond 
complexes, including a 13° dimer-dimer rotation and a disengaged loop 50-72 (21).  The 
dimer-dimer rotation induced by Fru-2,6-P2 is necessary for AMP/Fru-2,6-P2 synergism (22).  
A similar conformational change appears in the complex of FBPase with the 
nonphysiological inhibitor OC252 (23), which also inhibits synergistically with AMP. 
Escherichia coli FBPase (eFBPase) shares significant similarities in sequence and 
structure with mammalian FBPase (24).  Fru-2,6-P2, however, is not present in bacteria.  
Instead, glucose 6-phosphate (Glc-6-P) and AMP are synergistic inhibitors of eFBPase (25).  
eFBPase in solution exists in equilibrium between dimer and tetramer.  Dilution of eFBPase 
leads to the slow loss of activity, consistent with an equilibrium shift from tetramer to less 
active dimer (26).  Anion activators, such as phosphoenolpyruvate (PEP) bind to an allosteric 
site at the C1-C4 interface to stabilize the more active tetramer of eFBPase (24, 26).  The 
PEP binding loci in eFBPase map onto negatively-charged glutamate side chains of 
eukaryotic FBPases (residue 192 in porcine FBPase). 
The cooperative binding of AMP to FBPase (9-10) requires AMP binding to one site 
on each of two C1-C2 type dimers of the tetramer (13).  Point mutations at the C1-C4 
interface decrease the affinity and the cooperativity in AMP binding, and in some cases, 
change the kinetic mechanism of inhibition (27-31).  The relationship of AMP inhibition to 
changes in structure of mutant FBPases is unclear largely because of absent structural 
information.  Evaluated here are mutant FBPases with known changes in AMP cooperativity 
and two new FBPase point mutations, Lys
42→Met and Thr39→Ala.  Such mutant FBPases 
either exist in solution as C1-C2 dimers or as tetramers.  Representative mutant FBPases 
representing the stable tetramer (Arg
22→Met) and stable dimer (Glu192→Gln) are crystallized 
in the absence and presence of AMP.  AMP complexes of both mutant FBPases are 
comparable in conformation to the AMP complex of wild-type FBPase, whereas complexes 
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in the absence of AMP adopt conformations that differ significantly from that of wild-type 
FBPase.  The product complexes of Glu
192→Gln and Arg22→Met FBPases have 2 and 14° 
dimer-dimer rotations relative to the wild-type product complex.  AMP binding sites of these 
complexes in the absence of AMP have conformations similar to those observed in 
complexes of FBPases with AMP bound.  Conformational changes at the AMP site due to 
quaternary changes alone could be the basis for properties of AMP cooperativity and 
AMP/Fru-2,6-P2 synergism.  Moreover, results here indicate two mechanisms for loss of 
cooperativity in AMP inhibition: dissociation of tetramers into dimers with the concomitant 
loss of the C1-C4 interface and the dominance of a T-like quaternary state under R-state 
conditions. 
 
Experimental procedures 
Materials— Fru-1,6-P2, NADP
+
 and AMP were purchased from Sigma.  Glucose-6-phophate 
dehydrogenase and phosphoglucose isomerase were from Roche Applied Sciences.   FBPase-
deficient Escherichia coli strain DF 657 came from the Genetic Stock Center at Yale 
University.  Other chemicals were of reagent grade or equivalent. 
Directed mutations of wild type FBPase— Nucleotide base changes used the TransformerTM 
site-directed mutagenesis kit (Clontech).  Oligonucleotide primers for the following 
mutations were as previously reported: Arg
22Met (27), Ile190Thr (28), Gly191Ala (28), 
Glu
192Gln (31).  Thr39Ala and Lys42Met used 5’-CTCGCTGTGCGCCGCGGTCAAG 
-3’ and: 5’-CACCGCGGTCATGGCCATCTC-3’, respectively.  (Nucleotide bases altered 
from wild-type are underlined in bold typeface).  The mutation and the integrity of the 
construct were confirmed by sequencing the entire open reading frame as well as the 
promoter region.  The DNA sequence service was provided by Iowa State University 
sequencing facility using the fluorescent dye-dideoxy terminator method. 
Expression and Purification of Wild-type and mutated FBPases— Supernatant solutions of 
cell free extracts were loaded onto a Cibracon Blue-Sepharose column equilibrated with 20 
mM Tris-HCl, pH 7.5, 5mM MgCl2.  The column was washed with 20 mM Tris-HCl, pH 7.5.  
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The protein was eluted with 5 mM AMP, 20 mM Tris-HCl, pH 7.5.  The pH of eluted protein 
sample was adjusted to 8.5 before loading onto a DEAE-Sepharose column equilibrated with 
20 mM Tris-HCl, pH 8.3.  Purified enzyme was eluted with a NaCl gradient (0–0.5 M) in 10 
mM Tris-HCl, pH 8.3, and then dialyzed extensively against 50 mM potassium phosphate, 
pH 7.5, (AMP removal) and then against 50 mM Hepes, pH 7.5, (phosphate removal), before 
further characterization.  Purity and concentration of FBPase preparations were confirmed by 
SDS-polyacrylamide gel electrophoresis (32) and the Bradford assay (33), respectively. 
Kinetics Experiments— FBPase assays couple Fru-6-P production to the conversion of 
NADP to NADPH using phosphoglucose isomerase and glucose-6-phosphate dehydrogenase 
(1).  Specific activity measurements (Fru-1,6-P2 saturating at 20 μM) monitored NADPH 
formation by absorbance at 340 nm on UV spectrometer.  Other assays used the same 
coupling enzymes but monitored the fluorescence of NADPH with excitation and emission at 
340 and 470 nm, respectively.  Assays were done at 22 °C in 50 mM Hepes, pH 7.5, with 
EDTA and KCl at concentrations of 10 μM and 150 mM, respectively.  Assays were initiated 
by the addition of FBPase except for those assays that measured FBPase activity over 
extended time.  Grafit (34) was used in fitting data to models. 
Analytical Ultracentrifugation— Sedimentation equilibrium experiments were performed at 
4 °C using a Beckman XLA ultracentrifuge with an AN-60 rotor.  Three sample 
concentrations (280 nm absorbance of 0.3, 0.5 and 0.7) of each FBPase (wild-type and 
mutant enzymes) were prepared in 50 mM Hepes, pH 7.5.  Samples were subjected to 
rotational velocities of 15000, 18000 and 21000 rotations per minute until equilibrium.  
Absorbance data were recorded at 280 nm in triplicate for each sample at each rotational 
velocity.  The program UltraScan (35) was employed in global fitting of the data. 
Crystallization of Met
22
 and Gln
192
 FBPase— The method of hanging drops was used in the 
crystallization of Met
22
 and Gln
192
 FBPases.  2 μl of protein solution was mixed with 2μl of 
precipitant solution.  Wells contained 500 μl of the precipitant solution.  Crystals of the 
product complex of Met
22
 FBPase grew from a protein solution (10 mg/ml), Hepes (25 mM, 
pH 7.4), MgCl2 (5 mM), and Fru-1,6-P2 (5 mM) combined with a precipitant solution (Hepes 
100 mM, pH 7.4), polyethylene glycol 3350 (8% w/v), glycerol (27% v/v), and t-butyl 
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alcohol (5% v/v).  Crystals of the product complex of Gln
192
 FBPase grew from a protein 
solution (10 mg/ml), Hepes (25 mM, pH 7.4), ZnCl2 (5 mM), and Fru-1,6-P2 (5 mM) 
combined with a precipitant solution (Hepes 100 mM, pH 7.4), polyethylene glycol 3350 (8% 
w/v), glycerol (27% v/v), and t-butyl alcohol (5% v/v).  Crystals of AMP complex grew from 
a solution of either Met
22
 or Gln
192
 FBPase (10 mg/ml), Hepes (25 mM, pH 7.4), MgCl2 (5 
mM), Fru-1,6-P2 (5 mM), and AMP (5 mM) combined with a precipitant solution of Hepes 
(100 mM, pH 7.4), polyethylene glycol 3350 (12% w/v), glycerol (23% v/v), and t-butyl 
alcohol (5% v/v). Crystals were of equal dimensions (0.2–0.4 mm), growing in 
approximately 3 days at 20 °C.  Crystals can be transferred directly from droplet to liquid 
nitrogen as cryo-protectants were included in conditions of crystallization. 
Data collection, structure determination, and refinement— Data were collected at Iowa State 
University from single crystals on a Rigaku R-AXIS IV++ rotating anode/image plate system 
using CuKα radiation from an Osmic confocal optics system and a temperature of 110 K.  
Program D*trek (36) was used in reducing data. 
Structures in this report were solved by molecular replacement, using the R-state 
(PDBID: 1CNQ) as the initial model for the product complex of Gln
192
 FBPase and the T-
state (PDBID:1EYJ) as the initial model for the product complex of Met
22
 FBPase and the 
product-AMP complexes of both Gln
192
 and Met
22
 FBPases.  Model refinement employed 
CNS (37) with force constants and parameters of stereochemistry from Engh and Huber (38).  
A cycle of refinement consisted of slow cooling from 1000 to 300 K in steps of 25 K 
followed by 100 cycles of conjugate gradient minimization, concluding with the refinement 
of individual thermal parameters.  Restraints of 1.5 Å
2
 on nearest neighbor and next-to-
nearest neighbor main chain atoms, 2.0 Å
2
 on nearest neighbor side chain atoms, and 2.5 Å
2
 
on next-to-nearest neighbor side chain atoms were employed in thermal parameter 
refinement.  Waters were added to difference electron density of 2.5σ or higher until no 
significant decrease was evident in the Rfree value.  Allowable donor-acceptor distances 
separate all water molecules in the final models.  The stereochemistry of the models was 
analyzed by the use of PROCHECK (39). 
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Results 
Rationale— Several point mutations at the dimer-dimer (C1-C4) interface of FBPase 
eliminate cooperative binding of AMP: Arg
22→Met, Lys42→Ala, Lys42→Thr, Lys42→Glu, 
Ile
190→Thr, Gly191→Ala, and Glu192→Gln (27-28, 30-31) (Figure 1). Sidechains of Lys42 
and Glu
192
 from different dimers formed stable charge-charge interactions in all FBPase 
crystal structures.  Moreover, inter-dimer polar interactions occur between Glu
192
:OE1 and 
Thr
39
:OG1 and between Lys
42
:NZ and backbone carbonyls  of Ile
190 
and Gly
191
.  The side-
chain of Arg
22
 is within contact distance of backbone carbonyls of residues 108-110 in R-
state FBPase and hydrogen bonded to the backbone carbonyl of Thr
27
 in T-state of FBPase.  
The mutations Thr
27→Ala causes loss of AMP inhibition (27).  Although all mutations listed 
here eliminate the cooperative binding of AMP, they differ significantly in kinetic 
mechanisms of inhibition and in AMP binding affinity.  AMP inhibits Thr
42
, Thr
190
 and 
Ala
191
 FBPases non-competitively with respect to Mg
2+
 (28), whereas in Met
22
 and Glu
42
 
FBPases, AMP is a competitive inhibitor with respect to Mg
2+
 (same as wild-type enzyme) 
(27-28).  AMP inhibition of Glu
42
, Thr
42
, Thr
190
 and Ala
191
 FBPases is significantly weaker 
than wild-type enzyme, but in contrast around 5-times more potent for Met
22 
FBPase (27).  
Moreover, AMP inhibition of Ala
42
 and Gln
192
 FBPases is biphasic, causing potent but partial 
inhibition at low concentrations of AMP, and additional inhibition at concentrations above 5 
mM (30-31).  The mutations Arg
22→Met,  le190→Thr, Gly191→Ala, and Glu192→Gln, as well 
as two new point mutations Thr
39→Ala and Lys42→Met, are the basis for probing the role of 
interactions at the C1-C4 interface. 
Kinetics of wild-type and mutant FBPases— Parameters for Met22, Thr190, Ala191, and Gln192 
FBPase are in the literature (27-28, 30-31) and listed in Table I to facilitate comparisons to 
those determined here for Ala
39
 and Met
42
 FBPases.  As the mechanism of AMP inhibition of 
Gln
192
 FBPase was not determined in previous work, the properties of Gln
192
 FBPase were 
re-examined here.  All the assays are initialized with addition of FBPase. Most parameters 
(specific activity, Km for Fru-1,6-P2, Ka for Mg
2+
 and Ki for Fru-2,6-P2) for Ala
39
, Met
42
 and 
Gln
192
 FBPases are comparable to those of the wild-type enzyme (Table I). However, Ala
39
, 
Met
42
 and Gln
192
 FBPases exhibit biphasic AMP inhibition, though with different plateau 
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activity (Figure 2, A). AMP inhibition curves for both wild-type and mutated FBPases come 
from fits of Equation 1, in which measured velocities were put on a basis relative to the 
velocity measured in the absence of AMP.    
 r=
1- plateau
1 (
 
 Chigh
)
nhigh  
 plateau
1 (
 
 Clow
)
nlow     Equation 1 
where Vr, Vplateau, I, IChigh, nhigh, IClow and nlow indicate relative velocity, relative velocity at 
the plateau, AMP concentration, the concentration of AMP that causes 50% of the high 
affinity inhibition, the Hill coefficient for high affinity inhibition, the concentration of AMP 
that causes 50% of the low affinity inhibition and the Hill coefficient for the low affinity 
inhibition, respectively.  For wild-type FBPase, the Vplateau is set to zero during fitting. IChigh 
falls 4-fold for Ala
39
 FBPase relative to the wild-type enzyme, and Hill coefficient associate 
with AMP inhibition is 1.33.  IChigh is approximately 10-times higher for Gln
192
 and Met
42
 
FBPases than IChigh of wild-type FBPase, whereas IClow is near 10 mM.  For all three mutants, 
AMP inhibition is not cooperative and is linearly competitive with respect to Mg
2+
 at low 
AMP concentrations (Figure 2, B-D). 
Time dependence of FBPase activity— eFBPase has twice the specific activity in enzyme-
initialized assays than Mg
2+
-initialized assays (26).  Moreover, AMP binds to eFBPase with 
positive cooperativity in enzyme initialized assays, and with diminished cooperativity in 
Mg
2+
-initialized assays.  The activity of eFBPase decreases slowly with time upon dilution of 
the enzyme.  The same methods were applied here to wild-type and mutant FBPases to probe 
tetramer stability.  Enzymes were incubated in assay mixtures at 1000-fold dilution without 
metal cofactors, followed by the addition of 5 mM of MgCl2 (Figure 3).  For both wild-type 
and Met
22
 FBPases, activity was independent of incubation time.  In contrast, the activities of 
Ala
39
, Met
42
, Thr
190
, Ala
191
 and Gln
192
 FBPases dropped by 50% with incubation times up to 
5 hours, a behavior comparable to that of eFBPase.   
Native Gel Electrophoresis— Protein migration in non-denaturing polyacrylamide gel 
electrophoresis depends on molecular weight, net charge and shape, hence mobility does not 
always correlate with molecular size.  Nonetheless, wild-type FBPase has the least mobility, 
whereas mutant FBPases that exhibited time-dependent changes in activity upon dilution had 
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the highest mobilities (Figure 4).  Met
22
 FBPase exhibits a faster mobility than wild-type, but 
less than other mutant FBPases, a phenomenon perhaps due to a net increase in negative 
charge relative to the wild-type protein. 
Sedimentation Equilibrium— Wild-type and mutant FBPases at monomer concentrations of 
15.6 μM (A280=0.3), 26.0 μM (A280=0.5) and 36.5 μM (A280=0.7) were subjected to three 
different rotational velocities as described in the methods section.  Data were fit to single-
component, monomer-dimer equilibrium and monomer-dimer-tetramer equilibrium models 
using the program UltraScan (35).  The monomer-dimer-tetramer equilibrium model did not 
provide acceptable outcomes, so fitting results with only the single-component and 
monomer-dimer equilibrium models are in Table II.  On the basis of the single-component 
model, wild-type and Met
22
 FBPases exhibited molecular weights of approximately 110 kDa, 
whereas other mutant FBPases have molecular weights ranging from 60-75 kDa.  The 
molecular weight for wild-type enzyme compares favorably with the value of 122±4 kDa 
from dynamic light scattering (26).  Molecular weights from the monomer-dimer equilibrium 
model are similar to those from the single-component model; however, Kd values for the 
monomer-dimer equilibrium were over 1 molar, indicating a protein concentration range used 
in sedimentation equilibrium experiments far from the real Kd value for the monomer-dimer 
equilibrium.   
Crystal Structures of Gln
192
 FBPase (Protein Data Bank code 4H45 and 4GX6)— Crystals of 
the product complex of Gln
192
 FBPase belong to space group I222 and are isomorphous to 
the canonical R-state (17).  A single monomer of the tetramer is in the asymmetric unit.  The 
model begins with residue 10 and ends at residue 335.  Weak electron density covers residues 
56-71.  This region of the model also has elevated B-parameters.  Statistics for data 
collection and refinement are in Table III. 
The product complex of Gln
192
 FBPase approximates the wild-type R-state, with a 
dimer-dimer rotation of 2° (Table IV, Figure 6).  The active site has one molecule each of 
Fru-6-P and Pi and two Zn
2+
 at sites 1 and 2.  The R-state product complex of wild-type 
FBPase by comparison has Zn
2+
 at sites 1, 2 and 3 (17).  Loop 50-72 is in its engaged 
conformation, although weak electron density for residues 56-71 is consistent with the 
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absence of Zn
2+
 at metal site 3.  Asp
68
 coordinates metal cations at site 3 (18, 19) and 
structures in which that coordination is evident have strong electron density for the entire 
loop.  Helix HI (residues 10-21) shifts approximately 0.5 Å towards the center of tetramer 
relative to helix HII (residues 28-50) (Figure 6, B).  The hydrogen bond between Thr
14
 and 
Asn
35
, however, remains intact (donor-acceptor distance of 2.6 Å).  In the IR-state (3° dimer-
dimer rotation) of the AMP/product complex of Leu
54
 FBPase the hydrogen bond between 
Thr
14
 and Asn
35
 is lost at a donor-acceptor distance of 3.5 Å (19).  The side-chain of Ile
10
 
moves away from its R-state hydrophobic contact surface, as observed in the AMP/product 
complex of Leu
54
 FBPase in its IR quaternary state (3° dimer-dimer rotation).  The side chain 
of Gln
192
 shifts 0.5 Å away from its R-state binding partners Lys
42
 and Thr
39
 (Figure 6, C.) to 
donor-acceptor distances of 3.0 (Lys
42
:NZ to Gln
192
:OD1) and 3.5 Å (Thr39:OG1 to 
Gln192:OD1).  The corresponding distances are 2.9 and 2.7 Å in R-state and 2.7 and 3.7 Å in 
IR-state.  The contact between Arg
22
 and the backbone carbonyl of 108 is gone at a donor-
acceptor distance of 5.3 Å. 
Crystals of the AMP/product complex of Gln
192
 FBPase are isomorphous to those of 
wild-type FBPase in the canonical T-state (18), being in space group P21212 with an 
asymmetric unit of a C1-C2 dimer.  The model for Gln
192
 FBPase AMP goes from residue 9 
to 335, with weak electron density for residues 61-71.  The AMP/product complex of Gln
192
 
FBPase is similar to that of wild-type FBPase (T-state, disengaged loop, with tetramer 
RMSD 0.32 Å). The presence of AMP was confirmed by its strong electron density. Detailed 
description of T-state will not be covered here. 
Crystal Structures of Met
22
 FBPase (Protein Data Bank code 4GX3 and 4GX4)— Crystals of 
the product complex and AMP/product complex of Met
22
 FBPase are in space group P21212 
and isomorphous to crystals of the canonical T-state (18).  A C1-C2 dimer is in the 
asymmetric unit for both complexes.  Models start from residue 9 and end at residue 335.  
Electron density for residues 61-71 in the dynamic loop is weak, consistent with high values 
for B-parameters.  Statistics for data collection and refinement are in Table III. 
The product complex of Met
22
 FBPase (AMP absent) is in the T-state with a 14° 
dimer-dimer rotation and a disengaged loop 50-72.  One Fru-6-P molecule, two Mg
2+
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(occupying sites 1 and 2), and one Pi molecule are in the active site.  Strong electron density 
covers the side chain of Met
22
 and Pi at the 5'-phosphoryl locus of the AMP pocket (Figure 5).  
The shearing translocation of helices H1 and H2 observed in the product complex of Gln
192
 
FBPase is evident in the product complex of Met
22
 FBPase.  Moreover, the hydrogen bond 
between Thr
14
 and Asn
35
 is broken (donor-acceptor distance of 6.4 Å).  As loop 50-72 is 
disengaged, the hydrophobic interactions of Ile
10
 in the R-state are not only perturbed but are 
replaced altogether by hydrophobic interactions with disengaged loop 50-72 that evidently 
stabilize the T-state (19). 
The AMP/product complex of Met
22
 FBPase has strong electron density covering 
allosterically bound AMP and the side chain of Met
22
.  The active site has one each of Fru-6-
P and Pi, bound as products, with metal cations (Mg
2+
) occupying sites 1 and 2.  
AMP/product complexes of wild-type FBPase have metal ions (Zn
2+
 or Mg
2+
) at site 1 only 
(18); however, Leu
54
 FBPase has Mg
2+
 at sites 1 and 2 in its T-state, AMP/product complex 
(19).  Root-mean-square deviations in Cα coordinates after superposition (Table IV and 
Figure 5) indicate a quaternary state for Met
22
 FBPase that closely approximates the 
canonical T-state irrespective of AMP concentration.  A detailed description of T-state 
FBPase is elsewhere in the literature (18) and is not the focus of this report. 
Survey of conformational changes in AMP pockets— AMP pockets in product complexes of 
Met
22
 and Gln
192
 FBPase mimic the AMP bound conformation.  In fact, other FBPase 
complexes exhibit movement in helices H1 and H2 in the absence of bound AMP (Figure 7).  
AMP binding site inhibitors A37 and R15, which come from drug screening efforts and have 
substantially different binding modes that do not involve the carbonyl of Val
17
 and the side 
chain of Thr
31
, cause similar global and local conformational changes as does AMP (Figure 7, 
D and E) (46-47).  OC252 also comes from a drug screening effort and binds to the center of 
the FBPase tetramer (23).  Ligation of OC252 causes a 12° dimer-dimer rotation and helix 
movement at AMP binding site (23).  Fru-2,6-P2 binds to the active site of FBPase and  
induces 13° and 2° dimer-dimer rotations in wild-type and His
45
/Arg
46
/Tyr
186
 FBPases, 
respectively (21-22).  Fru-2,6-P2 complexes of FBPase show again the same helix 
movements at the AMP binding site.  Helix movements in the AMP pocket then are linked to 
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dimer-dimer rotations, whether they are caused directly by the binding of AMP or through 
the action of ligands elsewhere. 
 
Discussion 
Mammalian and yeast FBPases are stable homotetramers (26, 40-43); however, 
mutations on Thr
39
, Lys
42
, Ile
190
, Gly
191
 or Glu
192
, residues at or near the C1-C4 interface 
(Figure 1), similarly reduce the stability of the tetramer.  Such mutant FBPases migrate with 
higher mobility than the wild-type enzyme on non-denaturing polyacrylamide gel 
electrophoresis.  Equilibrium analytical ultracentrifugation indicated a mass half that 
expected for the tetramer.  Dilution of concentrated solutions of mutant FBPases resulted in a 
slow 50% loss of activity, similar to the behavior of eFBPase in the absence of anion 
activators (24-26).  Monomer forms of FBPase are inactive whereas dimers of FBPase have 
reduced activity when associated with a sepharose matrix (14).  FBPase subunit exchange 
happens at both the dimer (C1-C2) and monomer level (12-13, 44), with the exchange of C1-
C2 dimers preceding monomer exchange.  These observations taken together support a 
common mechanism for the loss of AMP cooperativity, the dissociation of the tetramer into 
C1-C2 dimers due to point mutations at the C1-C4 interface. 
The data here link tetramer stability to AMP cooperativity; however, loss of tetramer 
stability does not cause loss of AMP inhibition.  In fact, IChigh for AMP increases only from 
5- to 15-fold, for Ala
39
, Met
42
 and Gln
192
 FBPases, however, AMP inhibition is clearly 
biphasic for these mutant enzymes, even as potent AMP inhibition remains competitive with 
Mg
2+
 (Figure 2).  Kantrowitz and co-workers argue that biphasic inhibition of Ala
42
 FBPase 
by AMP is due to an active T-state (30).  Given that biphasic kinetics occurs in enzymes that 
are not or may not be tetramers (AMP inhibition of Ala
42
 FBPase is not cooperative), one 
cannot characterize such systems as either R- or T-state.  The observation of tetramers in 
crystal structures of Ala
42
 FBPase (30) and Gln
192
 FBPase (present work) may just be a 
consequence of the high concentration of protein used in crystallization experiments.  On the 
other hand, biphasic inhibition of Ile
10→Asp FBPase is cooperative (Hill coefficient of 2), 
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and the resulting crystal structures are FBPase tetramers, one of which is an AMP-bound 
tetramer in an intermediate state IT with an engaged dynamic loop (45).  The later suggest 
biphasic AMP inhibition can also be a property of the tetramer.  AMP inhibition is more than 
a thousand-fold weaker than that of the wild-type enzyme and becomes non-competitive with 
respect to Mg
2+
 for Thr
190
 and Gly
191
 FBPases (28).  Thr
190
 and Gly
191
 FBPases lack AMP 
cooperativity and are dimers, but do not exhibit biphasic AMP inhibition.  The absence of 
such inhibition, however, may be a consequence of almost a complete loss of AMP inhibition. 
That the loss of the C1-C4 interaction causes the loss of AMP cooperativity is no 
great surprise.  Hybrid mutant FBPases exhibit no cooperativity when AMP binds to the 
same C1-C2 dimer, but exhibit cooperativity when AMP binds to one subunit each of the C1-
C2 and C3-C4 dimers (13).  The mechanism of AMP cooperativity arises putatively from 
interactions at the C1-C4 (equivalent to C2-C3) subunit interface (19).  The base of AMP 
inserts between helices H1 and H2 of the C1 subunit and forms hydrogen bonds with the 
backbone carbonyl of Val
17
 (helix H1) and the side chain of Thr
31
 (helix H2).  Helices H1 
and H2 undergo a shear causing the loss of a hydrogen bond across the C1-C4 interface 
between Thr
39
 (helix H2, subunit C1) and Glu
192
 (subunit C4).  The loss of the C1-C4 
hydrogen bond facilitates the binding of a second molecule of AMP to subunit C4, which in 
turn disrupts the symmetry-related hydrogen bond between Thr
39
 (helix H2, subunit C4) and 
Glu
192
 (subunit C1).  Evidently, movement in helices H1 and H2 does not require AMP 
binding.  The rotation of dimer pairs in the absence of AMP in the product complexes of 
Met
22
 and Gln
192
 FBPases causes helix movement (Figure 7), albeit the effect is more certain 
in the case of Met
22
 FBPase which exhibits a 14° dimer-dimer rotation as opposed to Gln
192
 
FBPase, which exhibits but a 2° rotation.  Helix movement due to subunit-pair rotation 
should enhance the binding of AMP, and indeed, although AMP cooperativity is absent in 
Met
22
 FBPase, AMP binding affinity increases around 5-fold relative to the wild-type 
enzyme (27).  Moreover, the complexes of Ser
45→His/Thr46→Arg/Leu186→Tyr FBPase and 
wild-type FBPase with Fru-2,6-P2 exhibit 2° and 12° dimer-dimer rotations, respectively, and 
movement of helices H1 and H2 (21,22).  Any mechanism that causes a dimer-dimer rotation 
perhaps as little as 2° could transform the AMP pocket from a low affinity R-state 
conformation to a high affinity T-state conformation. 
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The loss of AMP cooperativity in Met
22
 FBPase clearly is by a mechanism altogether 
different from the other mutant FBPases examined here.  Met
22
 FBPase is a tetramer on the 
basis of time-independent kinetics upon dilution, with mobility nearly equal to the of the 
wild-type enzyme on non-denaturing polyacrylamide gel electrophoresis, and a molecular 
weight identical to that of the wild-type tetramer on the basis of analytical equilibrium 
ultracentrifugation.  The molecular weight of approximately 110 kDa is substantially less 
than the expected weight of 148 kDa; however, the non-globular shape of the tetramer could 
well be responsible for the deviation from expected mass.  The loss of AMP cooperativity is 
probably due to a tetramer locked in a T-like state, which already has maximal affinity for 
AMP.  On the other hand, Mg
2+
 binds to Met
22
 FBPase with Hill coefficient greater than 2, 
indicating the incorporation of more than two Mg
2+
 molecules.  Two Mg
2+
 molecules exist in 
both product complexes and AMP/product complexes of Met
22
 FBPase, in contrast to three 
metal cations in product complexes of wild-type FBPase and one metal cation in 
AMP/product complexes of wild-type FBPase.  The cooperativity may derive from binding 
of Mg
2+
 to different subunits, where Mg
2+
 cooperatively drives T- to R-state transition of 
Met
22
 FBPase.  Similar phenomena was observed in substrate binding: Fru-1,6-P2 binding 
curve changed from hyperbolic to sigmoidal with addition of Fru-2,6-P2, implying a 
cooperative transition from Fru-2,6-P2 bound state (close to T-state) to substrate bound state 
(R-state) (5).   
But why does methionine at position 22 overwhelmingly favor the T-state?  In the 
wild-type enzyme, Arg
22
 is in position to interact with backbone carbonyls 108-110 of the 
neighboring subunit.  The side-chain of Arg
22
 is poorly ordered, however, indicating either 
weak interactions, or multiple interactions that stabilize more than one conformation of the 
side-chain.  In contrast Arg
22
 hydrogen bonds with the backbone carbonyl of Thr
27
 and is 
well-ordered in the T-state.  If anything, Arg
22
 seems to have a greater stabilizing effect on 
the T-state rather than the R-state.  Met
22
 adopts a different conformation from Arg
22
 in the 
T-state, allowing the side-chain to become less solvent-exposed.  Hence, the increase in 
entropy due to the release of water molecules from the hydrophobic surface of Met
22
 in its T-
state conformation may outweigh the loss of the hydrogen bond between the guanidine group 
of Arg
22
 and backbone carbonyl 27. 
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The observation of conformational changes in the AMP pocket due to dimer-dimer 
rotation (Figure 7) suggests that if any rotation were to occur in the absence of AMP, then 
AMP cooperativity will decrease or vanish.  Indeed, the product complex of Met
22
 FBPase 
has a 14° dimer-dimer rotation and has no AMP cooperativity.  Fru-2,6-P2 enhances AMP 
binding by 8- and 2-fold for wild-type and His
45
/Arg
46
/Tyr
186
 FBPase, respectively, 
(consistent with the 12 and 2° dimer-dimer rotations) and both wild-type and 
His
45
/Arg
46
/Tyr
186
 FBPases in the presence of Fru-2,6-P2 are without AMP cooperativity (21-
22).  OC252 binds cooperatively to FBPase and inhibits synergistically with AMP or Fru-
2,6-P2 (23).  The presence of either AMP or Fru-2,6-P2 decreases OC252 cooperativity, 
although the effect of OC252 on AMP cooperativity is unknown.  The OC252/product 
complex of wild-type FBPase exhibits a 12° rotation.  The structural and inhibition data 
consistently point to the AMP binding site with sheared helices as having high affinity and 
that of the canonical R-state as having low affinity.  Cooperativity in AMP inhibition can 
come about from as little as a 2° dimer-dimer rotation. 
FBPase is a target for the development of drugs in the treatment of diabetes Type II 
(23,46,47,49-53).  A possible strategy for inhibiting multi-subunit enzymes is the disruption 
of quaternary structure, and in the case of mammalian FBPase the most vulnerable interface 
is between subunit C1 and C4.  On the basis of results here, however, the properties of a 
drug-bound C1-C2 dimer are uncertain.  A drug-stabilized dimer may have appreciable 
activity (up to 50% of the wild-type tetramer) and be 10-fold (or more) less susceptible to 
AMP inhibition.  Inhibition by Fru-2,6-P2, however, seems unabated in mutant dimers, 
although AMP/Fru-2,6-P2 synergism is not likely a property of such dimers.  Given the time 
and expense associated with the development of any drug, the search for molecules that 
promote the dissociation of the tetramer may not be rewarding.  On the other hand, Met
22
 
FBPase clearly demonstrates that a small change in FBPase tips the balance of quaternary 
states in favor of a form that is 10-fold move sensitive to AMP inhibition.  In fact, eukaryotic 
organisms may have taken advantage of this attribute in the evolution of Fru-2,6-P2, which 
independently stabilizes a T-like conformational state of FBPase that enhances AMP 
inhibition some 8-fold.  
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Table I.  Parameters from kinetics experiments using wild-type and mutant FBPases. 
FBPase 
type 
Specific 
activity 
mg
–1
 s
–1
 
KM 
Fru-
1,6-P2 
(μM) 
Hill-
coef. 
Mg
2+
 
Ka-
Mg
2+ 
(mM)
2
 
IChigh
a
 
 
nhigh
a
 
 
IClow
a
 
(mM) 
nlow
a
 
 
Ki 
Fru-2,6-
P2 
(μM) 
 
Ref 
Wild-
type 
25 1.47(7) 0.81(2) 1.71(7) 2.57(5) 2.25(9) NA NA 0.14(1)  
Ala39 16 0.78(8) 1.18(5) 2.1(2) 9.4(4) 1.33(7) 10(4) 0.9(4) 0.068(6)  
Met42 11 1.6(1) 1.94(7) 1.7(1) 30(4) 1.1(1) 15.2(6) 1.25(6) 0.13(3)  
Gln192 13 0.87(8) 1.69(7) 1.7(1) 31(8) 0.9(1) 18(1) 1.4(1) 0.072(5)  
Met22 70 2.5(1) 2.44(3) 0.3(1) 0.68(5)b 1.2(1) NA NA 0.16(3) 27 
Thr190 35 1.8(2) 1.6(1) 4.4(2) 10(1)c 1 NA NA 0.03(0) 28 
Ala191 35 0.84(7) 1.5(1) 10.7(9) 15(4)c 1 NA NA 0.03(0) 28 
a 
Parameters are from Equation 1 in the results section. The concentrations of Mg
2+
 in AMP inhibition assays 
are 5 mM for wild-type, Ala
39
, Met
42
, and Gln
192
 FBPases, 2 mM for Met
22
 FBPase, and 12 mM for Thr
190
 and 
Ala
191
 FBPases. The unit for IChigh is µM for wild-type, Ala
39
, Met
42
, Gln
192
, Met
22
 FBPases and mM for Thr
190
 
and Ala
191
 FBPase.  
b
 AMP is competitive inhibitor with respect to Mg
2+
 and noncompetitive inhibitor with respect to Fru-1,6-P2, 
same as wild-type FBPase. In ref 27, the reported Ki  (Ki = 3.0(5) μM; corresponding value for wild-type 
FBPase is 21(6) μM2) was derived from AMP inhibition at varying Fru-1,6-P2 concentration, with the presence 
of 5 mM Mg
2+
. The Hill coefficient for AMP inhibition is 1.The IC50 for AMP inhibition was re-examined here.  
c
 For both Thr
190
 and Ala
191
 FBPases, AMP inhibitions are noncompetitive with respect to Mg
2+
 and 
noncompetitive with respect to Fru-1,6-P2.  
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Table II.  Results of sedimentation equilibrium experiments using wild-type and mutant 
FBPases
a
 
Protein 
Single component, 
ideal 
Monomer-dimer equilibrium 
M.W. S.D.
b
 M.W. Kd (M) S.D.
b
 
Wild-type 112100 0.009 113900 2.718 0.01 
Met
22
 116300 0.006 118700 2.72 0.005 
Ala
39
 75250 0.006 71610 9.939 0.005 
Met
42
 68080 0.004 67490 31.84 0.004 
Thr
190
 60770 0.004 60750 2.719 0.004 
Ala
191
 71030 0.005 67370 8.058 0.005 
Gln
192
 60340 0.005 59860 44.67 0.005 
 
a 
The results were derived from global fitting of all data with software Ultrascan 
b 
Standard derivation of the global fitting 
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Table III.  Statistics of data collection and refinement for mutant FBPase. 
Enzyme/complex type
a
 
Met
22
 FBPase/ 
products, Mg
2+
 
Met
22
 FBPase/ 
products, Mg
2+
, 
AMP 
Gln
192
 FBPase/ 
products, Zn
2+
 
Gln
192
 FBPase/ 
products, Mg
2+
, 
AMP 
Space group 
a
 P21212 P21212 I222 P21212 
Resolution limit (Å) 2.25 2.50 3.00 2.50 
Number of measurements 110,910 100,552 26,740 91,023 
Number of unique reflections 32,141 27,370 7,665 25,867 
Completeness of data (%): 
   Overall 85.2 95.6 97.3 92,3 
   Last shell/range (Å) 69.2/2.33-2.25 96.3/2.59-2.50 99.9/3.11-3.00 94.1/2.59-2.50 
Rsym
b
 
   Overall 0.073 0.139 0.129 0.143 
   Last shell/range (Å) 0.299/2.33-2.25 0.427/2.59-2.50 0.426/3.11-3.00 0.331/2.59-2.50 
Reflections in refinement 30,514 25,977 7,304 24,546 
Number of atoms 5,412 5,358 2574 5,346 
Number of solvent sites 370 280 58 266 
Rfactor
c
 0.207 0.206 0.208 0.204 
Rfree
d
 0.264 0.262 0.294 0.261 
Mean B protein (Å
2
) 24.9 31.0 50.3 27.9 
Mean B AMP (Å
2
) - 30.2 - 25.7 
Root mean square deviations: 
   Bond lengths (Å) 0.020 0.018 0.016 0.017 
   Bond angles (degrees) 1.8 1.9 1.6 1.8 
a 
Unit cell lengths (a, b, c) in Å for product and AMP complexes of Met
22
 and Gln
192
 FBPase are (59.249, 
165.012, 79.135), (60.776, 166.535, 79.209), (53.996, 83.621, 166.220) and (59.923, 165.341, 79.112), 
respectively.  Unit cell angles (, , ) are 90 for space groups I222 and P21212. 
b 
Rsym = ji | Iij - <Ij> | /ijIij, where i runs over multiple observations of the same intensity, and j runs over all 
crystallographically unique intensities. 
c 
Rfactor =  || Fobs | - | Fcalc || / | Fobs |, where | Fobs | > 0. 
d 
Rfree based upon 10% of the data randomly culled and not used in the refinement. 
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Table IV.  Root mean square deviations (Å) in the superposition of selected Cα atoms of 
Met
22
 and Gln
192
 structures against canonical R and T-state FBPases
a
 
FBPase type/complex 
R-state (PDB ID 1CNQ) T-state (PDB ID 1EYJ) 
Monomer Dimer Tetramer Monomer Dimer Tetramer 
Met
22
/products, Mg
2+
 0.66 0.74 4.80 0.27 0.30 0.38 
Met
22
 products, Mg
2+
, AMP 0.70 0.78 4.86 0.22 0.24 0.27 
Gln
192
/products, Zn
2+
 0.39 0.45 0.64 0.59 0.74 4.64 
Gln
192
/products, Mg
2+
, AMP 0.67 0.75 4.8 0.29 0.25 0.32 
a Cα atoms of residues 10-50 and 72-330 were used in the alignment. 
122 
 
 
Figure 1.  Dimer-dimer interface in R- and T-state of FBPase. Schemes of R- and T-states of FBPase were 
present with labeled subunits and active site. FBPase was homo-tetramer with D2-symmetry. C1-C4 interface 
and C2-C3 interface were symmetrically identical and only key residues at C1-C4  interface was shown in 
sticks. The interaction between Glu
192
 and Lys
42
 was present in both R- and T-state of FBPase whereas Arg
22
 
changed its interacting partner during R- to T-state transition. 
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Figure 2.  AMP inhibition of Ala
39
, Met
42
, and Gln
192
 FBPase. A. AMP titrations are of wild-type ( ), Ala39 
( ), Met42 (●), and Gln192 ( ) FBPase in saturating Fru-1,6-P2 (20 μM) and Mg
2+
 (5-10 mM).  AMP 
inhibition versus Mg
2+
 concentration for Ala
39
 (panel B), Met
42
 (panel C), and Gln
192
 (panel D).  AMP 
concentrations are 0 (□), 2 (∆), 4 (○),8 ( ), and 16 μM ( ) for Ala39 FBPase and 0 ( ),3 ( ), and 10 μM ( ) for 
Met
42
 and Gln
192
 FBPases.  
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Figure 3.  Non-denaturing polyacrylamide gel electrophoresis of wild-type and mutant FBPases.  20 μg of 
pure protein was loaded in each lane. The names of the protein are labeled above each band.  
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Figure 4. Time Dependent Inactivition of Mutated FBPase. Wild-type (◊) and Met22 ( ) FBPase retained 
activities upon dilution whereas Ala
39
 ( ), Met
42
 (●), Thr190 (○), Ala191 (∆), and Gln192 (□) FBPase exhibited 
partial loss of activities within five hours upon dilution. 
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Figure 5.  AMP binding sites in product and AMP complexes of Met
22
 FBPase.  AMP binding sites of Met
22
 
FBPase (magenta) from its product complex (panel A) and its AMP/product complex (panel B) were aligned to 
wild-type FBPase T-state (dark green).  Electron densities of Pi, AMP and/or Met
22
 from Met
22
 FBPase are 
contoured at 1.5σ.  AMP, Pi and residues 22 and 27 are shown as stick models.  Pictures were prepared with 
pymol (54). 
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Figure 6.  Structural alignment of the product complex of Gln
192
 FBPase with R-state and IR-state of 
FBPase.  Dimer-dimer rotations in the product complex of Gln
192
 FBPase (magenta), IR-state (cyan) and T-state 
(black) is illustrated by residues 10-90 from the C1-C2 dimer (panel A).  Residues 10-90 of all four subunits of 
each protein are superimposed on the R-state (grey).  Helix H2 of the AMP binding site of Gln
192
 FBPase 
(magenta) is superimposed on R- (grey) and IR-state (cyan) FBPases (panel B).  Residues involved in AMP 
binding and C1-C4 subunit interactions using helix H2 to align structures of Gln
192
, R- and IR-state FBPases 
(grey,cyan, and magenta, respectively.  Viewing directions and regions given by the associated FBPase icons in 
the upper right of the illustration.  Pictures were prepared with pymol (54). 
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Figure 7.  Survey of AMP binding sites in FBPases differing by mutations an conditions of ligation.  T-
state (A, PDB ID: 1EYJ), IR-state (B, PDB ID: 1YYZ), IT-state (C, PDB ID: 2F3D), Ala
37
 FBPase complex (D, 
PDB ID: 2FHY), Arg
15
 FBPase (E, PDB ID: 2JJK), OC252-bound FBPase (F, PDB ID: 1Q9D), Fru-2,6-P2-
bound FBPase (G, PDB ID: 2QVV), Fru-2,6-P2-bound His
45
/Arg
46
/Tyr
186
 FBPase complex (H, PDB ID: 
4GWU), Met
22
 FBPase (I), and Gln
192
 FBPase complex (J) are colored magenta and aligned to R-state FBPase 
(PDB ID: 1CNQ) using helix H2.  Dimer-dimer rotations for each complex are on right side of each panel.   
Viewing direction and region is that of Figure 5, panel B. 
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CHAPTER VI.  FUNCTIONAL IMPORTANCE OF SUBUNIT-PAIR 
ROTATION IN THE REGULATION OF TETRAMERIC MAMMALIAN 
FRUCTOSE-1,6-BISPHOSPHATASE 
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Abstract 
Fructose-1,6-bisphosphate (FBPase) is a homo-tetrameric enzyme that governs 
gluconeogenesis.  In eukaryotic organisms, AMP inhibits FBPase allosterically and 
cooperatively, whereas fructose 2,6-bisphosphate (Fru-2,6-P2) is an active site inhibitor.  
AMP and Fru-2,6-P2 cause similar conformational changes in FBPase: AMP drives a 15° 
subunit-pair rotation, transforming FBPase from an active R-state to an inactive T-state;  Fru-
2,6-P2 causes a 13° rotation.  Mutant forms of FBPase, which have different inhibitory 
properties, from partial AMP inhibition to a loss of AMP cooperativity, exhibit a range of 
intermediate levels of subunit-pair rotations.  Mutations of Met
18
, located at the subunit-pair 
interface, were pursued in order to further test models that subunit-pair rotation accounts for 
the properties of AMP inhibition of wild-type and mutant FBPases.  The Met
18→Lys 
mutation resulted in FBPase dimers that crystallized as tetramers with no subunit-pair 
rotation in the presence of AMP and no sensitivity toward AMP in inhibitory assays.   The 
Met
18→Trp mutation resulted in FBPase tetramers that have subunit-pair rotations of 4° and 
13° in the absence and presence of AMP, respectively.  Trp
18
 FBPase exhibits partial AMP 
inhibition, no cooperativity in AMP inhibition and significantly reduced AMP/Fru-2,6-P2 
binding synergism.  The properties of Trp
18
 FBPase indicate that AMP cooperativity is linked 
to subunit-pair rotation and that full AMP inhibition requires full subunit-pair rotation. 
. 
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Introduction 
Fructose-1, 6-bisphosphate (D-fructose-1, 6-bisphosphate 1-phosphohydrolase; EC 3. 
1. 3; FBPase) governs a key regulatory step in gluconeogenesis, hydrolyzing fructose-1,6-
bisphosphate (Fru-1,6-P2) to fructose 6-phosphate (Fru-6-P) and inorganic phosphate (1-2).  
A futile cycle is formed by FBPase and Fructose-6-phosphate-1-kinase (PFK-1), the 
counterpart of FBPase in glycolysis (3).  Fructose 2,6-bisphosphate (Fru-2,6-P2) and AMP 
are inhibitors for FBPase and activators of PFK-1 (3-9).  Glucagon release in response to 
starvation leads to the phosphorylation of the bifunctional liver enzyme fructose-6-
phosphate-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2), which in turn activates 
phosphatase activity toward Fru-2,6-P2; whereas in the fed state, insulin reverses the effect of 
glucagon, leading to elevated levels of  Fru-2,6-P2 (10-13).  The presence of Fru-2,6-P2 
enhances AMP inhibition up to 10-fold, a property called AMP/Fru-2,6-P2 synergism (8-9).  
Thus, even though AMP concentration is relatively constant in vivo, varying concentrations 
of Fru-2,6-P2 to cause AMP to be a dynamic regulator FBPase activity (14). 
Porcine liver FBPase is homotetramer existing in at least two quaternary states, R and 
T.  Product complexes of FBPase with divalent metals as Mg
2+
, Mn
2+
 or Zn
2+
 structurally 
define the active R-state (15-16).  AMP complexes of FBPase (with product and divalent 
metals) define the inactive T-state (17-18).  The tetramer is an approximate square-planar 
assembly of subunits.  The upper subunit pair rotates 15° relative to lower subunit pair and an 
important dynamic loop (residue 50-72) moves from active site (engaged conformation) to an 
alternative conformation (the disengaged conformation) during the R- to T-state transition 
(16,18).  AMP cooperatively binds to allosteric sites some 28 Å away from the nearest active 
site and proximal to the subunit-pair interface.  The kinetic mechanism of inhibition by AMP 
is non-competitive with respect to substrate and competitive with respect to Mg
2+
(19).  In the 
R-state, loop 50-72 (engaged conformation) stabilizes two of three metal cations bound to the 
active site (16).  The binding of AMP drives subunit-pair rotation, the consequence of which 
is the destabilization of the engaged conformation of loop 50-72.  The AMP-induced 
displacement of loop 50-72 to its disengaged conformation leaves one divalent metal in the 
active site (18).  Introduction of proline into hinge of the dynamic loop reduces activity and 
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AMP inhibition of FBPase (20).  Molecular dynamics simulation of the R- to T-state 
transition pathway implies that the subunit-pair rotation precedes loop displacement (21).  
Experimentally, mutations that destabilize T-state lead to identification of two AMP-bound 
intermediate states (IR-state and IT-state), which have engaged dynamic loops and dimer-
dimer rotations of 3 and 11°, respectively (21-22). 
Fru-2,6-P2 is a competitive inhibitor with respect to Fru-1,6-P2 (5-6).  Although 
bound to the active site, Fru-2,6-P2 induces a13° subunit-pair rotation with disengaged loops 
similar to effect of AMP (15° rotation, disengaged loops) (23).  The similar end-states 
induced independently by AMP and Fru-2,6-P2 is the structural basis of AMP/Fru-2,6-P2 
synergism (23).  Mutations that reduce AMP/Fru-2,6-P2 synergism also reduce Fru-2,6-P2 
subunit pair-rotation (24).  For Escherichia coli FBPase (eFBPase), a structural homolog of 
porcine liver FBPase, has no AMP/Fru-2,6-P2 synergism and no Fru-2,6-P2-induced subunit-
pair rotation (23). 
Mutant FBPases that have different mechanisms of AMP inhibition fall into two 
groups, which are distinguished by their oligomeric states (29).  Mutant FBPases that exist as 
dimers in solution lack cooperativity in AMP inhibition, and exhibit wide range of sensitivity 
toward AMP, and in some instances exhibit partial inhibition at saturating levels of AMP 
(29).  A second group consistent with FBPase tetramers but with different subunit pair 
rotations exhibit reduced AMP cooperativity (29), or partial AMP inhibition (21). Mutations 
on Met
18
 provide further tests of the two structural determinants for AMP inhibition.  The 
mutation of Met
18→Lys causes dissociation of the tetramer.  AMP induces subunit-pair 
separation instead subunit-pair rotation. The resulting enzyme is insensitive to AMP, and 
thus lacks AMP cooperativity, yet conforms to the model proposed for AMP properties of 
FBPase dimers.  Met
18→Trp FBPase is a stable tetramer that lacks AMP cooperativity and 
exhibits partial inhibition by AMP.  Trp
18
 FBPase evidently cannot be in either the R- or T-
state, having instead subunit-pair rotations of 4° and 13° in the presence and absence of AMP, 
respectively.  Properties of Trp
18
 FBPase are consistent with AMP cooperativity originating 
from an R-state tetramer with little or no subunit-pair rotation, and full AMP inhibition 
requiring full subunit-pair rotation to the canonical T-state.  Moreover, Trp
18
 FBPase could 
137 
 
serve as a useful target in screening for inhibitors of FBPase that act synergistically with 
AMP and Fru-2,6-P2. 
 
Experimental procedures  
Materials— Fru-1,6-P2, NADP
+
 and AMP were purchased from Sigma.  Fru-2,6-P2 was 
produced by the method of Van Schaftingen and Hers (25).  Glucose-6-phophate 
dehydrogenase and phosphoglucose isomerase came from Roche Applied Sciences.  FBPase-
deficient E. coli strain DF 657 was from the Genetic Stock Center at Yale University.  Other 
chemicals were of reagent grade or equivalent. 
Mutagenesis of wild-type FBPase— All mutations were accomplished by specific base 
changes utilizing the Transformer
TM
 site-directed mutagenesis kit (Clontech).  Mutagenic 
primers were as follows: Met
18→Lys, 5'-ACCCGCTTCGTCAAGGAGGAGGGCAG-3'; 
Met
18→Trp, 5'- ACCCGCTTCGTCTGGGAGGAGGGCAG-3' (altered bases are underlined 
and in bold typeface).  Constructs were confirmed by sequencing the promoter region and the 
entire open reading frame.  The Iowa State University sequencing facility provided DNA 
sequences using the fluorescent dye-dideoxy terminator method. 
Expression and purification of wild-type and mutant FBPases— Supernatant solutions of cell 
free extracts were loaded onto a Cibracon Blue-Sepharose column previously equilibrated 
with 20 mM Tris-HCl, pH 7.5, 5mM MgCl2.  The column was washed with 20 mM Tris-HCl, 
pH 7.5.  Enzyme was eluted with a gradient of 0-1 M of sodium chloride in 20 mM Tris-HCl, 
pH 7.5, then dialyzed against 20 mM Tris-HCl, pH 8.5, before loading onto a DEAE-
Sepharose column equilibrated with 20 mM Tris-HCl, pH 8.3.  Purified enzyme was eluted 
with a sodium chloride gradient (0–0.5 M) in 20 mM Tris-HCl, pH 8.3, and then dialyzed 
extensively against 50 mM Hepes, pH 7.4, for kinetic investigations and for crystallization 
experiments.  Purity and protein concentrations of FBPase preparations were confirmed by 
sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (26) and the 
Bradford assay (27), respectively. 
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Kinetic experiments— Phosphoglucose isomerase and glucose-6-phosphate dehydrogenase 
are coupling enzymes in assays for FBPase activity (1).  The formation of NADPH was 
monitored by absorbance at 340 nm on UV spectrometer for specific activity measurement 
and by its fluorescence emission at 470 nm using an excitation wavelength of 340 nm for all 
other assays.  Assays were performed at 22 °C in 50 mM Hepes, pH 7.5, contained EDTA 
and KCl at concentrations of 10 μM and 150 mM, respectively, and were initialized by the 
addition of enzyme.  Kinetics data were fit to models with Grafit (28). 
Sedimentation equilibrium— Protocols for sedimentation equilibrium experiments are in 
reference 29.  Three protein concentrations (OD280 = 0.3, 0.5 and 0.7) of wild-type and 
mutant FBPases were centrifuged to equilibrium at 15000, 18000 and 21000 rpm and 4 °C, 
using a Beckman XLA ultracentrifuge with an AN-60 rotor.  Data were to single component 
and two-component equilibrium models using the program UltraScan (30). 
Crystallization of mutant FBPase— The method of hanging drops was used in the 
crystallization of FBPase.  Droplets on cover slips with 2 μl of protein solution mixed with 2 
μl of precipitant solution were suspended over wells containing 500 μl of the precipitant 
solution.  Crystals of product complex grew from a protein solution of FBPase (10 mg/ml), 
Hepes (25 mM, pH 7.4), MgCl2 (5 mM), and Fru-1,6-P2 (5 mM)) combined with a 
precipitant solution of Hepes (100 mM, pH 7.4), polyethylene glycol 3350 (8% (w/v)), 
glycerol (27% (v/v)), and t-butyl alcohol (5% (v/v))).  Crystals of the AMP/product complex 
grew from a protein solution of FBPase (10 mg/ml), Hepes (25 mM, pH 7.4), MgCl2 (5 mM), 
Fru-1,6-P2 (5 mM), and AMP (5 mM) combined with a precipitant solution of Hepes (100 
mM, pH 7.4), polyethylene glycol 3350 (12% (w/v)), glycerol (23% (v/v)), and t-butyl 
alcohol (5% (v/v)).  Crystals were of equal dimensions (0.2– 0.4 mm), growing in 
approximately 3 days at 20 °C.  Crystals can be transferred directly from droplet to liquid 
nitrogen as cryo-protectants were included in conditions of crystallization. 
Data collection, structure determination and refinement— Data were collected at Iowa State 
University from single crystals on a Rigaku R-AXIS IV++ rotating anode/image plate system 
using CuKα radiation from an Osmic confocal optics system and a temperature of 110 K.  
Program D*trek (31) was used in data reduction. 
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Product and AMP/product complexes of Lys
18
 FBPase and the product complex of 
Trp
18
 FBPase are isomorphous to R-state FBPase whereas the AMP/product complex of 
Trp
18
 FBPase is isomorphous to T-state FBPase.  Structures were solved by molecular 
replacement with R-state FBPase (PDBID: 1CNQ) and T-state FBPase (PDBID:1EYJ) as 
initial models.  The resulting models underwent refinement using CNS (32) with force 
constants and parameters of stereochemistry from Engh and Huber (33).  A cycle of 
refinement consisted of slow cooling from 1000 to 300 K in steps of 25 K followed by 100 
cycles of conjugate gradient minimization and concluded by the refinement of individual 
thermal parameters.  Xtalview (34) and Coot (35) were used in manually adjustments to 
structures.  Waters were added to difference electron density of 2.5σ or better until no 
significant decrease was evident in the Rfree value.  Stereochemistry of the models was 
examined by the use of PROCHECK (36). 
 
Results 
Rationale for position 18 mutations— Met18 is at the C1-C4 interface of FBPase (Figure 1).  
In the T-state, side chains of Met
18
 from subunits C1 and C4 pack mutually, whereas in the 
R-state the side chains are apart.  The mutation of Met
18
 to lysine should eliminate the T-state 
simply because two positively charged residues would occupy hydrophobic space filled by 
side-chains of methionine.  The mutation of Met
18
 to rigid tryptophan should significantly 
limit subunit-pair rotation, favoring intermediate conformational states for the tetramer. 
Kinetics experiments— FBPases that exhibit a dimer-tetramer equilibrium such as eFBPase 
or specific mutants of porcine FBPase also show a decline in activity over several hours upon 
dilution (29,37).  Lys
18
 FBPase exhibit similar behavior (data not shown), indicating an 
unstable tetramer.  Initializing assays with enzyme (as opposed to incubation of enzyme with 
reagents and initiation with metal cofactor) eliminates the effects of dilution as only the first 
few minutes of the linear progression curve determines the initial velocity.  Kinetic 
parameters from enzyme-initiated assays are in Table I. 
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Lys
18
 and Trp
18
 FBPass retain approximately 60% and 30% of wild-type activity, 
respectively, with Km for Fru-1,6-P2 unchanged.  Mg
2+
 activates wild-type and many mutant 
FBPases with positive cooperativity modeled empirically by Equation 1: 
v/ m=
1
1 (
A
0.5
A
)
n     (Equation 1) 
Where v, Vm , A, A0.5 and n are velocity, maximum velocity, Mg
2+
 concentration, Mg
2+
 
concentration that gives 50% activation and Hill coefficient for Mg
2+
 binding, respectively.  
The cooperative binding of Mg
2+
 in wild-type (n=1.7) and Lys
18
 (n=1.9) FBPase disappears 
in Trp
18
 FBPase (n=1.2).  The Michaelis-Menten constant for Mg
2+
 (Ka-Mg
2+
 in Table 1) 
employs Equation 2 in fitting initial velocity at different at different concentrations of Fru-
1,6-P2 and Mg
2+
: 
v/ m= 
An B
A2 B Ka B Kb A
n Kia Kb
    (Equation 2) 
Where v, Vm, A, B, Ka, Kb, and Kia represent initial velocity, maximum velocity, concentration 
of free Mg
2+
, concentration of free Fru-1,6-P2, the Michaelis-Menten constant for Mg
2+
, the 
Michaelis-Menten constant for Fru-1,6-P2, and the dissociation constant for Mg
2+
 from the 
enzyme-metal complex, respectively.  n is set to 2 for both wild-type and Lys
18
 FBPase and 
to unity for Trp
18
 FBPase.  Ka for Mg
2+
 decreases around 4- and 7-fold for Lys
18
 and Trp
18
 
FBPases, respectively, relative to wild-type FBPase.  Reduced Mg
2+
 affinity has also been 
observed in Arg
15→Ala and Glu19→Gln FBPases (38). 
AMP inhibition of Lys
18
 FBPase is essentially absent up to 10 mM (Figure 2).  In 
contrast, AMP is a potent inhibitor of Trp
18
 FBPase.  The AMP inhibition curve is a fit of 
Equation 3: 
v/ m= 
         
1 (
 
 0.5
)
n              (Equation 3) 
where v, Vm , Vplateau, I, I0.5 and n are velocity, maximum velocity, relative velocity at 
saturating levels of AMP, AMP concentration, AMP concentration that gives 50% activity 
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and Hill coefficient for AMP binding, respectively.  AMP binds to wild-type FBPase with 
positive cooperativity but to Trp
18
 FBPase with no cooperativity. 
AMP inhibition is competitive with respect to Mg
2+
.  Ki for AMP comes from fits 
using Equation 4: 
v/ m=
Ana
Ana Ka.(1 
 ni
Ki
)
   (Equation 4) 
where v is the velocity, VM is the maximum velocity, A is the concentration of Mg
2+
, I is the 
concentration of AMP, Ka is the Michaelis constant for Mg
2+
, and Ki is the dissociation 
constant for AMP from the enzyme-inhibitor complex, na and ni are Hill coefficients for 
Mg
2+
and AMP, respectively.  na and ni are set to 2 for wild-type FBPase and unity for Trp
18
 
FBPase.  For Lys
18 
FBPase is not inhibited by AMP. 
Concentrations of 10 mM Mg
2+
 and 20 μM Fru-1,6-P2 were employed in the 
determination of Fru-2,6-P2/AMP synergism.  AMP titrations were carried out using six fixed 
concentrations of Fru-1,6-P2 (0, 0.1, 0.3, 1, 3, and 10 μM, respectively) (Figure 3).  Equation 
3 is fit to data each series of constant concentration of Fru-1,6-P2.  For wild-type FBPase, I0.5 
for AMP inhibition decreases significantly as Fru-2,6-P2 concentration increases, indicating 
strong Fru-2,6-P2/AMP synergism; on the other hand, Trp
18
 FBPase showed only marginal 
change.  The I0.5 at different Fru-2,6-P2 concentration can be fit to Equation 5 (28): 
          
      
     
         
    
   
  
  
   (Equation 5) 
In the equation above, I0.5 is the AMP concentration that causes 50% inhibition,     
    
 
is the AMP concentration that causes 50% inhibition in the presence of an infinite 
concentration of Fru-2,6-P2,     
    is the AMP concentration that causes 50% inhibition in the 
absence of Fru-2,6-P2, Ib is the concentration of Fru-2,6-P2, αb is the concentration of Fru-
2,6-P2 that produce 50% of maximal synergism.  The value of (    
   /    
    
) is a measure of 
Fru-2,6-P2/AMP synergism.  For wild-type FBPase, AMP inhibition is enhanced 7.6 fold by 
Fru-2,6-P2, whereas for Trp
18
 FBPase, the     
   /    
    
 values is 1.6. 
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Sedimentation Equilibrium— Fitting results of sedimentation equilibrium data with single-
component and dimer-tetramer equilibrium models were reported in Table II.  Wild-type and 
Trp
18
 FBPase show molecular weights of approximately 110 kDa, whereas Lys
18
 FBPase has 
a molecular weight of 64 kDa, approximately half of wild-type value.  A similar molecular 
weight has been obtained for wild-type FBPase through dynamic light scattering (37).  
Molecular weights of all three FBPases from the dimer-tetramer equilibrium model are close 
to those from the single-component model.  Kd values from dimer-tetramer equilibrium 
model were over 1 M, which indicates the real Kd value for the dissociation of the tetramer 
into dimers is out of the concentration range used in sedimentation equilibrium experiments. 
Crystal Structures of product and AMP/product complexex of Lys
18
 FBPase (Protein Data 
Bank code 4GWW and 4GWY)— Crystals of product and AMP/product complexes of Lys18 
FBPase belong to space group I222, and are isomorphous to those of the canonical R-state 
(16).  A monomer exists in the asymmetric unit.  Models include residues 6-335 and 10-335 
for product and AMP/product complexes of Lys
18
 FBPase, respectively.  High B-parameters 
and weak electron density are associated with residues 54-70 of the dynamic loops in both 
complexes.  Statistics of data collection and refinement are in Table III. 
The product complex of Lys
18
 FBPase is in the R-state.  The root-mean-squared 
deviation between Lys
18
 and wild-type R-states is approximately 0.4 Å, indicating no 
significant differences in global conformations.  One Fru-6-P and Pi, and two metal cations 
(Mg
2+
 at sites 1 and 2) bind to the active site.  The NZ atom of Lys
18
 is 3.3 Å away from the 
backbone carbonyl of Ser
87
 of an adjacent subunit (C1-C4 interaction).  The structure is in 
other ways comparable to the canonical R-state, which is described in detail elsewhere (16). 
The AMP/product complex of Lys
18
 FBPase appears to be an R-like tetramer 
(subunit-pair rotation of 0°) with loops 50-72 in engaged conformations; however, subunit-
pairs C1-C2 and C3-C4 are separated by approximately 1 Å relative to the canonical R-state 
(Figure 4).  AMP binds to allosteric sites with Fru-6-P and Pi and three metal cations (Mg
2+
 
at sites 1, 2 and 3) at the active site.  The base of AMP hydrogen bonds with the side chain of 
Thr
31
 and the backbone carbonyl of Val
17
, inducing conformational changes (Figure 5) 
comparable to those in other R-like complexes in the absence and presence of bound AMP 
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(22, 29): Helix H1 shifts towards and helix H2 away from the center of the tetramer and the 
side chain of Ile
10
 moves away from its interaction with Ile
190
.  Lys
18
 undergoes a 
conformational change that allows it to avoid a collision with the side chain of Ser
87
 from a 
symmetry related subunit.  The separation of subunit pairs weakens C1-C4 interactions 
normally observed in stable tetramers.  Backbone carbonyls of residues 108-110 are no 
longer within donor-acceptor distance of Arg
22
 and that between Thr
39
 and Glu
192
 increases 
by 0.6 Å.  Similar changes occur in the IR-state of the AMP/product complex of Leu
54
 
FBPase; however, those changes are due to a 3° subunit-pair rotation rather than to the 
separation of subunit pairs without rotations as observed here. 
Crystal Structures of Product Complex and AMP complex of Trp
18
 FBPase (Protein Data 
Bank code 4GWX, 4GWZ)— Crystals of the product complex of Trp18 FBPase are in space 
group I222 (a = 53.422 Å; b = 82.646 Å; c = 165.423 Å), isomorphous to those of the 
canonical R-state (16).  Crystals of the AMP/product complex of Trp
18
 FBPase are in space 
group P21212 (a = 59.776 Å; b = 166.064 Å; c = 79.871 Å), isomorphous to those of the 
canonical T-state (18).  Both models start from residue 9 and end at residue 335.  Statistics 
for data collection and refinement are in Table III. 
Three metal cations (Mg
2+
 at sites 1, 2 and 3), Fru-6-P and Pi are at the active site of 
the Trp
18
 FBPase product complex.  Loop 50-72 is ordered and in its engaged conformation.  
As has been observed in the Fru-2,6-P2 complex of His
45
/Arg
46
/Tyr
186
 FBPase (24), the AMP 
binding site in product complex adopts conformational changes observed typically in the 
presence of bound AMP (Figure 6).  The C-terminal end of helix H1 shifts towards the center 
of the tetramer, and the side-chain of Ile
10
 leaves its hydrophobic contact with Ile
190
.  
The AMP/product complex of Trp
18
 FBPase has Fru-6-P and Pi at the active site with 
2 metal cations (Mg
2+
 at site 1 and 2), as well as strong electron density covering a molecule 
of AMP at the allosteric site.  Loop 50-72 is in its disengaged conformation with residues 62-
72 disordered (weak electron density and high thermal parameters). 
The quaternary structures of Trp
18
 FBPase with and without AMP differ by subunit-
pair rotations that are considerable less than those of the wild-type enzyme (Figure 7).  In the 
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absence of AMP, the product complex of Trp
18
 FBPase has a subunit-pair rotation of 4° and 
in the AMP/product complex a 13° of subunit-pair rotation. The corresponding values are 0° 
and 15° for wild-type FBPase.  The restricted subunit-pair rotation observed for Trp
18
 
FBPase is only in part due to steric constraints introduced by the rigid fused ring of the 
indole (Figure 6).  Assuming no only rigid-body motion, a subunit-pair rotation of 0° puts 
that side chain of Trp
18
 3.3 Å away from main-chain atoms of Ser
88
, and a subunit-pair 
rotation of 15° puts that side chain 3.1 Å from the Cα atom of Gly28.  Unlike the wild-type 
side chain of Met
18
, which falls into the steric well defined by helices H2 and H3 (R-state) or 
the well defined by helices H1 and H2 (T-state), the side chain of Trp
18
 remains in the steric 
well defined by helices H2 and H3, and evidently cannot transition into the well defined by 
helices H1 and H2.   nstead, the χ1 torsion angle of Trp18 may be the basis for two quaternary 
states.  The R-like state (subunit-pair rotation of 4°) has a χ1 angle of –63°, whereas in the T-
like state (subunit-pair rotation of 13°) the χ1 torsion angle is –176°.  Hence, the two energy-
minimum χ1 angles of Trp18 define the two quaternary states of Trp18 FBPase. 
 
Discussion 
Several mutant forms of porcine FBPase without AMP cooperativity are in the 
literature (29, 37-41).  Most are subunit-pair dimers in solution, and hence lose AMP 
cooperativity by the loss of C1-C4 interactions (29).  Arg
22→Met FBPase, however, is a 
tetramer in solution without cooperativity and is in a T-like quaternary state in the absence of 
AMP (29).  Presumably, cooperativity is absent in Met
22
 FBPase because a single molecule 
of AMP locks the tetramer into an inactive conformation.  Hence, mutant FBPases fall into 
two groups (solution dimers and tetramers), which require different models to account for the 
properties of AMP inhibition. 
The model for AMP cooperativity exhibited by the tetramer comes from the kinetics 
of hybrid tetramers (51) and the structure of an AMP-ligated R-like complex of Ala
54→Leu 
FBPase (22).  AMP ligation of hybrid tetramers with functional pockets in one of two 
subunit-pairs of the tetramer (for instance subunits C1 and C2) is non-cooperative, whereas 
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the binding of one molecule of AMP to each of two subunit-pairs is cooperative.  The 
AMP/product complex of Leu
54
 FBPase (IR-state, 3° subunit-pair rotation) putatively 
captures the effect of AMP binding to the R-state; however, are observed conformational 
changes due to the binding of AMP or the 3° subunit-pair rotation?  Trp
18
 FBPase is a 
tetramer in solution (Table II).  Its product complex exhibits a 4° subunit-pair rotation in the 
absence of AMP.  The displacement of Ile
10
 from the surface of Ile
190
 is evident; however, 
hydrogen bonds critical to the proposed mechanism of cooperativity are intact (Thr
39
 retains 
its hydrogen bond with Glu
192
 across the C1-C4 interface and Asn
35
 retains its hydrogen bond 
with Thr
14
).  Hence, a 4° subunit-pair rotation alone does not cause conformational change in 
the AMP pocket.  Such changes must come with the binding of AMP. 
If AMP pockets of the product complex of Trp
18
 FBPase are similar to those of wild-
type R-state, then why has the Ki for AMP increased by 10-fold (Table I)?  As in the wild-
type enzyme, the binding of AMP must shear helices H1 and H2 and consequently disrupts 
hydrogen bonds between Asn
35
 and Thr
14
 and between Thr
39
 and Glu
192
 (the latter reforms 
after transition to the T-state).  Additionally for Trp
18
 FBPase, χ1 of Trp18 must undergo a 120° 
rotation, which requires more AMP binding energy relative to the wild-type system, hence 
the increase in Ki. Moreover, Trp
18
 FBPase with AMP only harbors 13 degree subunit-pair 
rotation, 2 degree away from the optimal AMP binding conformation observed in wild-type 
enzyme. 
AMP is a non-cooperative inhibitor of Trp
18
 FBPase if the binding of a single 
molecule of AMP triggers the R- to T-state transition (the proposed model for the absence of 
AMP cooperativity for Arg
22→Met FBPase).  A single molecule of AMP maximally inhibits 
the mutant enzyme, so that the binding of additional molecules of AMP has no effect on 
reaction velocity.  The absence of cooperativity in the inhibition of wild-type FBPase by Fru-
2,6-P2 is subject to a similar explanation.  If a single molecule of Fru-2,6-P2 puts the wild-
type tetramer into a T-like state, then the cooperative binding of additional molecules of Fru-
2,6-P2 has no influence on activity.  The appearance of cooperativity in substrate-saturation 
curves in the presence of low levels of Fru-2,6-P2 (6) infers that an Fru-2,6-P2-stabilized T-
state can be driven back into the R-state by the binding of one or more molecules of Fru-1,6-
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P2.  The unoccupied active sites will necessarily have a higher affinity for substrate, hence 
the observed sigmoidicity in substrate-binding curves. 
The model for partial AMP inhibition of Ile
10→Asp FBPase applies to Trp18 FBPase.  
Both enzymes are tetramers (Asp
10
 FBPase retains a wild-type Hill coefficient for AMP 
inhibition of two).  Subunit-pair rotation in the tetramer correlates with AMP inhibition (24).  
Hence, the observed subunit-pair rotation of 13° in the AMP/product complex of Trp
18
 
FBPase is the basis for 10% activity in the presence of saturating levels of AMP.  Full 
inhibition by AMP in the tetramer requires full subunit-pair rotation (15°) as has been 
observed in the kinetics and structures of Arg
22→Met FBPase (29). 
Solution dimers represent the other subgroup of FBPase mutants, of which Lys
18
 
FBPase is evidently a member (Table II).  Loss of the C1-C4 interface abolishes 
cooperativity (29); however, levels of AMP inhibition vary widely, being absent (Lys
18
 
FBPase), or biphasic (Gln
192
 and Ala
39
 FBPases).   Perhaps the simplest model to account for 
these observations is one of a reversible dimer-tetramer equilibrium in which AMP stabilizes 
an inactive T-state tetamer (Scheme I): 
       
Scheme I 
AMP arrests subunit exchange (51), indicating a stabilizing effect on the tetramer.  
Lys
18
 FBPase differs from other mutant dimers in that it cannot form a stable T-state tetramer.  
In the T-state, side chains of Lys
18
 from subunits C1 and C4 would be in contact and buried 
at a hydrophobic interface (Figure 1).  Other dimers (for instance, Gln
192
 and Ala
39
 FBPases) 
bind AMP, presumably without inhibition, and form inactive T-state tetramers.  Velocity as a 
function of AMP concentration for the model (Figure 2, 29) depends on the constant 
governing the equilibrium between AMP-bound dimers and tetramers.  Partial activity is 
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determined by the fraction of AMP-bound dimers in the presence of saturating AMP, and the 
Hill coefficient for AMP inhibition is unity. 
Mg
2+
 cooperativity in Trp
18
 FBPase has fallen to near unity, but that of Lys
18
 FBPase 
is unchanged from the wild-type enzyme (Table 1).  Mg
2+
 cooperativity is a property of the 
FBPase monomer, and is due putatively to the coupled binding of Mg
2+
 to metal sites 2 and 3 
(42).  Hence, undiminished Mg
2+
 cooperativity for a solution dimer (such as Lys
18
 FBPase) 
comes as no surprise; however, the loss of Mg
2+
 cooperativity in Trp
18
 FBPase (a tetramer) is 
noteworthy.  The deletion of 7 and 10 residues from the N-terminus of FBPase reduces Mg
2+
 
cooperativity and increases the Ka for Mg
2+
 by 20-fold.  Mutations of Asp
2→Ala, Phe6→Trp, 
Asp
7→Ala and Asn9→Ala modestly elevate the Ka for Mg
2+
 and depress the Hill coefficient 
for Mg
2+
 (52).  Residues 1 to9 of FBPase have weak electron density R-state structures (and 
electron density altogether absent in the T-state), but Asn
9
 hydrogen bonds with Arg
15
and 
may indirectly stabilize the engaged conformation of loop 50-72 (52).  The likely 
consequence of a destabilized engaged conformation for loop 50-72 is weak binding of Mg
2+
 
at site 3, causing an increase in the Ka for Mg
2+
, reduced cooperativity and decreased activity.  
As Trp
18
 FBPase cannot reach the canonical R-state (its product complex has a 4° subunit-
pair rotation), its engaged loop 50-72 may be destabilized with the resulting impact on the 
properties of Mg
2+
 activation of catalysis. 
FBPase is a drug target for type II diabetes (44).  To date, most drug development 
efforts have focused on the AMP binding site (45-50); however, there is an inherent 
weakness in targeting the AMP site.  Firstly, the AMP binding site is hydrophilic and 
hydrophilic inhibitors pass through membranes with difficulty.  Secondly, adenine 
nucleotides pervade metabolism as regulators and substrates, necessitating the incorporation 
of specific attributes that are unique to the AMP pocket of FBPase.  The cavity occupied by 
Met
18
 in the T-state could be a good target for drug development.  Indeed, some inhibitors of 
FBPase occupy the Met
18
 pocket and the adenine pocket of T-state complexes of FBPase (46).  
In such complexes, Met
18
 remains in the well between helices H2 and H3 to create space for 
planar hydrophobic moieties from a pair of inhibitor molecules (Figure 8).  The T-like state 
of Trp
18
 FBPase leaves a comparable void also by remaining in the well defined by helices 
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H2 and H3.  Trp
18
 (the only tryptophan in this mutant form of FBPase) provides a reporter 
group for the binding of ligands to the Met
18
 pocket, which offers a simple fluorescence-
based assay for screening ligands.  Any ligand that occupies this cavity should in principle 
inhibit FBPase synergistically with AMP and Fru-2,6-P2. 
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Table I.  Kinetic parameters for wild-type and mutant FBPases. 
FBPase Specific 
Activity 
KM 
Fru-1,6-P2 
Hill 
Mg
2+
 
Ka 
Mg
2+
 
Hill 
AMP 
Ki 
AMP 
Ki 
Fru-2,6-P2 
 Units/mg/s μM  mM2 a  μM2 b μM 
Wild-type 25 1.47±0.07 1.7±0.1 0.70±0.05 2.2±0.1 0.76±0.08 0.14±0.01 
Lys
18
 16 1.2±0.1 1.9±0.1 3.3±0.7 N.D.
c
 N.D. 0.15±0.03 
Trp
18
 7.5 1.2±0.2 1.2±0.1 5.1±0.4 1.05±0.09 8.2±0.5 0.079±0.005 
a
 Ka for Mg
2+
 for Trp
18
 FBPase is in unit mM 
b
 Ki for AMP for Trp
18
 FBPase is in unit μM 
c
 Not determined 
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Table II. Sedimentation equilibrium data fitting for wild-type and mutated FBPase 
Protein 
Single component, 
ideal 
Monomer-dimer equilibrium 
M.W. S.D.
b
 M.W. Kd (M) S.D.
b
 
Wild-
Type 
112100 0.009 113900 2.718 0.01 
Lys
18
 64270 0.006 64270 2.718 0.006 
Trp
18
 114100 0.007 114100 2.718 0.007 
 
a 
The results were derived from global fitting of all data with software Ultrascan 
b 
Standard derivation of the global fitting 
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Table III.  Statistics of data collection and refinement for Lys
18
 and Trp
18
 FBPase. 
Crystalline complex
a
 
Product 
Complex of 
Trp
18
 
AMP/Product 
Complex of 
Trp
18
 
Product 
Complex of 
Lys
18
 
AMP/Product 
Complex of 
Lys
18
 
Space group I222 P21212 I222 I222 
Resolution limit (Å) 2.34 2.60 3.00 3.00 
Number of 
measurements 
56,218 89,544 21,589 26,433 
Number of unique 
reflections 
15,914 24,685 7,145 7139 
Completeness of data (%): 
   Overall 99.4 97.8 93.1 91.5 
   Last shell/resolution- 
   range (Å) 
99.9/2.43-2.35 99.6/2.69-2.60 96.6/3.11-3.00 94.3/3.11-3.00 
Rsym
b
 
   Overall 0.094 0.086 0.169 0.137 
   Last shell/resolution- 
   range (Å) 
0.313/2.43-2.35 0.338/2.69-2.60 0.488/3.11-3.00 0.401/3.11-3.00 
Number of reflections 
in refinement 
15,112 23,377 6,810 6,811 
Number of atoms 2,670 5261 2589 2,614 
Number of solvent 
sites 
139 166 38 75 
Rfactor
c
 0.204 0.205 0.223 0.210 
Rfree
d
 0.254 0.275 0.292 0.267 
Mean B (Å
2
) 
overall/protein 
32.7 37.0 63.6 43.0 
Mean B (Å
2
) for AMP - 39.1 - 62.4 
Root mean square deviations: 
  Bond lengths (Å) 0.021 0.017 0.015 0.016 
  Bond angles (°) 1.6 1.8 1.5 1.6 
a 
Unit cell lengths (a, b, c) in Å for product and AMP/product complexes of Trp
18
 and Lys
18
 FBPase are (53.971, 
83.272, 165.772), (59.776, 166.064, 79.871), (53.433, 82.646, 165.423) and (53.261, 82.571, 168.885), 
respectively.  Unit cell angles (, , ) are 90 for space groups I222 and P21212. 
b 
Rsym = ji | Iij - <Ij> | /ijIij, where i runs over multiple observations of the same intensity, and j runs over all 
crystallographically unique intensities. 
c 
Rfactor =  || Fobs | - | Fcalc || / | Fobs |, where | Fobs | > 0. 
d 
Rfree based upon 10% of the data randomly culled and not used in the refinement. 
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Figure 1.  R- and T-states of FBPase.  Cartoon representation of R-state (upper left) and T-state (upper right) 
defines the subunit-pair rotation which has subunits C1 and C2 move as a rigid body relative to subunits C3 and 
C4.  Bold lines and dark colors represent structural elements and ligands binding to the front face of the 
tetramer.  Thin lines and pastel colors represent structural elements and ligands on the back face of the tetramer.  
Shaded regions with arrows represent regions and viewing directions, respectively, for the panels below.  In the 
R-state (lower left), Met
18
 (stick representation) occupies the well between helices H2 and H3, whereas in the T-
state (lower right), Met
18
 is in contact with its symmetry partner and occupies the well between helices H1 and 
H2. 
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Figure 2.  AMP inhibition of wild-type and mutant FBPases.  Relative velocity as a function of AMP 
concentrations for wild-type ( ), Trp
18
 ( ) and Lys
18
 (●) FBPases were shown.  Curves come from fits of 
equation 3 for wild-type and Trp
18
 FBPase. 
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Figure 3.  Fru-2,6-P2/AMP synergism for wild type and Trp
18
 FBPase.  A and B represent data from wild 
type and Trp
18
 FBPase, respectively.  AMP titration curve (left panels) at different Fru-2,6-P2 concentrations: 0 
(○), 0.1 (□), 0.3 ( ), 1 (●), 3 ( ), and 10 μM ( ).  The I0.5 values determined from AMP titrations are plotted 
against Fru-2,6-P2 concentrations (right panels). 
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Figure 4.  Crystal structure of product and AMP/product complexes of Lys
18
 FBPase.  Lower dimer of the 
product (black) and AMP/product (grey) complexes of Lys
18
 FBPase are aligned to reveal the dimer-dimer 
separation the latter complex.  Ligands at the AMP site are depicted with associated electron densities. 
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Figure 5.  Conformational change at AMP binding site upon AMP ligation of Lys
18
 FBPase.  Subunit C1 
of product (dark grey) and AMP/product complexes (light grey) of Lys
18
 FBPase are aligned with top- (A) and 
side- (B) views of the AMP binding site presented.  Selected residues are in stick-model representation.  Grey 
dotted lines indicate donor-acceptor bonds, whereas red dotted lines in B indicate the potential conflict between 
Lys
18
 and Ser
87
 in the absence of the 1 Å dimer-dimer separation. 
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Figure 6.  Global conformational changes of Trp
18
 FBPase.  A. lower dimers of wild-type product complex 
(grey), wild-type AMP/product complex (black), Trp
18
 product complex (magenta) and Trp
18
 AMP complex 
(cyan) are aligned and the first 90 residues of the upper dimer of each structure are shown.  Dimer-dimer 
rotations and the rotational axis are indicated in the figure. B. Side-view of the alignment of the product 
complex of wild-type (grey) and Trp
18
 (magenta) FBPase is shown.  The potential conflict between sidechain of 
Trp
18
 and Ser
88
 is indicated by a dotted line.  C. Side-view of the alignment of AMP/product complex of wild-
type (black) and Trp
18
 (cyan) FBPase is shown.  The potential conflict between sidechain of Trp
18
 and Gly
28
 is 
indicated by a dotted line. 
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Figure 7.  Structure alignment of first two helixes of wild-type product complex (grey), Trp
18
 product 
complex (magenta) and His
45
/Arg
46
/Tyr
186
 Fru-2,6-P2 complex (cyan).  Helix 2 from all complexes is 
aligned to reveal the relative change between Helix 1 and Helix 2. 
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Figure 8.  Met
18
 cavity in T-state of FBPase.  T-state FBPase with AMP (PDB ID: 1EYJ) (grey) and A37 
(PDB ID: 2FHY) (cyan) are aligned.  A37 is an AMP binding site effector that spans both the AMP binding site 
and the Met
18
 cavity.  Binding modes of AMP and A37 are illustrated by stick representations. 
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Abstract 
Fructose-1, 6-bisphosphatase (FBPase) is a key regulatory enzyme in 
gluconeogenesis.  Porcine liver FBPase is a model for eukaryotic FBPases, being an active 
tetramer subject to inhibition by AMP and fructose 2,6-bisphosphate (Fru-2,6-P2).  In 
contrast, Escherichia coli FBPase, a model FBPase for many bacterial systems, is subject to 
feed-forward activation by phosphoenolpyruvate (PEP) and synergistic inhibition by AMP 
and glucose 6-phosphate (Glc-6-P).  To the best of our knowledge Fru-2,6-P2 is present in 
eukaryotic organisms, but in no bacterial system.  The dissimilarity in regulation of E. coli 
and porcine FBPases begs the question: What is the starting point in evolution for Fru-2,6-P2 
inhibition and AMP/Fruc-2,6-P2 synergism of eukaryotic FBPases?  FBPase from the 
bacterium Leptospira interrogans is one of a select group with key residues characteristic of 
eukaryotic FBPases.  Experiments here verify L. interrogans FBPase as a stable tetramer 
with cooperative AMP inhibition and AMP/Fru-2,6-P2 synergism, regulatory properties 
common to eukaryotic FBPases.  L. interrogans, however, lacks genes associated with Fru-
2,6-P2 biosynthesis.  Instead on the basis of tryptophan fluorescence, the product of the 
FBPase reaction (Fru-6-P) binds synergistically with AMP to L. interrogans FBPase.  
AMP/Fru-6-P synergism in a bacterial FBPase suggests an ancient mode of regulation that 
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may have been the basis in evolution for Fru-2,6-P2 inhibition and AMP/Fru-2,6-P2 
synergism in eukaryotic systems. 
 
Introduction 
Fructose-1,6-bisphosphatase (D-fructose-1, 6-bisphosphate 1-phosphohydrolase; EC 
3. 1. 3; FBPase) is a key regulatory enzyme in gluconeogenesis.  With divalent cations (Mg
2+
, 
Mn
2+
, or Zn
2+
) as cofactors, FBPase catalyzes the hydrolysis of fructose 1,6-bisphosphate 
(Fru-1,6-P2) to fructose 6-phosphate (Fru-6-P) and phosphate (Pi) (1, 2). 
Regulatory mechanisms of Type-1 FBPases vary widely with organism.  Fructose 
2,6-bisphosphate (Fru-2,6-P2) and AMP inhibit FBPases from eukaryotic organisms (4-6).  
AMP binds with positive cooperativity to an allosteric site on a stable tetramer (4).  Fru-2,6-
P2 not only competes with substrate for the active site but also enhances AMP inhibition by 
several fold, a property named AMP/Fru-2,6-P2 synergism (5, 6).  AMP/Fru-2,6-P2 
synergism is evident in plant cytosolic FBPase and yeast FBPase (7-8), as well as 
mammalian organisms (1).  AMP concentration in vivo is relatively constant, but fluctuating 
levels of Fru-2,6-P2, determined by the hormonal and nutritional status of the organism (9), 
insure that both AMP and Fru-2,6-P2 are dynamic inhibitors.  In eukaryotic organisms, 
FBPase and fructose-6-phosphate-1-kinase (PFK-1) from glycolysis define a futile cycle (3).  
In order to avoid the uncontrolled consumption of ATP in that cycle and maintain glucose 
hemostasis, FBPase activity is regulated coordinately with that of PFK-1.  Hence, Fru-2,6-P2 
is an allosteric activator of PFK-1 (3, 10-12). 
Other mechanisms of FBPase regulation differ substantially from that of eukaryotic 
systems.  FBPase from the chloroplast is insensitive to AMP (13).  The activity of chloroplast 
FBPase is controlled indirectly by light through a redox signaling pathway (14-15).  Bacterial 
systems lack Fru-2,6-P2 (16).  Escherichia coli FBPase (hereafter eFBPase) uses glucose 6-
phosphate (Glc-6-P) and AMP as synergistic inhibitors (17).  Moreover, anions such as 
sulfate, phosphoenolpyruvate (PEP) or citrate antagonize Glc-6-P/AMP inhibition and 
activate eFBPase (18, 19). 
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Porcine liver FBPase (pFBPase) is a model system for FBPases from eukaryotic 
organisms.  pFBPase is a stable homotetramer that adopts at least two quaternary states, an 
active R-state and an inactive T-state (20, 21).  pFBPase with bound product and divalent 
cations (Mg
2+
, Mn
2+
, or Zn
2+
) defines the R-state (20).  AMP and/or Fru-2,6-P2 drive the R- 
to T-state transition of pFBPase. The AMP and AMP/Fru-2,6-P2 complexes of pFBPase 
exhibit a subunit-pair rotation of 15° and that of Fru-2,6-P2 a 13° rotation relative to the R-
state (21-23).  The subunit-pair rotation is in part responsible for the displacement of an 
essential loop (loop 50-72) from its engaged conformation, which stabilizes the binding of 
substrate and three divalent cations at the active site.  Upon displacement, loop 50-72 
acquires its disengaged conformation, re-positioning catalytically essential residues some 30 
Å away from the active site.  The similar end-state caused by AMP and Fru-2,6-P2 
individually is the putative basis for AMP/Fru-2,6-P2 synergism (23).  Moreover, the central 
cavity of the pFBPase tetramer and the stable cluster of water molecules in that cavity, are 
factors in defining the quaternary state (24).  The mutation of Ser
45→His in pFBPase fills the 
cavity and eliminates AMP/Fru-2,6-P2 synergism as well as Fru-2,6-P2 induced subunit-pair 
rotation (25). 
eFBPase is similar in sequence (40% identical) and structure (same fold) to pFBPase 
(18).  AMP is a potent inhibitor of eFBPase and the binding of AMP drives a subunit-pair 
rotation similar to that observed in pFBPase (17); however, an important salt bridge in 
pFBPase (Lys
42–Glu192) at the dimer-dimer interface is missing in eFBPase (Lys34–Val186).  
As a consequence, eFBPase is in dimer-tetramer equilibrium, with the tetramer form more 
active (18).  Anion activators, such as PEP or citrate stabilize the tetramer by binding to the 
dimer-dimer interface (19).  Glc-6-P binds to an allosteric site at the C1-C2 interface and 
inhibits eFBPase synergistically with AMP (17).  Although not present in E. coli, Fru-2,6-P2 
is a potent inhibitor of eFBPase; however, AMP/Fru-2,6-P2 synergism is absent in eFBPase. 
Structurally, eFBPase lacks the large central cavity (histidine is at the position corresponding 
to Ser
45
 in pFBPase) and Fru-2,6-P2 does not cause a subunit-pair rotation (23). 
The full scope and evolution of FBPase regulatory mechanisms is the focus of the 
investigation here.  How Fru-2,6-P2 came to be a regulator of all known eukaryotic FBPases, 
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when there is no instance of Fru-2,6-P2 in non-eukaryotic organisms, is a mystery.  The 
dissimilarity in the regulation of eFBPase and pFBPase argues against one being a direct 
evolutionary precursor of the other.  Sequence analysis of Type-1 FBPases, however, 
indicates FBPases from Leptospira should have the regulatory properties of porcine and other 
eukaryotic FBPases (25).  Leptospira interrogans FBPase (herafter, lFBPase) has most of the 
key residues for AMP inhibition, AMP/Fru-2,6-P2 synergism, central cavity formation and 
tetramer stability, but lacks residues for anion activation and Glc-6-P inhibition.  Given the 
current status of our knowledge of allosteric regulation in FBPases, we predict lFBPase to 
have AMP/Fru-2,6-P2 synergism even though L. interrogans lacks the genes associated with 
Fru-2,6-P2 biosynthesis.  Presented here are the properties of lFBPase, which as predicted, 
are similar to those of pFBPase.  In addition, as lFBPase has a single, naturally-occuring 
tryptophan at the active site, we find for the first time in an FBPase the existence of 
AMP/Fru-6-P synergism.  Results here indicate that the existence of AMP/Fru-6-P synergism 
in a primordial FBPase may have enabled the evolution of AMP/Fru-2,6-P2 synergism in 
eukaryotic organisms. 
 
Experimental procedures 
Materials— Fru-1,6-P2, NADP
+
 and AMP came from Sigma.  Fru-2,6-P2 was produced 
according by published protocols (26).  Glucose-6-phosphate dehydrogenase and 
phosphoglucose isomerase were purchased from Roche Applied Sciences.  The FBPase-
deficient E. coli strain DF 657 was from the Genetic Stock Center at Yale University.  Other 
chemicals were of reagent grade or equivalent. 
Cloning, Expression and Purification of lFBPase— lFBPase (UniProt ID: Q8F421) was 
synthesized and cloned into pET24b plasmid by Genscript (http://www.genscript.com/).  The 
integrity of the construct was confirmed by sequencing the promoter region and the entire 
open reading frame.  Iowa State University sequencing facility provided DNA sequencing 
services with the fluorescent dye-dideoxy terminator method.  E. coli strain DF 657 was used 
for expression of lFBPase.  The cell culture of E. coli DF657 transformed with the lFBPase 
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plasmid grew to A600 of 1.0, at which time transcription was induced by the addition of 
isopropyl-β-D-thiogalactopyranoside (IPTG, final concentration 1 mM).  The culture was 
maintained (with shaking, 37 °C) for an additional 16 hrs before harvesting.  The supernatant 
component of the cell free extract was subject to ammonium sulfate fractionation.  The 30-50% 
ammonium sulfate fraction was collected and dialyzed thoroughly in 20 mM Tris, pH 8.0, 
before loading onto a DEAE-sepharose column.  Purified enzyme was eluted with a NaCl 
gradient (0–0.5 M) in 20 mM Tris-HCl, pH 8.0.  Enzyme was dialyzed extensively against 50 
mM Hepes, pH 7.4, prior to kinetics studies.  Purity and protein concentrations of FBPase 
preparations were confirmed by sodium dodecylsulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) (27) and by Bradford assay (28), respectively.  
Sedimentation Equilibrium— Sedimentation equilibrium experiments followed published 
protocols (29).  lFBPase with three protein concentrations (OD280 = 0.3, 0.5 and 0.7) was 
sedimented to equilibrium at angular speeds 15000, 18000 and 21000 rpm.  Equilibrium data 
were fit with the program UltraScan (30). 
Kinetic Experiments— Phosphoglucose isomerase and glucose-6-phosphate dehydrogenase 
were used as coupling enzymes in assays of FBPase activity (1).  For specific activity 
measurements, reduction of NADP to NADPH was monitored by absorbance at 340 nm on 
UV spectrometer.  Other assays used the same coupling enzymes but monitored the 
formation of NADPH by its fluorescence emission at 470 nm using an excitation wavelength 
of 340 nm.  Assays were performed at 22 °C in 50 mM Hepes, pH 7.5.  300 mM KCl was 
added in the assays for pFBPase but not for lFBPase.  Assay solutions contained EDTA at a 
concentration of 10 μM.  Enzyme initialized assay and Mg2+ initialized assay were both 
performed for AMP inhibition of pFBPase, which gave undistinguishable results, unlike 
eFBPase (19). All kinetics data reported were results from enzyme initialized assays except 
anion activation experiment, which used Mg
2+
 initialized assay. Data for AMP inhibition 
with respect to Mg
2+
 and Fru-2,6-P2 inhibition with respect to Fru-1,6-P2 were fit to several 
models and results from best fit were reported.  Data fitting was carried out with software 
Grafit (31).  
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Fluorescence experiment—Fluorescence measurements were made at room temperature 
using a 1-cm
2
 quartz cuvette on aSLM Amico 8000 fluorometer.  The excitation wavelength 
was 295 nm, and emission scans were integrated from 310 to 370 nm.  Fluorescence scans 
(repeat of 3 scans for each data point) were performed after additions of small volumes of 
ligand to 2 mL of a 2 μM lFBPase solution.  The total concentration of added titrant did not 
exceed 1% of the initial volume. Data fitting was carried out using protocols in the literature 
(32). 
 
Results 
Sequence Alignment— Sequence alignments of lFBPase, pFBPase and eFBPase reveal 
identities of 40–48% in pairwise combinations.  Active site residues are conserved for the 
most part among the three FBPases. Asp
121
, Gly
122
, Ser
123
, Asn
212
, Asn
215
, Arg
243
, Tyr
244
, 
Leu
248
, Tyr
264
, Lys
274
, and Arg
276
 (pFBPase numerology and type) form hydrogen-bonds with 
products (Fru-6-P and Pi) in the R-state of pFBPase (20).  Among these, only Tyr
215
 and 
Met
248
 differ (becoming asparagine and leucine, respectively) in both eFBPase and pFBPase.  
Divalent metal cations (Mg
2+
, Mn
2+
, or Zn
2+
) are essential co-factors for FBPase and three 
metal cations are required for each subunit for catalysis by pFBPase.  Metal binding residues 
are conserved (Glu
97
, Glu
98
, Asp
118
, Asp
121
, and Glu
280
) except for Asp
68
 of pFBPase which is 
glutamate in eFBPase and lFBPase.  Conservation of active site residues indicates a similar 
mechanism of catalysis for lFBPase, eFBPase and pFBPase. 
Although lFBPase shares higher identity with eFBPase (48%) than with pFBPase 
(41%), the key residues for regulation in lFBPase are more similar to those in pFBPase than 
eFBPase.  All three FBPases have signature residues for an AMP binding site (Figure 1); 
however, eFBPase has two allosteric binding sites, one for the anion activation between 
subunits at the C1-C4 interface and one for Glc-6-P inhibition between subunits at the C1-C2 
interface (17, 19).  These binding sites are not present in pFBPase, and signature residues are 
not present in the lFBPase sequence.  In contrast, position 45 (pFBPase numerology) is serine 
in lFBPase and pFBPase and histidine in eFBPase.  The small side chain (serine) in pFBPase 
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and lFBPase indicates a central cavity and the property of AMP/Fru-2,6-P2 synergism for 
lFBPase even though the genes associated with Fru-2,6-P2 synthesis are not present in this 
bacterial system.  The salt link between Lys
42
 and Glu
192
 in pFBPase is essential for tetramer 
stability (29).  The salt link is absent in eFBPase but present in lFBPase.  Key residues in the 
sequence of lFBPase indicate regulatory/structural properties similar to those of pFBPase, 
which include AMP inhibition, AMP/Fru-2,6-P2 synergism, and a stable tetramer with a 
central cavity. 
Expression and purification of LiFBPase— Expression and isolation procedures described in 
the methods section provide lFBPase with at least 95% purity as confirmed by sodium 
dodecylsulfate-polyacrylamide gel electrophoresis (data not shown). 
Sedimentation Equilibrium— Sedimentation equilibrium data are fit to single component and 
dimer-tetramer equilibrium models with UltraScan (Table 2).  Regardless of model, pFBPase 
and lFBPase give similar apparent molecular weights in sedimentation equilibrium 
experiments, 111.9 and 112.1 kDa for lFBPase and pFBPase, respectively.  The determined 
molecular weights are less than the calculated weight of 140 kDa for the tetramer. 
Enzyme activity—Parameters from the reaction kinetics of lFBPase and pFBPase are in Table 
1.  K
+
 is an activator for pFBPase at low concentration (1-2, 33) but an inhibitor for lFBPase.  
So KCl is only presented in the assays for pFBPase.  lFBPase catalyzes the hydrolysis of Fru-
1,6-P2 with specific activity and Km values comparable to those of pFBPase.  Mg
2+
 is an 
essential cofactor, but unlike pFBPase, Mg
2+
 activation is not cooperative in lFBPase 
catalysis (Hill coefficient of 0.77±0.08 compared to that of pFBPase of 1.7±0.1).  The 
dependence of initial velocity on concentrations of Fru-1,6-P2 and Mg
2+
 is given by Equation 
1: 
   
    
  
                  
 (Equation 1) 
where Vm, A, B, Ka, Kb, Kia , n represent the maximum velocity of the reaction, the 
concentration of free Mg
2+
, the concentration of free Fru-1,6-P2, the Michaelis-Menten 
constant for Mg
2+
, the Michaelis-Menten constant for Fru-1,6-P2, the dissociation constant 
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for Mg
2+
, and the Hill coefficient for Mg
2+
,  respectively.  n is set to 2 for pFBPase and unity 
for lFBPase.  Plots of reciprocal velocity versus reciprocal substrate concentration are 
consistent with a Random Bi Bi or Steady-State Ordered mechanism (Figure 2), both of 
which are consistent with Equation 1.  Comparable values for Ka and Kia for Mg
2+
 (Ka= 
1.3±0.1 µM versus Kia= 2.7±0.6 µM) implies no synergism in the binding of substrate and 
metal cofactor, which is consistent with the Random Bi Bi mechanism.  That Random Bi Bi 
mechanism has been demonstrated unequivocally for pFBPase by inhibition assays (34).  
AMP inhibition— AMP inhibits lFBPase with high affinity.  The I0.5 and Hill coefficient for 
AMP inhibition are determined by titration of AMP in the presence of a saturating 
concentration of substrate (20 µM) and Mg
2+
 (5 mM).  Data was fit to Equation 2, 
   
  
   
 
    
  
   (Equation 2) 
where v, Vm, I, I0.5 and n are velocity, maximum velocity, AMP concentration, AMP 
concentration that gives 50% activity and the Hill coefficient for AMP, respectively.  AMP 
inhibition for lFBPase is cooperative, with a Hill coefficient close to 2.  AMP is a 
competitive inhibitor with respect to Mg
2+
 (Ki = 0.58±0.05 µM, Figure 3) and an non-
competitive inhibitor with respect to Fru-1,6-P2 (Ki = Kis =0.83±0.05 µM).  AMP inhibition is 
comparable to that of pFBPase. 
Fru-2,6-P2 inhibition— Although not present in bacteria system, Fru-2,6-P2 is a highly 
potent inhibitor for lFBPase.  I0.5 for Fru-2,6-P2 inhibition in the presence of saturating 
substrate (20 µM) and Mg
2+
 (5 mM) is 0.33±0.02 µM, with a Hill coefficient 1.05±0.08.  The 
inhibition of Fru-2,6-P2 is competitive with respect to substrate (Figure 4).   
Effect of anions and Glc-6-P—Anion activators such as PEP or citrate activate eFBPase by 
promoting tetramer formation (19).  To test the effect of PEP on lFBPase, Mg
2+
 initialized 
assays were used. PEP activation is not present for lFBPase. Instead, milli-molar level PEP 
causes moderate inhibition.  Assays of Glc-6-P inhibition follow the published protocol for 
eFBPase (18). Glc-6-P inhibition becomes evident only at milli-molar level, which is around 
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50-times weaker than Glc-6-P inhibition in eFBPase.  Similar level of Glc-6-P inhibition has 
also been observed for pFBPase. 
AMP/Fru-2,6-P2 synergism—AMP/Fru-2,6-P2 synergism is indicated by the level of AMP 
inhibition in the absence and presence of Fru-2,6-P2.  Inhibition curves are fit to Equation 2. 
The AMP inhibition is enhanced by ~2 fold in the presence of small amounts of Fru-2,6-P2 
([Fru-2,6-P2] = I0.5 =0.33 µM).  Vice versa Fru-2,6-P2 inhibition is enhanced twofold in the 
presence of a small amount of AMP ([AMP] = I0.5 =1.8 µM). Moreover, the Hill coefficient 
for AMP inhibition drops from 2.2 to close to unity upon the addition of Fru-2,6-P2.  Similar 
phenomena have been observed in both wild-type pFBPase and mutant pFBPases with 
reduced AMP/Fru-2,6-P2 synergism (23, 25). 
Steady-state Tryptophan Fluorescence of lFBPase— lFBPase has but one tryptophan (Trp219).  
Assuming a structure for lFBPase similar to that of eFBPase and pFBPase, Trp
219
 is near the 
common binding sites for the 6-phosphoryl groups of substrate, product and Fru-2,6-P2.  
Steady-state fluorescence emission from Trp
219
 increases as levels of substrate, product or 
Fru-2,6-P2 increase (Figure 6A), whereas increasing concentrations of AMP cause little 
change.  Substrate, product, Fru-2,6-P2, and AMP have no effect on the fluorescence 
emission of 100 µM tryptophan in the absence of lFBPase.  The fluorescence change caused 
by Fru-6-P, Fru-1,6-P2, or Fru-2,6-P2 is arguably the result of a change in the local 
environment Trp
219
 due to the binding of 6-phosphore group at the active site.  Indeed, at 
saturating concentrations, the three active-site ligands induce nearly identical changes in 
fluorescence emission.  Data from titrations of 6-phosphoryl ligands carried out in the 
presence and absence of AMP are fit to Equation 3: 
  
  
 (
     
  
)  
 
    
  (Equation 3) 
where ΔF is the change in fluorescence caused upon addition of ligand L, F0 is the 
fluorescence in the absence of ligand, and Kd is the dissociation constant.  AMP does not 
affect the binding of Fru-1,6-P2 (Table 3).  In contrast, a small amount of AMP ([AMP] = I0.5 
= 1.8 µM) can enhance binding of Fru-2,6-P2 by approximately twofold, consistent with data 
from kinetics experiments.  AMP has a similar synergistic effect on the binding of Fru-6-P. 
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Discussion 
The sequence of lFBPase was identified by homology analysis of the genome 
sequence of Leptospira interrogans (35).  The experimental characterization of lFBPase here 
confirms the assignment.  lFBPase exhibits a Km for Fru-1,6-P2 and a specific activity 
comparable to that of pFBPase and eFBPase.  The reaction catalyzed by lFBPase requires 
Mg
2+
 as an essential co-factor.  Unlike the cooperative binding of Mg
2+
 to pFBPase, however, 
the binding of Mg
2+
 to lFBPase is non-cooperative.  This alteration in property may be due to 
the change in residue type from aspartate to glutamate at position 68 (pFBPase numerology).  
All other Mg
2+
 binding residues are identical among lFBPase, pFBPase and eFBPase.  The 
mutation Asp
68→Glu in pFBPase reduces Mg2+ cooperativity (36), and lFBPase and eFBPase 
have no Mg
2+
 cooperativity (37). 
On the basis of sequence similarity, lFBPase should be a stable tetramer, similar to 
pFBPase and dissimilar to eFBPase, the latter existing as an equilibrium mixture of dimers 
and tetramers.  Salt links (Lys
42–Glu192) between subunit-pairs of the pFBPase tetramer are 
essential for tetramer stability.  The mutation of Glu
192
 to glutamine disrupts the wild-type 
tetramer of pFBPase and creates a stable dimer with diminished activity (29).  lFBPase has 
the signature salt-links of pFBPase, and consistent with hypothesis, behaves identically 
(within experimental uncertainty) to pFBPase in sedimentation equilibrium.  In contrast, 
eFBPase exists as a fully active tetramer in equilibrium with a less active dimer (19).  
Dilution of eFBPase results in a slow loss of activity, which is not observed for either 
pFBPase or lFBPase. 
By hypothesis based on sequence similarity, AMP should inhibit lFBPase with 
cooperativity, and indeed this is confirmed here by experiment. AMP cooperativity for 
eFBPase is weak or absent in enzyme initialized assays and Mg
2+
 initialized assays, 
respectively (19).  Studies of pFBPase indicate that AMP cooperativity derives from 
nucleotide binding to each subunit-pair (C1-C2 and C3-C4) of the tetramer (38).  Disruption 
of the pFBPase tetramer causes a loss of cooperativity in AMP inhibition (29).  Hence the 
presence of AMP cooperativity in the inhibition of lFBPase is another manifestation of 
tetramer stability. 
175 
 
The large cavity at the center of the pFBPase tetramer is another attribute that 
distinguishes pFBPase from eFBPase (25).  That cavity is responsible for AMP/Fru-2,6-P2 
synergism in pFBPase and is largely filled by the side chains of His
45
 from each of four 
subunits of eFBPase.  lFBPase has serine at the position 45, the same residue type as in 
pFBPase.  Both kinetics and equilibrium binding experiments involving lFBPase reveal 
AMP/Fru-2,6-P2 synergism, again consistent with hypothesis derived from sequence 
comparisons.  Predictions of tetramer stability, cooperative inhibition by AMP, and 
AMP/Fru-2,6-P2 synergism for lFBPase have been confirmed by experiment. 
AMP/Fru-6-P binding synergism for lFBPase, observed by monitoring tryptophan 
fluorescence, has been missed in past studies of FBPase presumably because of assay design.  
FBPase activity is measured by coupling the formation of NADPH to that of Fru-6-P.  Hence, 
concentrations of Fru-6-P are not subject to controlled variation in kinetics as would be 
necessary to detect AMP/Fru-6-P synergism. 
AMP/Fru-6-P binding synergism arguably represents an evolutionary prelude to 
AMP/Fru-2,6-P2 synergism observed in eukaryotic organisms.  Properties of lFBPase then 
are not unlike those anticipated for a direct evolutionary precursor of eukaryotic FBPase.  At 
some point in evolution, the primordial FBPase may have existed as an equilibrium mixture 
of dimers and tertramers (Figure 7).  This primordial FBPase may have been subject to AMP 
inhibition, perhaps without cooperativity, and feedback inhibition by Fru-6-P.  One pathway 
of evolution stabilizes the tetramer through the creation of an anion-activation site.  Over 
time, this form of FBPase acquires a site for Glc-6-P inhibition which acts synergistically 
with AMP, in short becoming the present-day eFBPase.  An alternative pathway of evolution 
also led to a stable FBPase tetramer through the formation of Glu
192–Lys42 salt-links.  As this 
form of the tetramer is stable and at all times fully active, a robust mechanism of inhibition 
would presumably co-evolve with activation.  Mutation of position 45 from histidine to 
serine would create a nascent central cavity in the primordial enzyme without an effect on 
activity.  The introduction of the Glu
192–Lys42 salt link in a Ser45 ancestral FBPase would 
create a stable tetramer with a central cavity.  The central cavity would enable AMP/Fru-6-P 
synergism that would in turn be the counterpoint to enhanced activity of a stable tertamer.  
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Over time, some organism found survival advantage by replacing Fru-6-P with Fru-2,6-P2 as 
a dynamic regulator.  Crystal structures of Fru-2,6-P2 bound to pFBPase clearly show that all 
atoms except those of the 2-phosphoryl group occupy the positions of corresponding atoms 
of Fru-6-P (23).  Hence, Fru-2,6-P2 can be regarded as a high-affinity form of the product 
Fru-6-P. 
L. interrogans is a pathogenic bacterium with a metabolism strikingly different from 
that of mammals (35).  L. interrogans lacks hexokinase and cannot capture and directly use 
glucose from exogenous sources (35, 39).  Instead, lipid is the principal energy source for L. 
interrogans.  Enzymes of gluconeogenesis are present, however (35).  The apparent role of 
gluconeogenesis in L. interrogans is the generation of Fru-6-P exclusively as a precursor for 
sugar-nucleotide biosynthesis.  As a gene coding for glucose 6-phosphate dehydrogenase is 
absent in L. interrogans (35), Fru-6-P must enter the non-oxidative pentose phosphate 
pathway in order to produce ribose 5-phosphate.  The conversion of Fru-1,6-P2 into Fru-6-P 
in L. interrogans then represents the first committed step in ribose 5-phosphate biosynthesis.  
Enzymes that govern the first committed step of metabolic pathways (in this instance 
lFBPase) are often subject to feedback regulation.  Moreover, high levels of Fru-6-P should 
inhibit only lFBPase due to absence of glycolysis.  Feedback regulation of lFBPase by 
AMP/Fru-6-P synergism then seems a reasonable strategy of regulation.  When nucleotides 
are in demand, the concentrations of AMP and Fru-6-P (the latter being in equilibrium with 
the pool of ribose 5-phosphate) should be low and non-inhibitory; however, a surplus of 
nucleotides, and by inference ribose 5-phosphate, should cause levels of Fru-6-P to rise.  
Even if the concentration of AMP is constant under these conditions, AMP becomes 
inhibitory concomitantly with rising levels of Fru-6-P because of the property of AMP/Fru-6-
P synergism. 
Leptospira is the causative agent of Leptospirosis, a disease of global concern.  
Infection in human causes renal and hepatic damage, and in some instances sudden and fatal 
hemoptysis (35, 39).  Infections in livestock and domestic animals can expose individuals to 
Leptospira infections through sanitary waste or contaminated drinking water.  Little 
information is known about the metabolism of L. interrogans by direct experimentation.  
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Given the current status of our knowledge, one could regard FBPase from Leptospira as a 
potential target in the development of agents of anti-microbial growth. 
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Table 1.  Parameters from the kinetics of wild-type and mutant FBPases. 
Uncertainties in the last significant digit are in parentheses. 
FBPase 
Specific 
activity 
a
 
Units mg
–1
 s
–1
 
Km- 
Fru-1,6-P2 
b
 
(μM) 
Mg
2 
 
Hill-
coef.
c
 
Ka- 
Mg
2 
 
c
 
(mM
2
) 
AMP 
Hill-
coef.
d
  
Ki-AMP 
d
 
(μM
2
) 
Ki- 
Fru-2,6-P2 
e
 
(μM) 
pFBPase 25 1.47(7) 1.7(1) 0.70(5) 2.2(1) 0.76(8) 0.14(1) 
lFBPase 15 1.0(1) 0.77(8) 1.3(1)
f
 2.2(2) 0.58(5) 0.05(1) 
a
 Specific activity is determined at saturated Fru-1,6-P2 (20 µM) and Mg
2+
 (5mM) level. The reported 
results are average values of 5 repeats. 
b
 KM for Fru-1,6-P2 is determined at saturated Mg
2+
 (5mM) level. The Fru-1,6-P2 concentration varies 
from 0.3 to 20 µM.  
c
 Hill coefficient for Mg
2+
 is determined by titrating 0.2 to 10 mM Mg
2+
 to assays that contain 
saturated level of Fru-1,6-P2 (20 µM). The concentration ranges of Mg
2+
 and Fru-1,6-P2 in 
determination of Ka are 0.5 to 5 mM and 0.5 to 10 µM, respectively. 
d
 Hill coefficient for AMP is determined by titrating 0.1 to 100 µM AMP to assays that contain 
saturated level of Fru-1,6-P2 (20 µM) and Mg
2+
 (5 mM). The concentration of Mg
2+
 varies from 0.5 to 
5 mM and the concentration ranges of AMP are 0 to 5 µM for determination of Ki-AMP. 
e
 Assays contain Mg
2+
 (5mM). The concentration of Fru-1,6-P2 varies from 0.5 to 10 µM and the 
concentration ranges of Fru-2,6-P2 are 0 to 0.5 µM. 
f
 Ka-Mg
2+
 for lFBPase has units of mM 
  
179 
 
 
Table 2.  Fitting results of sedimentation equilibrium data for lFBPase and pFBPase 
a
. 
Protein 
Single component, 
ideal 
Monomer-dimer equilibrium 
M.W.
b
 S.D.
c
 M.W. Kd (M) S.D.
c
 
pFBPase 112100 0.009147 113900 2.718 0.010514 
lFBPase 111900 0.006866 112100 2.718 0.00597 
 
a 
The results were derived from global fitting of all data with software Ultrascan 
b 
Molecular weight in Dalton 
c 
Standard derivation of the global fitting 
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Table 3.  Effect of AMP on the binding of ligands to the active site. 
Standard deviation in last significant figure is given parenthetically. 
Ligand Kd (AMP = 0), µM Kd (AMP = 1.8 µM), µM 
Fru-1,6-P2 0.77(9) 0.73(5) 
Fru-2,6-P2 0.32(7) 0.17(2) 
Fru-6-P 105(9) 50(7) 
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Figure 1.  Key residues of FBPase catalysis and regulation.  A. Sequence alignment of lFBPase, pFBPase 
and eFBPase reveals residues for product binding and metal coordination (black), AMP inhibition (red), 
tetramer formation (yellow), central cavity (purple), anion activation (purple) and Glc-6-P inhibition (blue).  B. 
FBPase subunit with bound Fru-2,6-P2 (black, from PDB ID: 2QVU), AMP (red, from PDB ID: 1EYJ), Glc-6-P 
(blue, from PDB ID: 2Q8M), phosphoenolpyruvate (green, from PDB ID: 2OX3), and ordered water molecules 
in central cavity (purple, from PDB ID: 1YYZ), all shown in sphere representations.  Only subunit C1 of 
FBPase tetramer (right corner) is presented.  The figure is prepared by Pymol (40). 
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Figure 2.  Activation of lFBPase by Mg
2+
.  Plots of reciprocal velocity against 1/[Fru-1,6-P2] with fixed free 
Mg
2+
 concentrations of 0.5 (□), 0.9 ( ), 1.5 (○), 3 (◊) and 5 mM (x) are shown.  Lines in the figure are 
calculated based on Equation 2 in the results section. 
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Figure 3.  AMP inhibition of lFBPase.  Reciprocal velocities are plotted against 1/[Mg
2+
] at fixed AMP 
concentrations of  0 (x), 0.45 (◊), 0.7 (○), 1 ( ) and 1.5 µM (□). 
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Figure 4.  Fru-2,6-P2 inhibition of lFBPase.  Reciprocal velocities plotted against 1/[Fru-1,6-P2] at fixed Fru-
2,6-P2 concentrations of 0 (x), 0.05 (◊), 0.1 (○), 0.2 ( ) and 0.4 µM (□). 
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Figure5.  Determination of AMP/Fru-2,6-P2 synergism by kinetics.  A. AMP inhibition in the absence (□) 
and presence ( ) of Fru-2,6-P2 ([Fru-2,6-P2] = I0.5-Fru-2,6-P2 = 0.33 µM).  B. Fru-2,6-P2 inhibition in the 
absence (○) and presence (●) of AMP ([AMP] = I0.5-AMP = 1.8 µM).  All assays are carried out with saturating 
Fru-1,6-P2 (20 µM) and Mg
2+
 (5 mM). 
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Figure 6.  Ligand binding to the active site as revealed by fluorescence emission from tryptophan.  A. 
Saturating levels of Fru-1,6-P2 (20 µM, □), Fru-2,6-P2 (10 µM, ○), or Fru-6-P (500 µM, ) significantly 
increase Trp
219
 fluorescence emission whereas AMP (10 µM, x) causes little changes relative to baseline (solid 
curve).  Titrations for Fru-1,6-P2 (panel B), Fru-2,6-P2 (panel C), and Fru-6-P (panel D) performed in the 
absence (open symbols) and presence (filled symbols) of AMP ([AMP] = I0.5-AMP = 1.8 µM) reveal binding 
synergism between AMP and only Fru-6-P and Fru-2,6-P2.  Each titration data point represents integration of 
the Trp
219
 emission spectrum from 310-370 nm. 
 
  
187 
 
 
 
Figure 7.  Proposed evolution of the regulatory properties of FBPases.  Different mechanisms of tetramer 
stabilization (anion activation and salt-link formation) led E. coli-like and eukaryotic mechanisms of regulation. 
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CHAPTER VIII.  GENERAL CONCLUSION 
Mammalian FBPase exists as a stable tetramer in solution, with two distinct subunit 
interfaces (C1-C2 and C1-C4) and one large hydrophobic cavity at the center. All the potent 
regulatory sites identified to date locate on/nearby subunit interface or central cavity and 
communicate with active site and with each other allosterically. My dissertation work 
illucidated how key structural features of FBPase, including stable tetramer, subunit pair 
rotation within tetramer and central cavity, determine proper regulation of mammalian 
FBPase. 
Inspired by E. coli FBPase, which exists in dimer-tetramer equilibrium in solution, I 
have confirmed the key interaction at C1-C4 interface, the salt link Glu
192
-Met
42 
(Chapter V). 
Point mutations on or surrounding the salt link led to the formation of FBPase dimmers (C1-
C2 or C3-C4). Introduction of positive charge amino acid at position 18 also affected 
tetramer stability (Chapter VI). All mutant FBPases in dimer form are with diminished AMP 
cooperativity and exhibit a range of changes in AMP inhibition, from altered inhibitory 
mechanism, partial inhibition to totally loss of AMP inhibition. The result here indicated the 
importance of stable tetramer in AMP inhibition. 
Tetrameric FBPase exists in at least two quaternary states, active R-state and inactive T-
state, which are mainly distinguished by a 15 degree subunit-pair rotation (between C1-C2 
dimer and C3-C4 dimer). Ligation of AMP nearby C1-C4 interface disrupts local hydrogen 
bonds and triggers subunit-pair rotation (Chapter II). Small subunit-pair rotation correlates to 
catalytic efficiency of FBPase: the more of rotation towards T-state, the less active of FBPase 
(Chapter III). Subunit-pair rotation close to T-state generates close contacts on loop 50-72 
and drives the displacement of the essential catalytic loop 50-72 (Chapter II). Additionally, 
subunit-pair rotation governs AMP/Fru-2,6-P2 synergism and AMP binding cooperativity in 
tetrameric FBPase: restraining Fru-2,6-P2 induced subunit pair rotation reduces AMP/Fru-
2,6-P2 synergism (Chapter IV); subunit-pair rotation towards T-state eliminates AMP 
cooperativity (Chapter IV, V, VI). 
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The central cavity of FBPase is populated with ordered waters, verified by both 
crystallography and molecular dynamics simulation (Chapter III). The waters are most stable 
in IR-state of Leu
54
 FBPase (3 degree subunit-pair rotation), and in IT-state of Asp
10
 FBPase 
(12 degree subunit-pair rotation), both of which lie on the R- to T-state transition pathway. 
The extra stability of waters in intermediate states of FBPase would become an energy 
barrier that determines quaternary states of FBPase. Indeed, Leu
54
 FBPase in the presence of 
AMP exhibits different level of subunit-pair rotations in different solvent systems (Chapter 
III). The central cavity in E. coli FBPase is filled with large hydrophilic sidechains. The 
mimic of E. coli central cavity in mammalian FBPase reduces Fru-2,6-P2 induced subunit-
pair rotation and AMP/Fru-2,6-P2 synergism (Chapter IV). 
Our rich knowledge on allosteric regulation of porcine liver FBPase and FBPase from 
Escherichia coli allow us to predict the regulatory properties of all Type-I FBPases, for 
which sequence information is available. Subsequent expression of FBPase from a bacterial 
organism, predicted to have the regulatory properties of a eukaryotic FBPase, proved correct 
and established a basis for the evolution of regulatory properties for all Type-I FBPases 
(Chapter VII).  
In summary, my dissertation largely illustrates the structural basis for allosteric 
regulation of mammalian FBPase: stable tetramer is prerequisite for AMP inhibition; subunit 
pair rotation mediate communication between AMP sites from different subunit and between 
AMP site and active site; the central cavity acts as a thermodynamic hinge for subunit-pair 
rotation. The work here also provides future directions for drug screening/design towards 
FBPase. Anything that induce subunit-pair rotation would be an inhibitor of FBPase and will 
work synergistically with physiological inhibitors AMP and Fru-2,6-P2. 
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